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it’s rather the training of the mind to think.’ 
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Cells control the quality of the proteome through an integrative network of 
mechanisms that include protein degradation by autophagy. The regulation of this process by 
signaling pathways has been intensively studied but less is known about its transcriptional 
control. Because this degradative pathway has an essential cytoprotective role, especially 
under stress conditions, in this thesis we have analyzed the regulation of autophagy by the 
transcription factor Nuclear factor (erythroid-derived 2)-like 2 (NRF2), which is considered a 
master regulator of cellular homeostastis. NRF2 controls the expression of a wide battery of 
cytoprotective genes that have a tremendous impact on physiological responses such as 
inflammation, senescence or metabolism. However, its relevance in proteostasis is just 
starting to be unveiled. 
Therefore, we focused our study on the transcriptional regulation of two types of 
autophagy, i.e. macroautophagy and chaperone mediated autophagy (CMA). We have 
identified NRF2 enhancer sequences, termed antioxidant response elements (AREs), in the 
promoter region of 9 genes involved in different steps of macroautophagy and CMA. 
Consequently, we show that genetic and pharmacological manipulation of NRF2 results in the 
modulation of autophagy gene expression and activity.  
The role of NRF2 in the regulation of macroautophagy may have a significant 
relevance upon stressful conditions, including proteotoxic stress. To address the functional 
relevance of NRF2 in proteinopathy, we have generated a new mouse model of Alzheimer’s 
disease (AD) that reproduces the amyloid and TAU pathology in the presence or absence of 
NRF2 expression. NRF2 deficiency worsens some of the main hallmarks of AD, including 
low-grade chronic oxidative and inflammatory stress as well as exacerbated proteinopathy 
due, at least in part, to impaired macroautophagy. Moreover, our results reflect a positive 
correlation between the expression of NRF2 and macroautophagy in AD patients. 
We have also established the role of NRF2 in the basal and inducible regulation of 
CMA, based on the transcriptional regulation of the lysosomal receptor LAMP2A. This novel 
NRF2/LAMP2A axis may have important implications in the physiological response to stress 
and, consequently, be of interest for human pathology. In fact, data mining of The Cancer 
Genome Atlas showed a positive correlation between NRF2 an LAMP2 expression in gliomas 
and glioblastomas. 
Overall, this thesis describes a novel role of NRF2 in the regulation of 
macroautophagy and CMA, suggesting a new strategy to combat proteinopathies. 
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 Las células controlan la calidad del proteoma mediante una compleja red que integra 
diversos mecanismos, incluida la degradación de proteínas mediante autofagia. La regulación 
de este proceso a través de vías de señalización ha sido ampliamente estudiada, pero su 
control transcripcional es aún poco conocido. Debido a que esta vía de degradación tiene un 
papel citoprotector fundamental, especialmente en condiciones de estrés, en esta tesis hemos 
analizado la regulación de la autofagia por el factor de transcripción NRF2 (Nuclear factor 
(erythroid-derived 2)-like 2), considerado un regulador maestro de la homeostasis celular. 
NRF2 controla la expresión de una extensa batería de genes citoprotectores con un importante 
impacto en respuestas fisiológicas como la inflamación, la senescencia o el metabolismo. Sin 
embargo, su papel en proteostasis está aún comenzando a comprenderse.  
 Por todo ello, hemos centrado nuestro estudio en la regulación transcripcional de dos 
tipos de autofagia, la macroautofagia y la autofagia mediada por chaperonas (CMA). Hemos 
identificado elementos de respuesta a NRF2, llamados elementos de respuesta antioxidante 
(ARE), en la región promotora de 9 genes involucrados en diferentes pasos de la 
macroautofagia y la CMA. En consecuencia, mostramos que la manipulación genética y 
farmacológica de NRF2 resulta en la modulación de la expresión génica y la actividad de la 
autofagia. 
El papel del factor de transcripción NRF2 en la regulación de la macroautofagia podría 
ser importante en condiciones de estrés, incluido el estrés proteotóxico. Para analizar la 
relevancia funcional de NRF2 en proteinopatía, hemos generado un nuevo modelo animal de 
la Enfermedad de Alzheimer (EA) que reproduce la amiloidopatía y tauopatía en presencia o 
ausencia de NRF2. La deficiencia en NRF2 agrava algunos eventos característicos de la EA, 
como el estrés oxidativo e inflamatorio crónico de bajo grado, así como la proteinopatía 
debido, al menos en parte, a una desregulación de la macroautofagia. Además, nuestros 
resultados reflejan una correlación positiva entre NRF2 y marcadores de macroautofagia en 
muestras de EA. 
Hemos establecido también un papel de NRF2 en la regulación basal e inducible de la 
CMA, basado en la regulación transcripcional del receptor lisosomal LAMP2A. Este nuevo 
eje NRF2/LAMP2A podría tener implicaciones relevantes para patologías humanas. De 
hecho, el análisis de datos obtenidos de The Cancer Genome Atlas mostró una correlación 
positiva en la expresión de NRF2 y LAMP2 en gliomas y glioblastomas. 
Con todo ello, esta tesis describe un nuevo papel de NRF2 en la regulación de la 
macroautofagia y la CMA, sugiriendo una nueva diana para combatir proteinopatías. 
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AMPK  AMP-activated protein kinase 
Aox1   Murine gene encoding Aldehyde oxidase 1 
APP   Amyloid beta precursor protein 
ARE   Antioxidant response element 
ATG5   Autophagy related 5 
ATG5   Human gene encoding ATG5 
Atg5   Murine gene encoding ATG5 
ATG7   Autophagy related 7 
ATG7   Human gene encoding ATG7 
Atg7   Murine gene encoding ATG7 
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H2O2   Hydrogen peroxide 
HSC70  Heat shock protein family A (Hsp70) member 8 
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LAMP2A  Human gene encoding LAMP2A 
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NQO1   Human gene encoding NQO1 
Nqo1   Murine gene encoding NQO1 
NRF2   Nuclear factor (erythroid-derived 2)-like 2 
p62   Sequestosome 1 
PBS   Phosphate saline buffer 
PE   Phosphatidyl ethanolamine 
PFA   Paraformaldehyde 
PI   Protease inhibitors 
PI3P   Phosphatidylinositol(3,4,5)triphosphate 
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PI3K   Phosphatidylinositol 3 kinase 
PMSF   Phenylmethylsulfonyl fluoride 
PQ   Paraquat  
PSSM   Position-specific scoring matrix 
Rapa   Rapamycin 
RBX1   RING-box protein 1 
qRT-PCR  Quantitative real-time polymerase chain reaction 
RNAse A  Ribonuclease A 
ROS   Reactive oxygen species 
SEM   Standard error of the mean 
SD   Serum-deprived 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrilamide gel electrophoresis 
SFN   Sulforaphane 
SQSTM1  Human gene encoding p62 
Sqstm1  Murine gene encoding p62 
SS   Sarkosyl-soluble 
SI   Sarkosyl-insoluble 
shRNA  Short hairpin RNA 
TAU   Microtubule-associated protein TAU 
TBP   TATA box binding protein 
TFEB   Transcription factor EB 
ULK1   Unc-51 like autophagy activating kinase 1 
ULK1   Human gene encoding ULK1 
Ulk1   Murine gene encoding ULK1 
VEH   Vehicle 
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1. The transcription factor NRF2 
 
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a basic-leucine-zipper (bZIP) 
protein that belongs to the cap ‘n’ collar (CNC) family of transcription factors and is 
considered nowadays the master regulator of cellular homeostasis. 
 NRF2 was first identified in 1994 by Moi and co-workers using a tandem repeat of 
the consensus sequence for the transcription factors AP1 (activator protein 1) and NF-E2 
(nuclear factor-erythroid 2) in the β-globin gene 1. This sequence was similar to the cis-acting 
elements originally recognized in the promoter regions of the murine and rat genes coding for 
GSTYa (glutathione S-transferase) and NQO1 (NAD(P)H:quinone oxidoreductase) and is 
responsible for the induction of these genes by electrophiles 
2, 3. The consensus sequence 5’-
TGA
G
/CNNNGC-3’ was then confirmed to be conserved in a number of antioxidant genes, 
including Hmox1 (heme oxygenase 1), Gclc (glutamate-cysteine ligase catalytic subunit), 
Gclm (glutamate-cysteine ligase modifier subunit) or Gpx1 (glutathione peroxidase), and 
received the name of electrophilic/stress response element (EpRE/StRE), now widely known 
as antioxidant response element (ARE) 
4
. Venugopal et al connected NRF2 to ARE-driven 
gene expression in vitro 
5
, and subsequent studies in Nrf2-knockout mice confirmed NRF2-
dependent regulation of ARE-containing genes in vivo 
6-8
.  
NRF2 binds the ARE motif as a heterodimer with sMAF (small musculoaponeurotic 
fibrosarcoma) proteins (MAFF, MAFG, and MAFK). These proteins contain a bZIP domain 
but lack a transactivation domain, making heterodimerization with CNC transcription factors 
essential to regulate gene expression 
9
. It is believed that sMAF are responsible for the high-
affinity binding of the heterodimer to the ARE by preferentially recognizing the conserved 
GC residues 
10-12
. The bZIP transcription factor BACH1 (BTB and CNC homolog 1) can also 
bind sMAF, competing with NRF2 and repressing Hmox1 expression 
13
. 
 
1.1. Structure of the transcription factor NRF2 
 
NRF2 contains between 586 and 695 aminoacids depending on the species. This 
modular protein is composed by seven NRF2-ECH homology (Neh) domains. As shown in 
Fig. 1, the Neh1 domain comprises the CNC-bZIP region that dimerizes with sMAF proteins 
and binds DNA
14
. The Neh2 domain negatively controls NRF2 because, through its DLG and 
ETGE motifs, allows binding to the repressor KEAP1 (Kelch-like ECH associated protein 1) 
15, 16
. The C-terminal Neh3 region of NRF2 binds the transcriptional co-activator CHD6 
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(Chromo-ATPase/helicase DNA-binding protein 6) 
17
. The Neh4 and Neh5 regions represent 
transactivation domains that bind to CBP (cAMP response element-binding protein -CREB- 
binding protein) and/or RAC3 (Receptor-associated coactivator 3) 
18, 19
. The Neh6 domain 
negatively controls NRF2 because it is recognized, through the phosphorylated DSGIS and 
DSAPGS motifs, by the E3-ligase adaptor β-TrCP (β-transducin repeat-containing protein) 20-
22
. Finally, the Neh7 domain mediates repression of NRF2 by the RXRα (retinoid X receptor 
alpha) through a physical association between these two proteins 
23
. 
 
1.2.  NRF2 regulation 
 
1.2.1. KEAP1 regulation 
 
The activity of the transcription factor NRF2 is tightly controlled. Under homeostatic 
conditions, NRF2 is maintained at low levels due to continuous proteasomal degradation.  
The view that the E3-ligase adaptor KEAP1 is a major repressor of NRF2 is supported 
by the observation that disruption of Keap1 in the mouse 
24
 or knockdown in human cells 
25
 is 
sufficient to increase the levels and activity of this transcription factor. The mechanism of 
KEAP1 regulation elegantly explains how NRF2 levels adjust to oxidant fluctuations (Fig. 2). 
KEAP1 is a dimeric BTB-Kelch protein, and each of its two subunits contains a binding site 
for NRF2. The proposed ‘hinge-and-latch’ 26, also called ‘two tethering site’16, model 
proposes that under basal conditions newly synthesized NRF2 binds first one KEAP1 subunit 
 
 
 
 
Figure 1. Protein structure of the transcription factor NRF2. NRF2 contains seven conserved domains called 
Neh1-Neh7. Neh1 serves as the DNA binding and heterodimerization domain with sMAF proteins. Neh2 and 
Neh6 target NRF2 to degradation by the proteasome. The transactivation activity of NRF2 lies in Neh4 and Neh5. 
Neh3 was reported to interact with the co-activator CHD6 and Neh7 to repress NRF2 activity through the RXRα. 
Aminoacid numbers are indicated and correspond to the human protein. 
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through the high-affinity 79-ETGE-82 motif to form an ‘open’ conformation that allows 
association between the other KEAP1 monomer and the low-affinity 29-DLG-31 motif in 
NRF2 to form the ‘closed’ conformation. KEAP1 then functions as a bridge between NRF2 
and the E3 ligase complex formed by CUL3 (Cullin 3) and RBX1 (RING-box protein 1). This 
complex is responsible for NRF2 ubiquitination in a series of conserved Lys residues located 
between the 79-ETGE-82 and 29-DLG-31 motifs, allowing NRF2 proteasomal degradation. 
However, reactive oxygen species (ROS), electrophiles or xenobiotics can promote the 
formation of adducts or oxidation of sulfhydryl groups in some of the 25 Cys residues of 
KEAP1 (Cys-151, Cys-273 and Cys-288 are the most sensitive to thiol reactivity), promoting 
a conformational change that prevents NRF2 ubiquitination and subsequent proteasomal 
degradation. It was first proposed that this structural perturbation in KEAP1 would impair 
binding to the DLG sequence, necessary for maintaining NRF2 in a constrained position to be 
properly ubiquitinated. More recently, single-cell imaging showed that some inducers favor 
the ‘closed’ conformation of the KEAP1-NRF2 complex instead, but alter the stable 
positioning of the KEAP1 domains and thus induce an improper geometry for ubiquitination. 
In both cases, the unproductive KEAP1/NRF2 complex allows newly synthetized NRF2 to 
escape KEAP1-dependent degradation, accumulate in the nucleus and activate ARE-
containing genes 
15, 16, 26-30
. 
 
  
1.2.2. NRF2 regulation by GSK3/β-TrCP  
 
Our group described an alternative mechanism of regulation of NRF2 stability 
mediated by the phosphorylation by the Ser/Thr kinase GSK3β (glycogen synthase kinase 
3β). This kinase phosphorylates Ser-344 and Ser-347 in the 343-DSGIS-347 motif located in 
the Neh6 domain of NRF2. This phosphorylation creates a degron for the E3-ligase adaptor β-
TrCP that presents NRF2 to a CUL1 (Cullin 1)/RBX1 complex, leading to an alternative 
pathway for ubiquitin-dependent proteasomal degradation of NRF2. 
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Figure 2. KEAP1 is a major repressor of NRF2. A, In homeostatic conditions, KEAP1 targets NRF2 to 
ubiquitination through the CUL3-RBX1 ubiquitin ligase complex. As a consequence, NRF2 is directed to 
proteasomal degradation and, hence, maintained at low levels. B, Upon exposure to ROS, electrophiles or 
xenobiotics, Cys sensors in KEAP1 promote a conformational change that prevents NRF2 ubiquitination and 
proteasomal degradation. In this context, newly synthesized NRF2 accumulates, translocates into the nucleus and 
leads to the transcriptional activation of ARE-driven genes. 
 
The GSK3β/β-TrCP axis contributes to NRF2 repression under homeostatic 
conditions, as inhibition of GSK3β by highly selective drugs or siRNAs against GSK3 
isoforms results in increased NRF2 protein levels. Moreover, stabilization of NRF2 following 
GSK3β inhibition occurred in KEAP1-deficient mouse embryo fibroblasts and in an 
ectopically expressed NRF2 deletion mutant lacking the critical 79-ETGE-82
 
residues for 
high-affinity binding to KEAP1 (NRF2-ΔETGE), suggesting that GSK3β/β-TrCP regulation 
of NRF2 is independent on KEAP1 
20, 21
. Another β-TrCP recognition site was described 
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within the Neh6 domain (382-DSAPGS-387). Deletion of either binding sites in NRF2 
decreased β-TrCP-mediated ubiquitination of this transcription factor. However, while 
phosphorylation of the 343-DSGIS-347 site resulted in increased binding affinity, this was not 
the case for the 382-DSAPGS-387 motif, suggesting the absence of a functional GSK3β 
phosphorylation site 
22
. While the KEAP1-mediated regulation explains how NRF2 levels 
adjust to oxidant fluctuations, GSK3β/β-TrCP regulation connects NRF2 with signaling 
responses. 
 
1.2.3. Other layers of regulation 
 
NRF2 is a highly acidic protein because of abundant Asp and Glu residues (pI 4.6). 
Moreover, 17% of its aminoacids are phosphorylable residues (Ser, Tyr and Thr). Indeed, 
different kinases besides GSK3β have been shown to phosphorylate and regulate NRF2. 
Several studies have shown that ROS or xenobiotics can activate the signaling pathways 
involving MAPKs (mitogen activated protein kinases), namely JNK (c-Jun N-terminal 
kinase), ERK1/2 (extracellular signal–regulated kinase) and p38, which are Ser/Thr kinases 
directed to Pro. Although NRF2 contains six conserved Ser-Pro pairs that may be 
phosphorylated by MAPKs, its contribution to NRF2 activity remains unclear and is most 
likely indirect 
31-35
. NRF2 can be phosphorylated by PERK (double-stranded RNA-activated 
protein kinase-like ER kinase), one of the three arms of the unfolded protein response (UPR). 
When unfolded proteins accumulate in the ER, PERK phosphorylates Ser-40 in NRF2, which 
was reported to allow NRF2 dissociation from KEAP1 and translocation to the nucleus 
36
. 
PKC (protein kinase C) 
37
, CK2 (casein kinase 2) 
38
, Fyn (tyrosine-protein kinase Fyn) 
39
 or 
HIPK2 (homeodomain-interacting protein kinase 2) 
40
 have also been reported to modulate 
NRF2 stability through phosphorylation. However, the relevance of these phosphorylation 
events has not been fully established and, in some cases, like Fyn-mediated NRF2 
phosphorylation, has been questioned 
41
. 
NRF2 is submitted to other layers of regulation. These include inhibition by 
microRNAs (miRNAs), such as miR153, miR27a, miR142-5p, and miR144
42
. Abundant 
miRNAs in aged tissues may be in part responsible for impaired NRF2 activity with age
43
. 
Activation by CBP/p300-induced acetylation 
44
 and repressive methylation of cytosine-
guanine (CG) islands within the NRF2 promoter 
45
 constitute additional mechanisms of NRF2 
regulation. 
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1.2.4. NRF2 inducers and pharmacological modulators 
 
The majority of known physiological or pharmacological NRF2 inducers are 
electrophilic molecules that covalently modify by oxidation or alkylation critical Cys residues 
present in the thiol-rich KEAP1 protein 
46, 47
. The list of endogenous and exogenous NRF2 
inducers is continuously growing. 
In this study, we have used the pro-oxidants paraquat (PQ) and hydrogen peroxide 
(H2O2) to increase NRF2 activity (Fig. 3). PQ (1,1-dimethyl-4,4-bipyrimidyl chloride), widely 
used as an herbicide, belongs to a broad class of redox cycling compounds and inhibits 
complex I of the mitochondrial respiratory chain, leading to the generation of O2
-
 and 
subsequently H2O2 
48
. H2O2 was shown to increase intramolecular and intermolecular disulfide 
linking in KEAP1 
49
. 
Pharmacological activation of NRF2 was addressed with sulforaphane (SFN) and 
dimethyl fumarate (DMF) (Fig. 3). SFN is an isothiocyanate produced from enzymatic 
cleavage of glucoraphanin, which is present in sprouts of broccoli, cabbage and other 
Brassicacea plants. Isothiocyanates are characterized by the –N=C=S group, in which the 
central electrophilic C reacts rapidly but reversibly with the thiol group of Cys-151 in KEAP1 
to give rise to an inactive dithiocarbamate 
29, 50, 51
. DMF, and its metabolite monomethyl 
fumarate (MMF), are Michael acceptors that also react with Cys-151
 
in KEAP1 
52
. DMF is to 
date the only Food and Drug Administration– and European Medicines Agency–approved 
drug registered as NRF2 activator and is employed to treat psoriasis and remitting relapsing 
multiple sclerosis. Although the main mechanism of NRF2 activation in all these cases is 
oxidative modification of KEAP1, other pathways may be involved as well, since redox 
sensitive proteins others than KEAP1 may be targeted. For instance, DMF activates the 
PI3K/AKT pathway, thereby inhibiting GSK3 
53
. Considering the lack of selectivity of 
electrophiles, a new strategy is now based on the development of small molecules that inhibit 
the interaction of KEAP1 with NRF2. At the time of working on this thesis, these inhibitors 
are still under development and have not been used. 
Despite the high abundance of NRF2 inducers, no specific NRF2 inhibitors are 
currently available. As shown in Fig. 3, we have used trigonelline for NRF2 pharmacological 
inhibition. This alkaloid present in coffee and fenugreek seed, has different pharmacological 
activities 
54
, including the improvement of chemotherapy in different models via NRF2  
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Figure 3. Chemical structure of NRF2 inducers and pharmacological inhibitors used in this study. 
 
inhibition 
55-58
. Although the exact mechanisms of NRF2 inhibition by trigonelline are still 
unknown, prevention of NRF2 nuclear import has been proposed 
55
. 
 
1.3.  Physiological function of NRF2 
 
For many years, NRF2 has been considered the master regulator of biotransformation 
and the cellular antioxidant response, as it controls the expression of genes that participate in 
phase I, II and III detoxification reactions (NQO1, GSTA1, ABCC1, etc.), glutathion (GCLC, 
GCLM, GPX1, etc.) and peroxiredoxin/thioredoxin metabolism (PRDX1, TXN1, TXNRD, 
etc.)
59
. However, nowadays we know that NRF2 controls the basal and stress-inducible 
expression of over 250 ARE-containing genes and the current view is that it represents a 
master regulator of cellular homeostasis (Fig. 4).  
The NRF2-directed transcriptional program allows the cell to adapt and survive under 
various stress conditions, not only oxidative stress. Cellular protection also requires 
alterations in metabolism and bioenergetics. In fact, it is becoming increasingly clear that 
NRF2 has a profound effect on mitochondrial function and intermediary metabolism, 
regulating the expression of genes implicated in NADPH production through the pentose 
phosphate pathway and malic enzyme as well as enzymes involved in fatty acid oxidation and 
iron metabolism (G6PD, ME1, HMOX1, FTH1, etc.)
59
.  
Moreover, the NRF2 transcriptional response acts as a brake for inflammation. On one 
hand, the antioxidant activity of many NRF2-regulated genes counteracts several pro-
inflammatory signals (i.e., NFκB pathway or migration and infiltration of immune cells) 60. 
On the other hand, NRF2 directly up-regulates the expression of some immunomodulatory 
genes, such as those coding for MARCO (macrophage receptor MARCO), CD36 (platelet 
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glycoprotein 4), IL17D (interleukin 17D) and LTB4DH (leukotriene B4 dehydrogenase)
60, 61
. 
More recently, NRF2 was shown to directly inhibit the expression of the pro-inflammatory 
cytokines IL6 (interleukin 6) and IL1β (interleukin 1 beta)62, 63.  
Finally, NRF2 activation may have an impact on proteostasis. Thus, NRF2 regulates 
the expression of genes involved in the metabolism of glutathione, critical for an adequate 
folding of proteins in the endoplasmic reticulum (ER) and specifically GPX8 (glutathione 
peroxidase 8), involved in the unfolded protein response (UPR). Moreover, NRF2 activation 
has been shown to induce a transient increase in the expression and activity of specific 
proteasome subunits, which may have an important role in the degradation of oxidized 
proteins
64-66
. More recently, NRF2 has been reported to control the expression of the 
autophagy cargo receptors p62/SQSTM1 (sequestosome 1) and NDP52/CALCOCO2 
(calcium-binding and coiled-coil domain-containing protein 2)
67, 68
, which will be further 
addressed in the following sections. 
 
2. Autophagy  
 
Protein homeostasis, proteostasis, necessarily depends on the continuous maintenance 
and renewal of the whole proteome. For this purpose, cells have developed a wide quality 
check network that assures adequate protein synthesis, folding, conformational maintenance 
and degradation of disused or defective proteins. Two main cellular degradation systems are 
found in mammals: the ubiquitin-proteasome system (UPS), which degrades individual short-
lived proteins, and the autophagy-lysosomal system, which is able to degrade single long-
lived proteins, aggregates and whole organelles
69
.  
 
 
 
 
Figure 4. NRF2 as a master regulator of cell 
homeostasis. NRF2/MAF heterodimers bind the 
enhancer sequence termed antioxidant response 
element (ARE) in the regulatory regions of over 
250 genes implicated in different homeostatic 
processes.  
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The term “autophagy”, derived from the Greek term for “self-eating”, embraces all the 
processes by which cellular components (proteins, organelles, aggregates and intracellular 
pathogens) are delivered to lysosomes for degradation. Lysosomes contain more than 60 acid 
hydrolases which degrade almost every type of macromolecule: nucleases, proteases, lipases, 
glycosidases
70
. The resulting products are re-cycled into the cytoplasm by specific 
transporters located at the lysosomal membrane
71, 72
. 
 
2.1.  Types of autophagy in mammals 
 
Several distinctive types of autophagy co-exist in mammals according to the way in 
which cargoes are delivered to lysosomes: a) macroautophagy, in which portions of the 
cytosol are engulfed by a growing double membrane that originates a vesicle that eventually 
fuses with the lysosome; b) chaperone mediated autophagy (CMA), which allows proteins 
bearing a certain motif to specifically be delivered to lysosomes or c) microautophagy, a 
process whereby the lysosome itself swallows up small components of the cytoplasm by 
inward invagination of the lysosomal membrane. Macroautophagy and CMA are the best 
described types of autophagy in mammals and constitute the focus of this study. 
 
2.1.1. Macroautophagy 
 
Macroautophagy (often referred to as simply ‘autophagy’) was first described in the 
late 60s by Christian De Duve, who identified intracellular organelles with a double 
membrane and a lumen similar to the cytoplasm
73
. In fact, macroautophagy is a process 
whereby portions of the cytoplasm are sequestered by the expansion and closure of 
membranous cisterna (termed “phagophores”), to produce double- or multiple-membraned 
vesicles called “autophagosomes,” which eventually fuse with lysosomes for degradation of 
the sequestered content.  
 
a. Steps in macroautophagy 
 
It was not until the identification of the Atg genes in yeast that the molecular players 
implicated in macroautophagy have started to be unveiled 
74
. Indeed, this process is 
evolutionarily conserved in eukaryotes 
75
 and many autophagy-related proteins (ATGs) 
orthologues have also been identified in mammals 
76
.  
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Macroautophagy can be non-selective, implying in bulk sequestration of random 
portions of the cytosol; or selective, when specific substrates are recognized and degraded. 
According to the specific material to be degraded, macroautophagy can be named as 
xenophagy (when cargoes for degradation are pathogens), mitophagy (mitochondria), 
lipophagy (lipid droplets), etc. Although cell-specific or context-dependent regulatory 
mechanisms may direct the process, there are some common players involved in the 
autophagosome formation, which are represented in Fig.5. 
Initiation relies on the ULK complex (ULK1/ULK2-ATG13-FIP200-ATG10l), which 
is activated by different signals, enabling phagophore nucleation and assembly. The exact 
origin of the nucleation membrane is still a matter of debate, but some reports suggest that it 
derives from the plasma membrane, the outer mitochondrial membrane or the ER membrane 
77
. ULK1/2 kinase is capable of auto-phosphorylating itself and also ATG13 and FIP200. The 
activated ULK complex recruits a class III phosphatidylinositol-3 kinase complex (PI3K-
III/VPS34-BECLIN1-VPS15-ATG14 or UVRAG) which locally produces 
phosphatidylinositol-3-phosphate (PI3P) in the phagophore membrane in order to recruit other 
proteins to the nucleation site, including WIPIs (WD repeat protein interacting with 
phosphoinositides) or ATG2. The phagophore expansion step is associated with two 
ubiquitination-like reactions. First, ATG7 acts as an E1 ubiquitin-activating enzyme and 
ATG10 as an E2 ubiquitin conjugating enzyme, enabling ATG12 conjugation to ATG5. 
Second, ATG12-ATG5 complexes interact non-covalently with ATG16L. This complex acts 
as an E3-ligase, facilitating the second ubiquitin-like reaction, where LC3 (microtubule-
associated protein 1A/1B light chain 3) and GABARAP (γ-aminobutyric acid receptor-
associated protein) are conjugated to phosphatidylethanolamine (PE) by ATG7 (E1-like) and 
ATG3 (E2-like) to form LC3-II and GABARAPs-II anchored to the phagophore membrane. 
In selective autophagy, different autophagy cargo receptors, such as p62 and NDP52, interact 
with ubiquitin-labelled proteins as well as with LC3s and GABARAPs, enabling specific 
substrates to be engulfed by autophagosomes. ATG12-ATG5 complexes dissociate from the 
autophagosomal membrane once autophagosome formation is complete, while ATG4 is 
necessary for the de-lipidation and recycling of LC3-II and GABARAPs-II, as well as for the 
initial proteolytic activation of newly expressed pro-LC3 and pro-GABARAP proteins. 
Autophagosomes are delivered, along microtubules, to lysosomes, where fusion subsequently 
occurs mediated by SNARE (soluble NSF attachment protein receptor) and ESCRT 
(endosomal sorting complex required for transport) complexes. Once inside lysosomes, the 
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material is degraded by acid hydrolases and the resulting breakdown products are released 
through permeases for recycling at the cytosol 
78, 79
. 
 
b. Regulation of macroautophagy 
 
Provided that it is a catabolic process, macroautophagy must be tightly regulated so 
that it is induced only when necessary. One of the most evolutionarily conserved functions of 
macroautophagy is adaptation to starvation through the degradation of proteins and other 
macromolecules 
80-82
 and subsequent release of their primary constituents to the cytosol, 
which can be used for the synthesis of specific proteins needed under these conditions or 
employed for energy production. As shown in Fig. 5, two main regulators participate in the 
up-regulation of macroautophagy upon nutritional stress: mechanistic target of rapamycin 
kinase (mTOR) and AMP-activated protein kinase (AMPK) 
83
. 
mTOR is a highly conserved Ser/Thr kinase that integrates signals from different 
stimuli, including aminoacids, energy levels, oxygen or growth factors. During nutrient-rich 
conditions, mTOR phosphorylates and inhibits ULK1/2 and ATG13, thereby repressing 
autophagy initiation. mTOR inhibition (upon starvation or rapamycin treatment, for instance) 
results in mTOR removal from the ULK complex, allowing ULK1/2 to autophosphorylate 
and phosphorylate subsequent substrates 
84, 85
. AMPK directly senses increased levels of 
ADP/AMP, indicative of energetic stress. This Ser/Thr kinase is an essential activator of 
autophagy by, at least, three different mechanisms: mTOR inhibition 
86, 87
, direct 
phosphorylation and activation of ULK1
85
 and activation of VPS34 complexes 
88, 89
. 
Additional stress conditions, such as hypoxia, mitochondrial dysfunction, genomic 
damage, ER stress or oxidative stress also activate macroautophagy via different signaling 
pathways in order to eliminate damaged proteins or organelles
90
. Thus, ROS have been shown 
to affect upstream regulators and macroautophagy core components, generally resulting in its 
up-regulation 
91, 92
. An elegant example of the essential role of redox signaling in 
macroautophagy is provided by the generation of ROS upon nutrient starvation. ROS can 
oxidize key Cys residues in AMPK, generating S-glutathionylated derivatives with increased 
kinase activity 
93, 94
. Mitochondria-generated ROS were reported to induce autophagy via  
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Figure 5. Schematic representation of the different steps in macroautophagy and main protein complexes 
implicated: 1) initiation (ULK initiation complex); 2) membrane nucleation and phagophore formation (PI3K 
complex); 3) autophagosome elongation and 4) autophagosome closure (ATG5-ATG12 and LC3 conjugation 
systems); 5) lysosome fusion, and 6) degradation.  
 
AMPK, and this was prevented by overexpression of the antioxidant enzyme manganese-
superoxide dismutase 2, pre-treatment with a ROS scavenger or AMPK inhibition
95
. 
Moreover, the protease ATG4 contains reactive cysteines prone to oxidation that transiently 
inhibit its de-lipidation activity. As explained before, ATG4 has the dual role of; first, 
cleaving pro-LC3 and pro-GABARAPs at the C-terminus so that they can be conjugated to 
PE and, second, de-lipidating LC3 and GABARAPs to be re-cycled once the process is 
completed. It was proposed that starvation-induced H2O2 in the vicinity of the place of 
autophagosome formation would locally inactivate the de-lipidation activity of ATG4 
maintaining its protease activity and allowing autophagosome formation. As the 
autophagosome is trafficked to lysosomes, low H2O2 concentrations would allow ATG4 
reactivation to de-lipidate LC3 and GABARAPs 
96
. On the other hand, oxidation of catalytic 
thiols in ATG3 and ATG7 was shown to prevent LC3 lipidation, inhibiting starvation-induced 
autophagy 
97
. Therefore, the impact of redox signaling in macroautophagy may depend on the 
type, localization and levels of ROS. 
Recent studies have directly connected autophagy with the KEAP1/NRF2 axis (Fig. 
6). A KEAP1 interacting region (KIR) was identified in the autophagy cargo receptor p62, 
which allowed binding to KEAP1 in the same basic surface pocket and with a binding affinity 
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similar to the 79-ETGE-82
 
motif in NRF2, suggesting competition between p62 and NRF2 
67, 
98-101
. In fact, p62 overexpression led to reduced NRF2 ubiquitination and subsequent 
stabilization as well as induction of its target genes
98
, whereas silencing of p62 increased 
KEAP1 stability in parallel with a decrease in NRF2 levels 
101
. The phosphorylation of Ser-
351 in the KIR motif in p62 (349-DPSTGE-354) was shown to increase its affinity for 
KEAP1, competing with NRF2 binding and allowing its accumulation and transcriptional 
activation of its target genes 
102
. The kinases mTORC1 (mammalian target of rapamycin 
complex 1) and TAK1 (TGF-β-activated kinase 1) involved in nutrient sensing and 
inflammation, respectively, were suggested to participate in this phosphorylation 
102, 103
. The 
observations that the levels of KEAP1 were increased in Atg7-knockout mice and reduced 
upon starvation 
104
, led to the suggestion that KEAP1 is targeted for degradation by 
autophagy. Therefore, p62 accumulation (due to, for instance, autophagy impairment) and/or 
phosphorylation would result in KEAP1 sequestration and degradation, favoring NRF2 
transactivation of its target genes. Importantly, p62 contains a functional ARE in its gene 
promoter 
67
, creating a positive feedback loop. It is possible that this non-canonical 
mechanism of NRF2 induction would result in prolonged NRF2 signaling relative to the 
canonical KEAP1 pathway, activating the NRF2 transcriptional network in order to restore 
cell homeostasis. 
 
 
Figure 6. NRF2 levels are regulated by the autophagy adaptor protein p62. p62 competes with NRF2 for binding 
to KEAP1 through its STGE motif. Phosphorylation of the Ser in this KEAP1 interacting region (KIR) of p62 
increases its binding affinity for KEAP1. Therefore, increased and/or phosphorylated p62 displaces NRF2 and 
enables the transcriptional activation of its target genes, including SQSTM1 (coding for p62) in a positive 
feedback loop. 
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In addition to p62, NRF2 also controls the expression of the cargo recognition adaptor 
NDP52. Five putative AREs were found in the gene coding for NDP52, called CALCOCO2, 
and three of them were identified with different mutant constructs and ChIP assays as 
indispensable for NRF2-mediated transcription 
68
.  
Transcriptional control of macroautophagy gene expression is increasingly emerging 
as a fundamental regulatory mechanism. In fact, whereas most studies on macroautophagy 
regulation have focused on post-translational modifications and protein-protein interactions, 
transcriptional control of autophagy may represent an enduring regulation essential for cell 
type- and stimulus-dependent responses. In this regard, the transcription factor TFEB 
(transcription factor EB) is considered the master regulator of lysosomal biogenesis and has 
an essential role in the transcriptional response to starvation 
105
. When nutrients are present, 
mTOR inhibits TFEB at the lysosomal membrane. However, upon starvation or other types of 
lysosomal stress, mTOR is released from the lysosome, being unable to inhibit TFEB, which 
progressively accumulates in the nucleus 
106
. TFEB controls the expression of genes such as 
Lamp1, Atg9b or Sqstm1 
107, 108
. Members of the FOXO family of transcription factors have 
also been reported to control the expression of several autophagy-related genes, including 
Atg4, Atg12 or Ulk1 in muscle 
109-111
.  
 Considering the recent advances in understanding the impact of NRF2 in 
macroautophagy as well as the important roles of both processes in the response to oxidative 
stress, one of the main goals of this work was to analyze a mechanistic link between NRF2 
and macroautophagy gene expression. 
 
2.1.2. Chaperone mediated autophagy 
 
Chaperone mediated autophagy (CMA) is a selective degradative process that 
contributes to the maintenance of proteostasis in mammals. In this case, proteins with a 
specific motif are recognized in the cytosol, delivered to lysosomes and individually 
translocated through a lysosomal receptor for degradation. 
 
a. Steps in CMA 
 
The concept of selectivity for lysosomal degradation first came from the observation 
that starvation in animals or serum removal in cultured cells for more than 8-10 h accelerated 
the lysosomal degradation of specific proteins. This led to the identification of a common 
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targeting motif and a chaperone recognizing it 
112, 113
. Thus, soluble cytosolic proteins bearing 
a KFERQ-like motif are recognized by HSC70 (heat shock cognate protein of 70 kDa)
114, 115
. 
The genuine KFERQ motif is present in ribonuclease A (RNAse A), the first protein 
identified as a CMA substrate 
112, 116
. However, HSC70 can recognize KFERQ-like sequences 
as far as they follow this rule: flanking Q (either at the beginning or at the end of the 
sequence); up to two of the allowed hydrophobic residues (I, F, L or V) or two of the allowed 
positive residues (R or K), and only one negative charge provided either by E or D.  
HSC70 delivers cargoes to the lysosomal surface, where they interact with LAMP2A 
(lysosomal associated membrane protein type 2A)
117
 (Fig. 7). In contrast to the highly 
abundant cytosolic HSC70, levels of LAMP2A at the lysosomal membrane are limiting for 
CMA and, hence, subject to tight regulation 
118
. Binding of substrates to the cytosolic tail of 
LAMP2A induces the organization of this single span membrane protein into a multimeric 
complex that facilitates substrate translocation in an unfolded conformation 
119
. Protein 
unfolding is thought to occur after binding to LAMP2A, but prior to translocation 
120
. Then, 
proteins are pulled inside lysosomes by an intra-luminal HSC70 form 
121
 and eventually 
degraded by lysosomal proteases. Once the substrate protein crosses the lysosomal 
membrane, the translocation complex disassembles into monomeric forms of LAMP2A to 
allow a new cycle of substrate binding and translocation 
119
. 
 
b. Regulation of CMA 
 
Although basal CMA activity can be detected in most cell types 
122
, this process is 
maximally activated in response to stressors such as starvation 
123
, oxidative stress 
124
, 
hypoxia 
125
 or genotoxic stress 
126
. Activation of CMA is associated with increased levels of 
LAMP2A and its multimerization to form membrane translocation complexes, lysosomal 
enrichment in HSC70 and relocation of lysosomes to the perinuclear region 
123, 124, 127
.  
LAMP2A is one of the three proteins that originate from alternative splicing of the 
LAMP2 gene. All LAMP2A, LAMP2B and LAMP2C isoforms share identical luminal 
regions but differ in their cytosolic and transmembrane tails 
128
. Moreover, they are expressed 
in a tissue-specific manner, pointing to different cellular functions and a cell-specific yet 
unknown regulation of differential splicing 
129-131
. Nevertheless, LAMP2A is the only 
LAMP2 variant required for CMA 
117, 132
. In fact, the availability of LAMP2A at the 
lysosomal membrane is the limiting step of CMA, as knockdown or overexpression of 
LAMP2A results in a proportional decrease or increase in CMA, respectively 
117, 132
. 
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Figure 7. Schematic representation of the different steps in CMA. Proteins bearing a KFERQ-like motif are 
recognized by HSC70 and delivered to lysosomes, where they interact with the lysosomal receptor LAMP2A. 
LAMP2A multimerizes and the unfolded protein is translocated inside lysosomes assisted by luminal HSC70. 
The substrate protein is degraded inside lysosomes and LAMP2A multimer is disassembled. 
 
Levels of LAMP2A at the lysosomal membrane are tightly regulated by lysosomal 
degradation of this receptor and a dynamic equilibrium between the matrix and the membrane 
of the lysosome. Therefore, activation of CMA during starvation implies reduced LAMP2A 
degradation as well as re-location of internalized LAMP2A to the lysosomal membrane 
118
. 
Furthermore, LAMP2A organizes inside and outside lipid-enriched microdomains in the 
lysosomal membrane, being active outside them and susceptible to proteolytic cleavage and 
degradation while located inside 
133
.  
More recently, a signaling mechanism involving GFAP (glial fibrilar acidic protein), 
mTORC2 (mammalian target of rapamycin complex 2) and PHLPP1 (PH domain leucine-rich 
repeat-containing protein phosphatase 1) was described to regulate CMA. GFAP favors the 
stabilization of the LAMP2A multimeric complex at the lysosomal membrane, allowing 
substrate translocation and degradation. Under basal conditions, however, mTORC2 
phosphorylated- lysosome-associated AKT1 (RAC-alpha serine/threonine-protein kinase) 
phosphorylates GFAP. Phosphorylated GFAP displays reduced binding affinity for LAMP2A, 
not contributing to its stabilization. However, starvation leads to the recruitment of the 
phosphatase PHLPP1 to lysosomes. This phosphatase inactivates AKT1 and the resulting de-
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phosphorylated GFAP can now contribute to the stabilization of the LAMP2A multimer under 
these conditions 
134
. 
Macroautophagy is early activated upon starvation, reaches its maximum at about 6 h 
and then gradually declines 
132
. Meanwhile, CMA increases after 8-10 h of starvation and 
remains activated even for days 
123
. This might represent a switch to a more selective 
proteolytic mechanism in order to avoid degrading proteins and structures essential for cell 
survival, while at the same time degrading proteins of lesser importance in such conditions 
(such as glycolytic enzymes 
135
 or catalytic subunits of the 20S proteasome 
136
). 
CMA is also induced by several pro-oxidant factors 
132, 137
, indicating its essential role 
in the cellular response to stress. Oxidized proteins are more easily degraded by CMA 
124
, 
although the exact mechanisms have not been fully clarified. This supports the possibility of 
regulating CMA at the level of the KFERQ-like motifs. On one hand, these motifs can be 
hidden and become accessible for HSC70 at some point: motifs in the core of the protein will 
only be exposed when unfolding (caused by oxidation for instance); motifs placed in regions 
of protein/protein interaction will become accessible when the protein is no longer part of a 
complex; motifs close to an enzyme catalytic site can only become accessible in the absence 
of substrate 
138
. On the other hand, post-translational modifications can complete or create a 
KFERQ-like motif.  
In contrast to nutritional stress, CMA induction upon oxidative stress may result from 
transcriptional up-regulation of Lamp2a 
124
. In the case of T cell activation, the generation of 
ROS results in NFAT (nuclear factor of activated T-cells)-mediated Lamp2a transcription 
139
. 
However, a generic mechanism that might regulate the expression of Lamp2a under these and 
other circumstances remains unknown. Consequently, one aim of the present study was to 
analyze a potential connection between the transcription factor NRF2 and CMA. 
 
3. Dysfunctional redoxtasis and proteostasis in chronic diseases 
 
NRF2 and autophagy play a crucial role in cell homeostasis, as already described. 
Consequently, dysregulation of these pathways is intimately related to many chronic diseases, 
including neurodegenerative diseases such as Alzheimer’s Disease or cancer.  
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3.1.  Alzheimer’s disease 
  
Alzheimer’s disease (AD) is a proteinopathy characterized by the accumulation of 
insoluble aggregates of amyloid β (Aβ) peptides along with other components in senile 
plaques, as well as the presence of neurofibrillary tangles of hyperphosphorylated TAU 
(microtubule-associated protein TAU). At the molecular level, AD is characterized by 
mitochondrial dysfunction, oxidative stress, low-grade chronic neuroinflammation and a loss 
of proteostasis. However, the causal relationship between these molecular events remains 
elusive. 
The brain is highly susceptible to oxidative stress due to reliance in oxidative 
metabolism for energy and lower levels of antioxidant systems compared to other organs  
140
. 
In fact, oxidative damage has been shown to increase in the brain with age 
92
, and even further 
in subjects with conditions ranging from mild cognitive impairment to advanced AD 
141, 142
. 
This imbalance in the brain redox state likely represents an early marker of AD prior to the 
appearance of the histopathological hallmarks 
143, 144
 and probably contributes to 
mitochondrial dysfunction 
145, 146
, neuroinflammation 
147
 and the aggregation of damaged and 
misfolded proteins 
148-150
. 
The Aβ peptides that build up senile plaques are originated from APP (amyloid 
precursor protein). Under physiological conditions, APP is mostly cleaved by α- and γ-
secretases, resulting in a secreted form of APP and C-terminal fragments. Although the exact 
physiological role of APP and its products remains unknown, APP appears to be important for 
neuronal and synaptic function 
151
. In AD, an imbalance towards cleavage of APP by β- and 
γ-secretases results in the generation of Aβ peptides, which vary in length and are considered 
toxic 
152
.  
TAU normally binds to and stabilizes the microtubules. In AD, however, different 
post-translational modifications of TAU, including hyperphosphorylation, alter TAU binding 
to microtubules 
153
. In this regard, hyperactivation of GSK3β has been proposed to participate 
in the abnormal phosphorylation of TAU in AD, resulting in its aggregation, formation of 
neurofibrillary tangles and interruption of axonal transport 
154
.  
Autophagy impairment is intimately connected to the loss of proteostasis in AD. In 
fact, autophagy ablation in mice is sufficient to produce neurodegeneration 
155-157
. Overall 
reduced rates of protein degradation with age were first observed almost three decades ago 
158
 
and the levels of core macroautophagy and CMA proteins in various tissues were reported to 
be reduced with age in distinct organisms 
159-162
. Thus, excessive accumulation of 
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autophagosomes and autophagic vacuoles (AVs), together with p62 and ubiquitinated 
proteins, has been shown in the brains of AD patients 
163, 164
. This is likely due to incomplete 
autophagosome-lysosome fusion and digestion, which may favor the accumulation of 
aggregated proteins and damaged organelles, and lead to the abnormal production of ROS. 
Overall, AD is considered a multifactorial process in which genetic and environmental 
factors along with increased susceptibility to stress with age influence each other, resulting in 
the loss of neuronal and brain homeostasis. Given NRF2 wide cytoprotective functions, it is 
possible that a single pharmacological hit in NRF2 might mitigate the effect of the main 
culprits of AD, including oxidative, inflammatory and proteotoxic stress. In fact, some 
evidence support a key role of NRF2 in AD. On the one hand, NRF2 activity declines with 
age 
165, 166
 and GSK3β hyperactivation in AD would presumably decrease NRF2 levels. 
Moreover, NRF2 deficiency has been shown to aggravate and, conversely, NRF2 activation to 
ameliorate the phenotype of mouse models of AD 
66
. Interestingly, one haplotype allele in the 
NFE2L2 gene promoter, encoding NRF2, was associated with an earlier onset of AD, 
implying that common variants of the NFE2L2 gene might affect AD progression 
167
. A better 
understanding of the impact of NRF2 in AD is necessary in order to eventually take 
advantage of its therapeutic potential. 
 
3.2.  Cancer 
 
The term ‘cancer’ refers to a group of disorders caused by genetic alterations that 
affect cellular signaling pathways and lead to abnormal cell proliferation and tumor 
generation. The evolution of a normal cell to a malignant one involves the activation of genes 
stimulating proliferation or protection against cell death (called oncogenes) and the 
inactivation of genes which would normally inhibit proliferation (called tumor suppressor 
genes). 
NRF2 seems to have context-dependent and even opposing effects on tumor behavior. 
Under normal conditions, NRF2 has a protective role and it inhibits tumor initiation and 
metastasis by eliminating carcinogens, ROS and other DNA-damaging agents. However, 
persistently activated NRF2 may be advantageous to cancer cells for survival to ROS, 
chemotherapy, radiotherapy or adaptation to the tissue microenvironment. In fact, missense 
mutations in KEAP1 and NFE2L2 genes that disrupt its interaction and result in constitutive 
NRF2 activation have been identified in many human cancers 
168, 169
. However, it is believed 
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that the increase in NRF2 activity results from selection during tumor development rather 
than being a cancer initiating event 
170
. 
Autophagy plays a dual and complex role in cancer as well. Defects in autophagy 
result in p62 accumulation, oxidative stress, DNA damage and cell death, leading to chronic 
tissue damage and creating an ideal environment for tumor initiation. However, once cells 
have undergone transformation, they upregulate macroautophagy and CMA probably because 
of inherent deficiencies in the microenvironment and to the increased metabolic and 
biosynthetic demands imposed by deregulated proliferation. In this scenario, activating 
autophagy may increase resistance to cytotoxic stressors and sustain the specific metabolic 
needs of tumor cells 
171, 172
. Therefore, it is thought that autophagy prevents cancer 
development, but, once cancer is established, increased autophagic flux enables tumor cell 
survival and growth 
171
. This is supported by several studies showing improved outcomes in 
models of cancer when autophagy is inhibited. For instance, increased CMA activity was 
reported in several types of cancer 
173-175
, and LAMP2A blockage in different cancer cell lines 
reduced its tumorigenic activity 
173
. Moreover, clinical interventions to manipulate autophagy 
in cancer therapy are already under way and usually directed towards autophagy inhibition 
171
.  
In this study, we have employed gliomas as a model of cancer, as they constitute the 
most common brain malignancies. Gliomas are neuroepithelial tumors originating from the 
supporting glial cells of the central nervous system. Therefore, gliomas can be classified 
according to the presumed cell of origin into astrocytomas, oligodendrogliomas, 
ependymomas, and mixed gliomas. Glioblastomas are the most malignant and frequently 
occurring type of primary astrocytoma. Therefore, all glioblastomas are gliomas, but not all 
gliomas are glioblastomas 
176
. Because of the poor prognosis of these patients, it is imperative 
that novel avenues for therapy are explored. 
 AD and cancer are analyzed in this work as two examples of the deleterious effects of 
reduced and enhanced autophagy and NRF2 activity on physiology, respectively.  
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Both autophagy as well as NRF2 transcriptional activity are essential for maintaining 
cell homeostasis, especially upon stressful conditions such as oxidative stress. Therefore, our 
aim in this work is to analyze the role of the transcription factor NRF2 in the regulation of the 
best characterized forms of autophagy in mammals, namely macroautophagy and chaperone 
mediated autophagy (CMA). Our specific objectives are the following: 
 
1. Analysis of the regulation of macroautophagy genes by NRF2 
 
1.1. In silico identification and further validation of putative antioxidant response 
elements (AREs) in the promoter regions of macroautophagy-related genes 
1.2. Analysis of the regulation of macroautophagy by NRF2 
1.3. Generation and characterization of a new mouse model of Alzheimer’s disease 
(AD) in a wild type or an Nrf2-knockout background 
1.4. Relevance of NRF2 in controlling macroautophagy in the new AD model of 
proteinopathy 
1.5. Translation of our observations to AD pathology in human brain samples 
 
2. Analysis of the regulation of CMA by NRF2  
 
2.1. In silico identification and further validation of putative antioxidant response 
elements (AREs) in the LAMP2 gene  
2.2. Analysis of the regulation of LAMP2A expression by NRF2 
2.3. Role of NRF2 in CMA activation by oxidative stress 
2.4. Relevance of the regulation of CMA by NRF2  
2.5. Pathophysiological significance of the NRF2/LAMP2A axis in cancer 
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1. Materials 
 
1.1. Reagents 
 
Cell culture: DMEM (Dulbecco’s Modified Eagle Medium) and PBS (Phosphate 
Buffered Saline) were prepared by the Culture Media Preparation Facility at the Instituto de 
Investigaciones Biomédicas “Alberto Sols” (UAM-CSIC); minimum essential medium 
(MEM), phenol red-free neurobasal, horse serum, fetal bovine serum, B27 supplement, 
glutamine, sodium pyruvate and trypsin (Gibco-Invitrogen); gentamicin (Genta Gobens); 
glucose, rapamycin, heparin, polybrene, puromycin (Sigma-Aldrich); human fibroblast 
growth factor and epidermal growth factor (hFGF-2 and hEGF (Peprotech); metrizamide (AK 
Scientific); plastic material (Nunc, Falcon y Sarstedt).  
 
Pharmacological activators, inhibitors and other compounds: Paraquat, hydrogen 
peroxide, trigonelline, dimethylfumarate and leupeptin hemisulfate salt (>95%) (Sigma-
Aldrich). R,S-sulforaphane (SFN) (LKT Laboratories). 
 
DNA manipulation and extraction: Antibiotics: ampicillin (Sigma-Aldrich). Plasmid 
DNA preparation: Genopure Plasmid Maxi Kit (Roche Applied Science) and “Miniprep Kit” 
(Qiagen). Plasmid digestions: restriction enzymes (Thermo Fisher Scientific, Invitrogen and 
New England Biolabs). DNA cloning: alkaline phosphatase (Roche), T4 polynucleotide 
kinase and T4 DNA ligase (Promega). DNA electrophoresis: agarose (CONDA laboratories) 
and low melting temperature agarose (Nusieve
®
, agarose, Lonza). DNA molecular weight 
markers: DNAλ HindIII (Thermo Fisher Scientific). DNA purification from band in agarose 
gel: “Geneclean® Kit” (MP Biomedicals). 
 
Protein electrophoresis, transfer and immunoblotting: Protein quantification 
(Pierce
TM
 BCA Protein Assay Kit). Molecular weight markers “Bench protein ladder” 
(Invitrogen), TEMED, ammonium persulfate, acrylamide/bys-acrylamide (BioRad), 
Immobilon-P membranes (Millipore), enhanced chemiluminescence substrate (Amersham
TM
 
ECL
TM
 Select Western Blotting Detection Reagent, GE Healthcare).  
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RNA extraction and qRT-PCR: TRIzol
®
 Plus RNA Purification Kit (Invitrogen). 
Retrotranscriptase (High Capacity RNA-to-cDNA Kit, Applied Biosystems). SYBR green, 
PCR plates (Applied Biosystems), chloroform, isopropanol (Merck).         
 
Luciferase activity: Dual-Luciferase
®
 Reporter Assay System (Promega). 
 
NADP/NADPH measurement: NADP/NADPH Assay Kit (Abcam). 
 
Immunofluorescence and immunohistochemistry: Normal goat serum (Millipore), 
paraformaldehyde, formic acid, triton X-100 and 3´-3´-diaminobenzidine tetrahydrochloride 
(DAB) (Sigma-Aldrich), gelatin and cupric sulfate (Panreac), DePeX (Thermo Fisher 
Scientific), ProLong (Life Technologies).  
 
1.2. Antibodies 
 
1.2.1. Primary antibodies 
 
Primary antibodies used in this study have been listed in Table 1. 
 
1.2.2. Secondary antibodies 
 
The corresponding secondary antibodies conjugated to horseradish peroxidase (HRP) 
were supplied by Life Technologies (anti-goat), Amersham (anti-rabbit and anti-mouse) and 
Chemicon (anti-rat). The secondary antibodies for immunofluorescence and 
immunohistochemistry were acquired from Molecular Probes and Chemicon, respectively. 
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Antibody Source Catalog number Clonality Isotype Dilution 
ACTB Santa Cruz Biotechnology sc-1616 Polyclonal G 1/5000 (WB) 
APP/Aβ (4G8) Covance SIG-39220-200 Monoclonal M 
1/2000 (WB) 
1/1000 (IHC-f/p) 
APP/Aβ (6E10) Covance SIG-39320-200 Monoclonal M 
1/2000 (WB) 
 
APP/Aβ (22C11) EMD Millipore MAB348 Monoclonal M 1/2000 (WB) 
ATG5 Abcam ab108327 Monoclonal R 
1/2000 (WB) 
1/200 (IHC-f) 
ATG7 Abcam ab53255 Polyclonal R 1/2000 (WB) 
NDP52/CALCOCO2 ProteinTech 12229-1-AP Polyclonal R 1/1000 (WB) 
CD11B Abcam ab53187 Polyclonal R 1:100 (IHC-f) 
GABARAPL1 Abcam ab86497 Polyclonal R 
1/2000 (WB) 
1/200 (IHC-f) 
GAPDH Calbiochem CB1001 Monoclonal M 1/5000 (WB) 
GFAP Sigma Aldrich G3893 Monoclonal M 1:500 (IHC-f) 
GCLC Dr. Terrance Kavanagh  Polyclonal R 1/2000 (WB) 
HMOX1 Enzo life sciences OSA110 Monoclonal M 1/2000 (WB) 
HSC70 (13D3) Novus Biologicals NB1202788 Monoclonal M 
1/5000 (WB) 
1/500 (ICF) 
IBA1 Wako 019-19741 Polyclonal R 1:500 (IHC-f/p) 
Table 1. Antibodies used in immunoblots, immunofluorescence and ChIP. IHC-f, immunohistochemistry on floating slices; IHC-p, immunohistochemistry on paraffin slices; 
WB, western blot; ChIP, chromatin immunoprecipitation; R, rabbit; M, mouse; G, goat; 
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IgG2a Abcam ab18413 Monoclonal M 1/250 (ChIP) 
LAMIN B Santa Cruz Biotechnology sc-6217 Polyclonal G 1/5000 (WB) 
mLAMP2A (Igp96) Zymed/Invitrogen 51-2200 Polyclonal R 
1/1000 (WB) 
1/100 (ICF) 
hLAMP2A Abcam ab18528 Polyclonal R 1/1000 (WB) 
LAMP2B Cuervo lab  Polyclonal R 1/1000 (WB) 
LAMP2C Cuervo lab  Polyclonal R 1/1000 (WB) 
LAMP1 (1D4B) Hybridoma Bank 1D4B Monoclonal Rat 
1/1000 (WB) 
1/250 (ICF) 
LC3B Cell signaling 2775 Polyclonal R 
1/2000 (WB) 
1/250 (IHC-f/p) 
NQO1 Abcam ab2346 Polyclonal G 1/2000 (WB) 
NRF2 Cuadrado lab  Polyclonal R 1/2500 (WB) 
hNRF2 Abyntek AJ1555a Monoclonal R 1/2000 (WB) 
hNRF2 Thermo Scientific PA138312 Polyclonal R 1/200 (IHC) 
p62/SQSTM1 Sigma Aldrich P0067 Polyclonal R 
1/2000 (WB) 
1/250 (IHC-f/p) 
TAU (HT7) Thermo Scientific MN1000B Monoclonal M 
1/2000 (WB) 
1/250 (IHC-f/p) 
TAU (TAU46) Sigma Aldrich T9450 Monoclonal M 1/4000 (WB) 
p-TAU (PHF1) Dr. M Pérez gift  Polyclonal R 1/1000 (WB) 
Table 1 (continued). Antibodies used in immunoblots, immunofluorescence and ChIP. IHC-f, immunohistochemistry on floating slices; IHC-p, immunohistochemistry on 
paraffin slices; WB, western blot; ChIP, chromatin immunoprecipitation; R, rabbit; M, mouse; G, goat; 
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p-TAU (AT8) Thermo Scientific MN1020 Monoclonal M 1/1000 (IHC-f) 
ULK1 Abcam ab128859 Monoclonal R 
1/2000 (WB) 
1/200 (IHC-f) 
V5 Life Technologies 37-7500 Monoclonal M 1/250 (ChIP) 
 
 
 
 
 
 
 
 
 
Table 1 (continued). Antibodies used in immunoblots, immunofluorescence and ChIP. IHC-f, immunohistochemistry on floating slices; IHC-p, immunohistochemistry on 
paraffin slices; WB, western blot; ChIP, chromatin immunoprecipitation; R, rabbit; M, mouse; G, goat; 
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1.3. Plasmids 
 
pcDNA3.1-mNrf2-V5/HisB: plasmid that contains the wild type sequence of murine 
Nrf2, with a V5 tag (GKPIPNPLLGLDST)  in the C-terminus. This plasmid was originally 
provided by Dr. J. D. Hayes. 
 
pcDNA3.1-mNrf2-
ΔETGE
-V5/HisB: plasmid that contains the KEAP1-insensitive 
version of murine NRF2, with a V5 tag in the C-terminus. This construct lacks residues 79-
ETGE-82, responsible for the high affinity binding to KEAP1. This plasmid was originally 
provided by Dr. J. D. Hayes. 
 
pTK-Renilla: plasmid employed as an internal control in the luciferase assays. It 
contains the sea pansy (Renilla reniformis) luciferase gene under the control of the thymidine 
kinase promoter from Herpes Simplex Virus for its constitutive expression in mammalian 
cells. 
 
LAMP2 ARE-LUC and ARE*-LUC reporters: artificial oligonucleotides with three 
tandem repetitions of the putative AREs identified in the LAMP2 gene or its mutated 
versions* (underlined sequences) separated with a BamHI site (bold green colored) and a 
random separating-sequence (bold orange colored), as well as the oligonucleotides that 
contain an aleatory sequence used as negative control are shown below. These 
oligonucleotides were subcloned into the NheI and XhoI sites of a pGL3bv vector (Promega) 
with the 29 bp-long minimal promoter from the human SOD1 gene described in 
177
 
controlling the expression of the firefly (Photinus pyralis) luciferase. Cloning of the insert 
eliminated the NheI site to facilitate re-ligated vectors exclusion with NheI digestion prior to 
transformation. Scramble-LUC included also a SalI site (bold purple colored) instead of the 
random separating-sequence to facilitate differentiation between constructs. 
 
Lamp2 ARE1-LUC: 
5’- CTAGTATGACACTGCAGGATCCATGACACTGCAACGTGAATGACACTGCAC    -3’ 
3’-     ATACTGTGACGTCCTAGGTACTGTGACGTTGCACTTACTGTGACGTGAGCT-5’  
Lamp2 ARE2-LUC: 
5’- CTAGTTTGACTCAGCGGGATCCTTGACTCAGCGACGTGATTGACTCAGCGC    -3’ 
3’-     AAACTGAGTCGCCCTAGGAACTGAGTCGCTGCACTAACTGAGTCGCGAGCT-5’  
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Lamp2 ARE3-LUC: 
5’- CTAGTATGACAAACCAGGATCCATGACAAACCAACGTGAATGACAAACCAC    -3’  
3’-     ATACTGTTTGGTCCTAGGTACTGTTTGGTTGCACTTACTGTTTGGTGAGCT-5’ 
Lamp2 ARE1*-LUC: 
5’- CTAGTATGACACTACAGGATCCATGACACTACAACGTGAATGACACTACAC    -3’ 
3’-     ATACTGTGATGTCCTAGGTACTGTGATGTTGCACTTACTGTGATGTGAGCT-5’  
Lamp2 ARE2*-LUC: 
5’- CTAGTTTGACTCAACGGGATCCTTGACTCAACGACGTGATTGACTCAACGC    -3’ 
3’-     AAACTGAGTTGCCCTAGGAACTGAGTTGCTGCACTAACTGAGTTGCGAGCT-5’  
Scramble-LUC: 
5’- CTAGTTCAGATTCACGGGATCCTCAGATTCACGGTCGACTCAGATTCACGC    -3’  
3’-     AAGTCTAAGTGCCCTAGGAGTCTAAGTGCCAGCTGAGTCTAAGTGCGAGCT-5’ 
 
pMD2.G: plasmid that encodes the G protein from the envelope of the Vesicular 
Stomatitis Virus used for lentiviral production (Addgene, #12259).  
 
pSPAX2: packaging plasmid that encodes the Gag and Pol proteins from the Human 
Immunodeficiency Virus necessary for lentiviral production (Addgene, #12260). 
 
pLKO.1-TRC control: plasmid used for the generation of lentiviral particles with the 
sequence CCGCAGGTATGCACGCGT to be used as a non-hairpin control (Addgene, 
#10879). 
 
pLKO.1-puro shNRF2 (mouse): plasmid used for the generation of lentiviral 
particles with the sequence CCAAAGCTAGTATAGCAATAA transcribed into a short 
hairpin RNA (shRNA) sequence against murine Nfe2l2 gene (MISSION shRNA, Sigma-
Aldrich). 
 
pLKO.1-puro shNRF2 (human): plasmid used for the generation of lentiviral 
particles with the sequence AGTTTGGGAGGAGCTATTATC transcribed into a shRNA 
sequence against human NFE2L2 gene (MISSION shRNA, Sigma-Aldrich). 
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pWPXL-GFP: plasmid for the generation of lentiviral particles expressing the green 
fluorescence protein (GFP) under the control of the Elongation Factor 1α promoter. This 
plasmid was originally provided by Dr. D. Trono. 
 
pWPXL-mNrf2-
ΔETGE
-V5/HisB: plasmid for the generation of lentiviral particles 
expressing the murine version of NRF2 lacking residues 79-ETGE-82
 
and with a V5 tag in the 
C-terminus. The mNrf2-
ΔETGE
-V5/HisB insert from pcDNA3.1-mNrf2-
ΔETGE
-V5/HisB was 
subcloned into the BsteII and SmaI/PmeI restriction sites of the pWPXL-GFP vector. 
 
1.4. Buffers and solutions 
 
General buffers: Luria-Bertani medium (LB) for the growth of bacteria, LB agar 
plates, phosphate saline buffer (PBS), 1 M Tris-HCl pH 7.5, 1 M Tris-HCl pH 8.8, 1 M Tris-
HCl pH 6.6, 1 M HEPES pH 7.5, 10% SDS, 0.5 M EDTA pH 8.0 and 0.5 M EGTA pH 7.5 
were provided by the Culture Media Preparation Facility at the Instituto de Investigaciones 
Biomédicas “Alberto Sols” (UAM-CSIC). 
 
Cellular lysis buffer: 1% NP-40, 10% glycerol, 137 mM NaCl, 20 mM Tris-HCl pH 
7.5, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 20 mM sodium phosphate, 
1g/ml leupeptin and 1 mM PMSF. 
 
Animal tissue lysis buffer (RIPA buffer): 1% NP-40, 150 mM NaCl, 25 mM Tris-
HCl, pH 7.5, 1% sodium deoxycholate, 0.1% SDS, 1 mM EGTA, 1 mM sodium 
orthovanadate, 1 mM sodium phosphate, 1g/ml leupeptin and 1 mM PMSF. 
 
Protein loading buffer for SDS-PAGE: 50 mM Tris-HCl pH 6.8, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol, 150 mM β-mercaptoethanol. 
 
Electrophoresis running buffer: 0.37% EDTA, 1.44% glycine, 0.1% SDS and 0.3% 
Tris. 
 
Transfer buffer: 25 mM Tris, 190 mM Glycine and 20% Methanol. 
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Tris buffered saline with Tween 20 (TTBS): 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl and 0.1% Tween-20. 
 
DNA loading buffer: DNA Gel Loading Dye (6X) (Thermo Scientific), consisting on 
10 mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol 
and 60 mM EDTA. 
 
Tris buffered saline (TBS): 100 mM Tris and 225 mM NaCl.  
 
Tris-EDTA buffer (TE): 10 mM Tris-HCl and 1 mM EDTA. 
 
Tris base, acetic acid and EDTA buffer (TAE): 40 mM Tris, 20 mM acetic acid and 
1mM EDTA. 
 
1.5. Bacterial stocks 
 
The DH5- E.coli bacterial strain competent for transformation was provided by the 
Culture Media Preparation Facility from the Instituto de Investigaciones Biomédicas 
“Alberto Sols” (UAM-CSIC). 
 
1.6. Cell lines 
 
A549: human lung adenocarcinoma epithelial cell line initiated in 1972 by Dr. D.J. 
Giard through explant culture of lung carcinomatous tissue from a 58-year-old Caucasian 
male. A549 harbour KEAP1 protein with a Gly to Cys change at amino acid 333 
178
 and 
exhibit hypermethylation of the KEAP1 promoter 
179
, leading to constitutive NRF2 activation. 
 
HEK293T: cell line derived from human embryonic kidney cells, generated in 1987 
in Dr. Michele P. Calos (Standford University, USA) by stable insertion of the simian virus 
40 (SV40) large T antigen in the HEK293 cell line. This allows a very efficient replication of 
vectors carrying the SV40 region of replication, achieving remarkable expression levels. 
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HEK293T/17: specific clone (clone 17) from HEK293T cells that was selected for its 
high transfectability (Rockefeller University, USA), which makes them especially suitable for 
lentiviral and retroviral production. 
 
Hippocampal/cortical neurons from Nrf2-KO and wild type mice: primary 
hippocampal/cortical neurons from Nrf2-KO and their wild-type counterparts were stablished 
in Dr. Cuadrado Laboratory by Dr. Ana I Rojo and Marta Pajares with the method described 
in section 2.2. 
 
HT22: immortalized mouse hippocampal neuronal cell line subcloned from the HT4 
cell line by Dr. David Schubert (Salk Institute for Biological Research, USA). The parental 
HT4 cell line was originally immortalized from primary mouse hippocampal neuronal cells 
with a temperature sensitive SV40 T-antigen. 
 
Immortalized hepatocytes from Nrf2-KO and wild-type mice: primary hepatocytes 
from Nrf2-KO and their wild-type counterparts were stablished in Dr. Cuadrado Laboratory 
by Dr. Patricia Rada and immortalized with the SV40 large T antigen. 
 
Mouse embryo fibroblasts (MEFs) from Nrf2-KO and wild-type mice: primary 
embryo fibroblasts from Nrf2-KO and their wild-type counterparts were stablished in Dr. 
Cuadrado Laboratory by Dr. Isabel Lastres-Becker. 
 
N2A (Neuro-2a): mouse neuroblastoma cells established by R.J. Klebe and F.H. 
Ruddle from a spontaneous tumor of a strain A albino mouse. This tumor line was obtained 
from the Jackson Laboratory (USA). 
 
1.7. Animals 
 
Animals were housed under a 12 h light-dark cycle. Food and water were provided ad 
libitum and mice were cared according to protocols approved by the Ethics Committee for 
Research of the Universidad Autónoma de Madrid following institutional, Spanish and 
European guidelines (Boletín Oficial del Estado of 18 March 1988; and 86/609/EEC, 
2003/65/EC European Council Directives).  
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C57/BL6J-Nrf2
-/-
 (Nrf2-KO) mice and their wild type counterparts were kindly 
provided by Dr. M. Yamamoto (Tohoku University, Sendai, Japan). C57/BL6J-Nrf2
-/-
 mice 
bear a lacZ-neo cassette replacing a 1.2 kb long segment from the fifth exon of Nrf2. Where 
indicated, food was removed for 24 h but water was still provided ad libitum. Where stated, 
mice received intraperitoneal injections of vehicle (0.9 % saline buffer) or leupeptin (2 
mg/100 g body weight) 16 h and 2 h before sacrifice. 
APP(V717I) mice expressing in heterozygosis the human APP695 isoform with the 
V717I mutation under the control of the neuron-specific elements of the mouse Thy1 
promoter 
180
, were backcrossed with C57/BL6J-Nrf2
+/+
 or C57/BL6J-Nrf2
-/-
 mice for over 5 
generations. Similarly, TAU(P301L) mice, expressing in homozygosis the longest isoform of 
human TAU with the P301L mutation (Tau.4R/2N-P301L) under control of the mouse Thy1 
gene promoter, were backcrossed with C57/BL6J-Nrf2
+/+
 or C57/BL6J-Nrf2
-/- 
mice for over 5 
generations. APP-TAU-Nrf2
+/+
 (AT-Nrf2-WT) and APP-TAU-Nrf2
-/- 
(AT-Nrf2-KO) mice 
were obtained by crossing the proper founder mice from above. Genotypic characterization of 
the AT-Nrf2-WT transgenic mice was described previously 
181-183
).  
 
1.8. Human material 
 
Frozen post-mortem brain tissues were obtained from five control subjects (age range 
from 59 to 78 years) and five patients with AD (age range from 73 to 94 years) within a 5 h 
post-mortem interval, according to the standardized procedures of the Tissue Bank of 
Fundación CIEN. Information on patient samples is provided in Table 2. Brain samples used 
for AD analysis belong to patients with a clinical history with no familiar cases of AD. 
Control subjects had no background of neuropsychiatric disease and relevant brain pathology 
was excluded by a full neuropathological examination. AD diagnosis was confirmed by 
HT100 staining on frozen tissue sections from the same cases used in the 
immunofluorescence studies. All procedures were approved by the Ethics Committee of the 
Tissue Bank of Fundación CIEN (Madrid, Spain). 
Human glioblastomas were derived from brain surgery biopsies in the Hospital Ramón 
y Cajal (Madrid, Spain) and were kindly supplied by Dr. Marta Izquierdo (Centro de Biología 
Molecular “Severo Ochoa” - UAM), with the approval of the Ethics Committees.  
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2. Methods 
 
2.1. In silico analysis of putative AREs in autophagy genes 
 
Putative antioxidant response elements (AREs) in autophagy-related gene promoters 
were identified in The Encyclopedia of DNA Elements at UCSC (ENCODE) 
(https://genome.ucsc.edu/encode/) for human genome (Feb. 2009), taking as reference the 
available chromatin immunoprecipitation (ChIP) information of the ARE-binding factors 
MAFF, MAFK and BACH1. These sequences were localized in 200-400 pb long DNase-
sensitive and H3K27Ac-enriched regions, i.e. most likely regulatory promoter regions. On the 
other hand, a frequency matrix of the consensus human ARE sequence based on the JASPAR 
database was converted to a PSSM (Position Specific Scoring Matrix) (see Table 6 in the 
‘Results’ section) by turning the frequencies into scores through the log2(odd-ratio) (odd ratio: 
observed frequency/expected frequency). One unit was added to each frequency to avoid 
log(0). Then, a script was generated with Python 3.4 (Appendix I) to scan the promoter 
sequences with candidate AREs retrieved from the ENCODE with the PSSM. The max score 
was calculated by adding the independent scores for each of the 11 bp of the consensus 
Patient Disease Sex Age ApoE 
BCPA56 Control M 75 E3/E3 
BCM65 Control M 78 E3/E3 
BCM537 Control F 74 ND 
BCM 98 Control F 62 ND 
BCM121 Control F 59 ND 
BCM64 AD (Braak II) M 73 E3/E3 
BCM67 AD (Braak III) M 84 E3/E3 
BCM74 AD (Braak IV) F 90 E3/E3 
BCPA234 AD (Braak V) F 94 E3/E3 
BCPA399 AD (Braak V) F 79 ND 
Table 2. Information about human samples from control and AD patients used in this study. M, male; F, female; 
ND, not determined. 
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human ARE sequence with the PSSM. The relative score (score relative) was calculated from 
this max score (score of the sequence max) as: score relative = (score of the sequence max – score 
min possible)/ (score max possible – score min possible). The min possible score (score min possible) is 
calculated as the lowest possible number obtained for a sequence from the PSSM and the max 
possible score (score max possible) is the highest possible score that can be obtained. The PSSM 
and the script were courtesy of Natalia Jiménez-Moreno (present address: University of 
Bristol, UK). We considered putative ARE sequences those with a score relative higher than 
80%, which is a commonly used threshold for the TFBS (computational framework for 
transcription factor binding site) analysis using PSSM.  
 
2.2. Cell culture 
 
Adenocarcinoma human alveolar A549 cells, mouse embryo fibroblasts (MEFs), 
mouse hippocampus-derived HT22 cells, neuroblastoma N2A, human embryonic kidney 
HEK293T and HEK237T/17 cells were grown in DMEM supplemented with 10% FBS and 
80 μg/ml gentamicin. HT22 medium was further supplemented with 2 mM glutamine. 
Immortalized mouse hepatocytes were grown in the same medium supplemented with 2 mM 
glutamine, 1 mM sodium pyruvate and 5 mM HEPES pH 7.4.  
Hippocampal/cortical neurons were obtained from E17-18 mouse embryos. Briefly, 
embryonic hippocampi were incubated in 0.25% papain (Sigma-Aldrich) plus 1 mg/ml 
DNAse-I (Roche) at 37 °C for 20 min. After mechanical dissociation and centrifugation (900 
g, 5 min) cells were plated in minimum essential medium supplemented with 0.1 mM 
glutamine, 20% glucose, 5% horse serum, 5% fetal bovine serum and 80 μg/ml gentamicin, 
and incubated for 24h. After plating, the medium was changed to phenol red-free neurobasal 
medium supplemented with B27. Neurons were selected with cytosine β-D-arabinofuranoside 
(Ara-C, Sigma-Aldrich), an anti-mitotic reagent that intercalates into the DNA, inhibits 
replication and results in DNA fragmentation. Thus, Ara-C removes proliferating cells (glial 
cells) and allows neuronal selection. Neurons were maintained under these conditions for 10 
days in vitro.  
Glioblastoma cells obtained from patient explants were maintained in stem cell culture 
conditions with DMEM:F12 (1:1) supplemented with 2 mM glutamine, 5 mg/ml Albumax I, 6 
mg/ml glucose, B27 supplement (without Vitamin A), 15 ng/ml hFGF-2, 20 ng/ml hEGF, 2 
μg/ml heparine and 80 μg/ml gentamicin. 
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All cell cultures were maintained under a controlled atmosphere of 95% relative 
humidity, 5% CO2 concentration and 37ºC.  
 
2.3. Transient transfections 
 
Transient transfections in HEK293T were performed with TransFectin
TM
 Lipid 
Reagent (Bio-Rad) according to the manufacturer’s instructions. Transient transfections in 
MEFs were done with GenJet
TM
 In Vitro DNA Transfection Reagent (SignaGen Laboratories) 
following the manufacturer’s instructions.  
 
2.4. Production of lentiviral stocks and infection 
 
Recombinant lentiviral stocks were produced in HEK293T/17 cells. These cells were 
plated on 10-cm plates until they reached 85% confluence and co-transfected with 10 μg of 
transfer vector (the one that encodes the DNA of interest), 6 μg of envelope pMD2.G and 6 
μg of packaging plasmid pSPAX2, using Lipofectamine® 2000 Reagent (Invitrogen by Life 
Technologies). After 12 h at 37°C the medium was replaced with fresh DMEM containing 
10% FBS and viral particles were harvested 24 h and 48 h post-transfection.  
For viral infection, cells were incubated with the lentivirus in the presence of 4 μg/ml 
polybrene during 24 h and cell extracts were collected 3 and/or 10 days after lentiviral 
transduction, unless otherwise indicated. Selection of infected cells was done with 1 μg/ml 
puromycin. In the case of cells originated from glioblastomas, they were first disgregated and 
plated with OptiMEM supplemented with 10% FBS. 24 h after adhesion, cells were incubated 
with the lentivirus in the presence of 4 μg/ml polybrene. The next day, cells were again grown 
in stem cell culture conditions and selected with 1 μg/ml puromycin. 
 
2.5. Chromatin immunoprecipitation assays 
 
HEK293T cells were grown on 10-cm plates until they reached 85% confluence and 
transfected with an NRF2 expression plasmid that lacks the high affinity binding site for 
KEAP1 and contains a V5 tag (pcDNA3.1-mNrf2-
ΔETGE
-V5/HisB). For chromatin 
immunoprecipitation (ChIP), a protocol modified from the Upstate protocol was applied.  
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Briefly, cells were cross-linked with 1% formaldehyde (Fluka) for 12 min and the 
reaction was stopped with 125 mM glycine (Bio-Rad). Cells were then washed twice with 
cold PBS, lysed and sonicated in order to obtain adequate fragment sizes of DNA (200-800 
Gene 
product 
Forward primer (5’-3’) Reverse primer (5’-3’) ARE sequence 
HMOX1 CCCTGCTGAGTAATCCTTTCCCGA ATGTCCCGACTCCAGACTCCA GTGACTCAGCA 
NQO1 TGCACCCAGGGAAGTGTGTTGTAT CCCTTTTAGCCTTGGCACGAAA GTGACTCAGCA 
SQSTM1 (1) CTCCTGATATGGGGGCTGT CATTGCTGACCCCTCTCTTC ATGACTCAGCA 
SQSTM1 (2)* CTCTCAGGCGCCTGGGCTGCTGAG CGGCGGTGGAGAGTGGAAAATGCC GTGACTCAGCA 
SQSTM1 (3) AGGATGCCATGCGCTGTAAGAGG TGGGCCTGGCCATGACTCAGCAAT GCGACCTAGCA 
SQSTM1 (4) AGCCACTCCCCAGCCCAGCCT GAGGCCTCCCGGAGGTAAACAAG GTGAGTCAGCG 
CALCOCO2* ACTTGTCCCTGCAGACCGAGTTTA CCAAAGTGCTGGGATTACAGGCAT ATGAGTAAGCC 
ULK1 GACCAGCTGGCTTTCGTG TGGGCTCAGTAAACAGGTCA ATTAGTCAGCA 
ULK2 TGGATAGGAGGTTGGCTCTG GCAGAGATTGCAGTGAGCTG GTGACAGAGCA 
ATG2B GATGCTGGCCTTGCAATTTGCTCCA GTTTTAACCTTACTAATCAGTGAAT CTGCCTAAGCA 
ATG3 GGAGAAGCGGCTTATCCCGC GTCCTCGCTTTGCTTCACTCGCGC None 
ATG4C TTAGATCGCTCCTGGAAAGC TTGGGCATAGAAACGTAACAAA ATGAAATAGCA 
ATG4D TTCCTGCCCAGAGGTGAGCCATAGG GGCATGAGCCACCGTTTCCAACC ATGACAATGCA 
ATG5 GCTGAGATGGGGAGTGATGT CTCCCAAAGTGCTGGGATTA CTGACCTTGCA 
ATG7 GCTTTCTTTGCCTTCCCTCT GCTAGCTTTCAATGGCCAGA ATGAGTCAGCA 
GABARAPL1 GCTTTTAAAACCCCGTATGC CTAACCAGTCTCGCCCACAG GTGACTCAGCA 
ATG9B TGGGAAGCACAGTGTCCATA CAGGGAGGAGCTGAACTGAG CTGACTCAGCC 
ATG10 AAAAATTCAGCCTGGTGTGG TCAGCGCTCCTCATGTCATA CTGACTCAGCA 
ATG16L1 CAGCTGGAAGCCATATCACC TACTGCCCATCAGGAAAACC ATGATTCAGCA 
WIPI2 GCCTACATAGGAGGGCAGGT CAACGCGGGAAAATAAATTG ATGACTGAGCA 
LAMP1 ATCCGTCTGCCCTTTCTCC ACCCTGGACCCACGTGAC GTGACCCGGCC 
AMBRA1 GGCATTTTCTCCTCATCAGCA ACTGATGGGAAGAAGTCAGAGG TTGACTTAGCT 
LAMP2     (1) TATTGCTAGCATTATGTTCTTC TGGGGGAATGGAACAAGACCCTGTCA ATGACACTGCA 
LAMP2     (2) AGGGAAACCGAAGGATTGAT TAAATTCAAGGAGGCCGTTT TTGACTCAGCG 
LAMP2     (3) AAACGGCCTCCTTGAATTT ATGAATTTGGCTAAATGAATTGAC ATGACAAACCA 
ACBT CACCCAGCACATTTAGCTAGCTGA TTCAGAGCAACTGCCCTGAAAGCA None 
NQO1* TCTCAGTTTTTGCCCTTATTTAATC TAAAAAGTAGAGTGGTTGGAGTGATGAC None 
Table 3. Primers used for chromatin immunoprecipitation (ChIP) analysis indicating the specific ARE amplified 
in each gene. 
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bp). Supernatant was diluted 10-fold with ChIP dilution buffer (0.01% sodium dodecyl 
sulfate, 1.1% Triton X100, 1.2 mM ethylenediaminetetraacetic acid, 16.7 mM Tris-HCl pH 
8.1, 167 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin) and pre-cleared 
with Protein G Sepharose (GE Healthcare). Transfected NRF2 was immunoprecipitated with 
anti-V5 antibody and an anti-IgG antibody was used as a negative control. DNA was eluted 
and purified, analyzing the presence of previously identified putative AREs by quantitative 
real-time polymerase chain reaction (qRT-PCR) with specific primers (Table 3). Samples 
from at least three independent immunoprecipitations were analyzed. 
 
2.6. Cellular and tissue lysis 
 
Cells were washed twice with cold PBS and lysed in the adequate volume of lysis 
buffer with a cell scraper. Mice were sacrificed by cervical dislocation and organs of interest 
were anatomically dissected on ice. Tissues were lysed with RIPA buffer and mechanically 
homogenized with a Potter-Elveihem. Protein quantification in cell and tissue samples was 
done with the BCA method (Pierce 
TM
 BCA Protein Assay Kit) and protein loading buffer 
was added. Samples were sonicated, boiled at 95ºC for 5 min and cellular debris was 
eliminated by centrifugation at 13,000 rpm for 5 minutes. 
 
2.7. Electrophoresis and immunoblotting 
 
Protein electrophoresis was performed as previously described by Laemmli 
184
. 
Proteins were separated in SDS-PAGE and transferred to 0.45 μm pore size Immobilon-P 
membranes.  
For immunoblotting, membranes were hydrated in methanol for 1 min, washed with 
TTBS buffer for 3 min and blocked with either 4% bovine serum albumin (BSA) or 5% non-
fat dry milk in TTBS. Membranes were incubated with the appropriate dilution of the primary 
antibodies in 0.4% TTBS for 2 h. After washing the membranes three times with TTBS (10 
min each), membranes were incubated with 1:10.000 secondary antibodies coupled to HRP in 
0.4% TTBS for 1 h. Proteins were detected by enhanced chemiluminescence (GE Healthcare) 
after washing the membranes three times with TTBS (10 min each wash). 
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2.8. Messenger RNA analysis by quantitative real time PCR (qRT-PCR) 
 
Total RNA extraction was done with TRIzol according to the manufacturer’s 
instructions. One μg of RNA, quantified with a NanoDropTM spectrophotometer (Thermo 
Fisher Scientific), was used to synthesize cDNA in a 20 μl volume with the High Capacity 
RNA‐to‐cDNA kit (Applied Biosystems). The quantitative real time polymerase chain reaction 
(qRT-PCR) was done in a volume of 10 μl with the Sybr Green Master Mix (Applied 
Biosystems) and 5 pmol of each specific oligonucleotide (Table 4 and 5). The reaction took 
place in a StepOne thermocycler (Applied Biosystems). After an initial 10 min denaturation at 
95°C, 40 cycles with the following conditions were applied: 15 s at 95°C (denaturation), 30 s 
at 60 °C (annealing) and 30 s at 60 °C (elongation). The melting curve analysis enabled us to 
assess the specificity of the amplification with each pair of oligonucleotides. The threshold 
cycle (Ct), inversely related to the amount of amplified DNA, was measured as the cycle at 
which fluorescence emission exponentially exceeded the background fluorescence. Messenger 
RNA (mRNA) levels were estimated with the ΔΔCt method, using Actb, Gapdh and/or Tbp 
house-keeping genes as reference. Samples were analyzed in quatriplicates.  
 
Gene product Forward primer (5’-3’) Reverse primer (5’-3’) 
SQSTM1/P62 CTGGGACTGAGAAGGCTCAC GCAGCTGATGGTTTGGAAAT 
CALCOCO2/NDP52 ACCATGGAGGAGACCATCAA TTCTGGACGGAATTGGAAAG 
ULK1 TCATCTTCAGCCACGCTGT CACGGTGCTGGAACATCTC 
ATG2B AACTCACAAACAGAATGGTTCAAA AAGGGTACCAGGAAGACACCA 
ATG3 CATGCAGGCATGCTGAGGTG CGTTAACAGCCATTTTGCCACT 
ATG4D CACATCCTCAGGAAAGCCGT GACCACAGACTTCCACTCGG 
ATG5 GGGAAGCAGAACCATACTATTG AAATGTACTGTGATGTTCCAAGG 
ATG7 AGGAGATTCAACCAGAGACC GCACAAGCCCAAGAGAGG 
GABARAPL1 ACCATGGGCCAACTGTATGA TGGGCTTCCAACCACTCATTT 
HMOX1 TGCTCAACATCCAGCTCTTTGA GCAGAATCTTGCACTTTGTTGC 
ACBT TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT 
LAMP2A GTGCAACAAAGAGCAGACTGT GGCACAAGGAAGTTGTCGTC 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
 
 
 
Table 4 . Human primers used for quantitative real time polymerase chain reaction (RT-PCR). 
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Gene product Forward primer (5’-3’) Reverse primer (5’-3’) 
Sqstm1/p62 GGCGCACTACCGCGATGAGGA TGTTCCCGCCGGCACTCCTT 
Calcoco2/NDP52 TGGCAACTTCTCTCAGGTCCTGTT TCCTTGCGTCGAGGGATGAACTTT 
Ulk1 TGCCCTTGATGAGATGTTCC AGTCTCCTCTCAATGCACAGC 
Atg2b TGATCCCAACTATCGTTCCCG CGGATCTCCATTCTCTTGCTTC 
Atg3 CCATTGAAAACCATCCTCATCTC GCCTTCTGCAACTGTCTCAATAATT 
Atg4d ACGTCAAGTATGGTTGGGCA ATGTCACCCTCTCCCTCGAA 
Atg5 ATATCAGACCACGACGGAGC TTGGCTCTATCCCGTGAATC 
Atg7 GGCCTTTGAGGAATTTTTTGG ACGTCTCTAGCTCCCTGCATG 
Gabarapl1 GACCTCACTGTTGGCCAGTTC GTGGGAGGGATGGTGTTGTT 
Lamp2a AGGTGCTTTCTGTGTCTAGAGCGT AGAATAAGTACTCCTCCCAGAGCTGC 
Lamp2b ATGTGCTGCTGACTCTGACCTCAA TGGAAGCACGAGACTGGCTTGATT 
Lamp2c GGTGCTGGTCTTTCAGGCTTGATT ACCACCCAATCTAAGAGCAGGACT 
Hmox1 CACAGATGGCGTCACTTCGTC GTGAGGACCCACTGGAGGAG 
Aox1 CTTTTGACCAAAGCATCAGTCTC CCCTTTCTCCCAGTCTATATTCGA 
Nqo1 GGTAGCGGCTCCATGTACTC CATCCTTCCAGGATCTGCAT 
Nrf2 CCCGAAGCACGCTGAAGGCA CCAGGCGGTGGGTCTCCGTA 
Cd11b CCTTGTTCTCTTTGATGCAG GTGATGACAACTAGGATCTT 
Gfap TCCTGGAACAGCAAAACAAG CAGCCTCAGGTTGGTTTCAT 
Il6 CCTACCCCAATTTCCAATGCT TATTTTCTGACCACAGTGAGGAATG 
Nos2 CCTCCTTTGCCTCTCACTCTTC AGTATTAGAGCGGTGGCATGGT 
Adam10 CGCACAACTCTGGCTGAAAG CCGGAGAAGTCTGTAGTCTG 
Adam17 CAGAAGAAGTGCCAGCAGGCTA GTTGTCAGTGTCAACGCATGC 
Bace1 GGGCTGGCCTATGCTGAGATTGC GCACCACAAAGCTGCAGGGAGAA 
Psen1 TGGCCACCATCAAATCAG TCATGATGGCCGCATTCAG 
Actb TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT 
Tbp TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
Gapdh CGACTTCAACAGCAACTCCCACTCTTCC TGGGTGGTCCAGGGTTTCTTACTCCTT 
Table 5 .Mouse primers used for quantitative real time polymerase chain reaction (RT-PCR). 
 
Materials and Methods 
 
77 
2.9. Measurement of luciferase activity  
 
Nrf2-KO MEFs were seeded in 24-well (75,000 cells per well) plates and transiently 
transfected with GenJET according to the manufacturer’s instructions. 48 h after transfection, 
cells were lysed in 100 μl lysis buffer (Promega) and 40 μl of this lysate was employed for the 
luciferase assay, performed according to the manufacturer’s instructions. Luciferase 
expression was quantified as luminol oxidation with a GloMax 96 microplate luminometer 
with dual injectors (Promega). Each sample was measured in triplicate and normalized to 
Renilla levels. 
 
2.10. Morris water maze 
 
After a 1-day habituation trial (day 0), in which preferences between quadrants in the 
different experimental groups were ruled out, the animals were placed in the swimming pool 
during 4 trials/day, 60 s each trial plus 20 s in the platform for 5 consecutive days, so that they 
learned to find the hidden platform. If an animal failed to reach the platform, it was placed on 
it by the experimenter. Subsequently, the animals were subjected to two trials on the 7
th
 day, 
the first without the platform to assess possible differences in swimming speed and preference 
for the platform quadrant. And in the second, a cued version protocol using a visible platform 
was conducted to determine sensorimotor and motivational status of the animals. The animal 
behavior was recorded through an automated tracking system (Smart video tracking system, 
version 2.0.14, Panlab; Harvard Apparatus). 
 
2.11. Electrophysiological recordings 
 
Electrophysiological recordings were obtained from six urethane-anaesthetized 
(1.6g/kg i.p.) adult mice per group as described in 
185
. Briefly, field potentials were recorded 
through tungsten macroelectrodes (1 MΩ; World Precision Instruments) stereotaxically 
implanted in the dentate gyrus (A:-2,3; L: 2; H: 3.5 mm from Bregma according to the 
Paxinos and Watson Atlas). Twisted bipolar electrodes for electrical stimulation were placed 
at the perforant path (A: -2.5; L: 0.5; H: 3.5 mm from Bregma). Baseline recordings were 
taken with test stimuli (10-50 µA, 0.3 ms, 0.5 Hz) for 15 min before tetanic stimulation 
consisting of three pulse trains of 10-50 µA, lasting each pulse 0.3 ms and at 50 Hz. Trains 
lasted 500 ms and the inter-train interval was 2 s. Recording was maintained for 30 min after 
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tetanic stimulation. Field potentials were 0.1 Hz–1 kHz band-pass filtered, amplified (P15 
Amplifier, Grass Co., USA), and digitalized at 10 kHz (CED 1401; Cambridge Electronic 
Design). Signal analysis was carried out with Spike 2 software (Cambridge Electronic Design, 
Cambridge, UK). Field potential segments of 5 min were analyzed to obtain the response 
average. The mean average response during the 15 min period before the tetanic stimulation 
was considered as 100%. Recordings were accepted for analysis when baseline variability 
was less than 10%. 
 
2.12. Animal perfusion and brain sectioning with the microtome 
 
Animals were anesthetized with 8 mg/kg ketamine and 1.2 mg/kg xylazine and 
perfused through the left heart ventricle with PBS. Brains were sectioned along the sagittal 
axis. Left hemispheres were rapidly dissected and frozen for biochemical analysis. Right 
hemispheres were post-fixed in 4% paraformaldehyde during 16 h and cryoprotected by 
soaking in 30% sucrose solution in PB until they sank. A frozen-tissue-sectioning manual 
microtome (Hyrax) was used to obtain 30 µm thick sagittal or coronal slices, which were 
collected in PB for the immediate use or preserved in anti-freeze solution (33.3 % glycerol, 
33.3 % ethylene glycol, 20 mM PB). 
 
2.13. Immunofluorescence  
 
Cells were seeded on sterile coverslips in 24-well plates (75,000 cells per well), 
cultured for 16 h and treated as indicated. Cells were washed with cold PBS and fixed in 4% 
paraformaldehyde for 15 min at room temperature or with cold methanol for 2 min at room 
temperature. After three 5-min washes with PBS, cells were incubated with blocking solution 
(0.2% powdered milk, 2% normal goat serum, 0.1 M glycine, 1% bovine serum albumin and 
0.01% Triton X-100) for 30 minutes at room temperature. After briefly washing twice with 
PBS, slides were incubated with the indicated primary antibodies (Table 1) for 90 minutes at 
room temperature in a humidified chamber. Then cells were washed three times with PBS and 
incubated with secondary antibodies for 45 minutes under the same conditions. To visualize 
the nuclei, cells were stained with DAPI (4,6-diamidino-2-phenylindole). After washing with 
PBS and sterile water, coverslips were mounted on slides with a drop of ProLong. 
Mouse brain free-floating 30 µm-thick sections were washed three times with PBS for 
5 min. When necessary, antigen retrieval was performed by incubation with 10 mM citrate 
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buffer pH 6 at 90 ºC for 20 min. Antigen retrieval for APP and Aβ detection was performed 
by incubating the sections in formic acid for 5 min. Sections were then incubated with 
blocking solution (5% normal goat serum and 0.3 % Triton X-100 in PBS). Sections were 
incubated with primary antibodies diluted in 0.5% normal goat serum and 0.3 % Triton X-100 
in PBS (Table 1) for 24 h at 4ºC. After washing twice with PBS (5 min each), sections were 
incubated with secondary antibodies coupled to Alexa fluorophores diluted in 0.5% normal 
goat serum and 0.3 % Triton X-100 in PBS for 1 h at room temperature. To visualize the 
nuclei, cells were stained with DAPI and the surplus antibody was removed with two 
additional 5 min-washes with PBS. Brain sections were mounted on gelatin-coated slides with 
a drop of ProLong. 
Fluorescence images were captured using appropriate filters in a Leica SP5 confocal 
microscope (Confocal Microscopy Facility from the Facultad de Medicina, UAM). 
 
2.14. Immunohistochemistry 
 
Free-floating sections were incubated with 10% methanol and 3% H2O2 in TBS for 30 
min at room temperature to inactivate endogenous peroxidase. Antigen retrieval was 
performed with 10 mM citrate buffer pH 6 for 20 min at 90ºC (or formic acid for 5 min at 
room temperature for APP/Aβ). Slices were incubated with blocking solution (10% normal 
goat serum and 0.4% Triton X-100 in TBS) for 2 h. Incubation with the appropriate dilutions 
of the primary antibodies was done for 24 h at room temperature in an humidified chamber 
Detection was enhanced with biotinylated secondary antibodies and the avidin/biotin system 
with the Vectastain
R
 ABC Kit (Vector Laboratories) according to manufacturer’s instructions. 
Sections were then developed with 0.003% H2O2, 0.05% 3-3’diaminobenzidine 
tetrahydrochloride (DAB) in TB pH 8 until the appearance of the desired intensity. Staining 
development was stopped with consecutive washes with TBS in all sections at the same time. 
Sections were mounted on gelatin-coated slides, de-hydrated by consecutive immersions in 
70%, 96%, 100% ethanol and xylol. Eventually, sliced were covered with DePeX (Serva) and 
a slide cover.  
Four µm-thick paraffin fixed consecutive human brain sections were incubated at 65ºC 
in a heater overnight. The following day, slides were hydrated by consecutive incubations in 
xylol, 100%, 96%, 70% ethanol and sterile water. Endogenous peroxidase was inhibited with 
3% H2O2 and antigen retrieval was performed with 10 mM citrate buffer pH 6 for 3 min in the 
microwave (or formic acid for 15 min at room temperature for APP/Aβ). Sections were 
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immunostained with the Histostain-SP Kits Invitrogen LAB-SA Detection System 
(Invitrogen) following the manufacturer’s instructions.  
 
2.15.  Determination of reduced and oxidized glutathione, protein carbonyls and   
lipid peroxidation 
 
Reduced glutathione (GSH) levels were determined with the following fluorometric 
protocol. Mouse brains were homogenized in 1 ml of EDTA-phosphate pH 8.0 buffer 
supplemented with 300 μl HPO3 (25 %). Proteins were eliminated by centrifugation at 3,000 g 
for 15 min. We next separated 500 μl of the supernatant and added 500 μl of EDTA-
phosphate buffer supplemented with 100 μl o-phthalaldehyde (OPA). Samples were dark-
incubated for 15 min at room temperature. Fluorescence was detected in a Synergy HT (Bio-
Tek) with excitation at 350 nm and emission at 420 nm. Values were interpolated from a 
standard GSH curve, corrected upon total protein content and expressed as μg of GSH per mg 
of protein. Oxidized glutathione (GSSG) was determined in the remaining 500 μl of 
supernatant with 100 μl dithiothreitol (DTT) (25 mM) to reduce disulfur bonds and obtain 
total GSH content. Samples were incubated for 30 min at 4ºC and centrifuged at 5,000 g for 
10 min. Supernatants were then used to measure GSH as described above and GSSG 
concentration was obtained by substracting GSH values to total GSH values. Values were 
expressed as μg of GSH per mg of protein.  
To determine protein carbonyl quantity, mouse brains were homogenized in EDTA-
phosphate buffer, incubated with streptomycin sulfate for 1 h and centrifuged at 6,000 g in 
order to eliminate nucleic acids. Supernatants were then treated with 2,4-
dinitrophenylhydrazine (DNPH) (10 mM) in phosphate-HCl buffer (2N) and incubated under 
dark and shaking-conditions for 1 h at room temperature. Afterwards, proteins were 
precipitated with 20 % trichloroacetic acid (TCA) and centrifuged at 3,000 g for 10 min. The 
pellet was resuspended in guanidine hydrochloride (1M). Carbonyl content was estimated as 
the generation of hydrazones after the reaction of DNPH with protein aldehydes, which 
absorb at 370 nm. Protein carbonylation content was expressed as nm of carbonyl per mg of 
protein (molar extinction coefficient = 22.000 M
-1
 cm
-1
). 
Lipid peroxidation can be determined as the generation of malondialdehyde (MDA). 
200 μL of mouse brain homogenates were mixed with 300 μl of TBA solution (0.375 g 
thiobarbituric acid, 7.5 g trichloroacetic acid, 2.5 ml HCl) and incubated for 30 min at 100ºC. 
Samples were kept for 5 min on ice and then centrifuged at 3,000 g for 15 min. The presence 
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of peroxidized lipids results in the appearance of a pink pigment that can be measured at 490 
nm. Values in our samples were interpolated from a tetramethoxypropane (TMPO) standard 
curve and presented as nmol of MDA per mg of protein.  
 
2.16. Aβ determination by ELISA 
 
Aβ measurements were performed with two ELISA kits, one for each fragment (Aβ1-
40 and Aβ1-42) (Novex®, Thermo Fisher Scientific) following the manufacturer’s 
instructions. Samples were sonicated (5 s) in 10 volumes of protein lysis buffer (20 mM (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.9, 100 mM NaCl, 1 mM ethylene glycol 
tetraacetic acid, 1 mM ethylenediaminetetraacetic acid, 1% Triton-X100, 5 mM dithiothreitol, 
2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and complete protease inhibitor 
cocktail). The lysate was centrifuged (18,000 g for 10 min at 4°C). The supernatant was 
considered soluble and the pellets were further extracted in formic acid by sonication, and 
centrifuged. Results were expressed as pg/mg of protein measured by the BCA method, using 
BSA as standard. 
 
2.17. Aβ oligomers detection 
 
Hippocampal samples were fractionated by a four step extraction method previously 
described 
186
. Briefly, mouse hippocampi were lysed in NP-40 buffer (50 mM Tris–HCl, pH 
7.6, 0.01% NP-40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS). After centrifugation, the 
supernatant was sequentially centrifuged allowing the recovery of the extracellular enriched 
fraction and the original pellet was resuspended in TNT-lysis buffer (50 mM Tris–HCl, pH 
7.4, 150 mM NaCl, 0.1% Triton X-100). After centrifugation, the supernatant was centrifuged 
different times to collect the intracellular enriched fraction, whereas the pellet was lysed with 
RIPA buffer to extract membrane-bound proteins. After centrifugation, the supernatant will 
correspond to membrane-bound proteins and the pellet is further processed with 70% formic 
acid. After elimination of endogenous immunoglobulins with protein G-sepharose beads, one 
hundred micrograms of protein per sample was electrophoresed on 10-20% SDS-
polyacrylamide Tristricine gels (Bio-Rad). Proteins were transferred to PVDF and membranes 
were boiled in PBS for 5 min after immunoblotting. 
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2.18. TAU extraction 
 
Mouse brain tissue was homogenized in 0.2 ml of ice-cold buffer (0.1 M 3-(N-
morpholino)propanesulfonic acid, pH 7.0, 1 mM ethylenediaminetetraacetic acid, 0.5 mM 
MgSO4, 1 M sucrose containing 1 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl 
fluoride, 10 μg/ml aprotinin and 1μg/ml leupeptin). The homogenates were cleared by 
centrifugation at 50,000 g for 20 min at 4°C, and the supernatants were collected as soluble 
fractions. To prepare the sarkosyl-insoluble fractions, pellets were resuspended in lysis buffer 
(0.1 M 3-(N-morpholino)propanesulfonic acid, pH 7.0, 10% sucrose, 2 mM (ethylene glycol 
tetraacetic acid, 0.5 mM MgSO4, 500 mM NaCl, 1 mM MgCl2, 10 mM NaH2PO4, 20 mM 
NaF) containing 1% N-lauroylsarcosine (sarkosyl) (Sigma-Aldrich) with protease inhibitors, 
vortexed for 1 min at room temperature, incubated at 4°C for 16 h and then centrifuged at 
200,000 g for 30 min at room temperature. The supernatants were collected as sarkosyl-
soluble fractions, while the pellets were resuspended in sodium dodecyl sulfate protein 
loading buffer and incubated at 95°C for 5 min (sarkosyl-insoluble fractions). 
  
2.19. NADP/NADPH measurement 
 
NADP and NADPH levels were measured with the NADP/NADPH Assay Kit 
(Abcam) following the manufacturer’s instructions. 
 
2.20.  ROS measurement with dihydroethidium  
 
The probe dihydroethidium (DHE), also called hydroethidine, is a cell-permeable 
fluorescent dye used as a redox indicator. It exhibits a weak blue-fluorescence in the cytosol 
but it is highly sensitive to reactive oxygen species (ROS), especially superoxide, which 
oxidizes it to ethidine, exhibiting a bright red fluorescence and intercalating within the 
cellular DNA. In our experiments, cells were stained with 5 µM DHE for 1 h at 37ºC and then 
visualized in a Leica DMIL fluorescence microscope (Confocal Microscopy Facility from the 
Facultad de Medicina, UAM). The probe was excited at 488 nm and emitted between 557 nm 
and 740 nm. 
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2.21. Lysosomal isolation  
 
For in vivo analysis, lysosomal enriched fractions or CMA active lysosomes from 
Nfe2l2-WT and Nfe2l2-KO mouse livers were obtained as previously described 
187
. Briefly, 
livers were mechanically homogenized in 0.25M sucrose with a Potter-Elvehjem. Samples 
were then filtered through double gauze and centrifuged at 6,800 g. The supernatant was 
centrifuged at 17,000 g and the pellet was resuspended with a ‘cold finger’ (dry glass test tube 
filled with ice). This step was repeated twice to wash the lysosomal enriched fraction. 
Lysosomes active for CMA were isolated by further centrifugation of the lysosomal enriched 
fraction (light mitochondria and lysosomes) in a discontinuous metrizamide density gradient. 
The fraction of broken lysosomes at the moment of isolation was measured with the β-
hexosaminidase latency assay, as this enzyme is released when the lysosomal membrane is 
disrupted 
188
.  
In some experiments, a crude lysosomal fraction was prepared from hepatocytes 
derived from wild type and Nfe2l2-KO mice using the Lysosome Isolation Kit (BioVision) 
according to the manufacturer’s instructions. 
 
2.22. Measurement of chaperone mediated autophagy in intact cells  
 
To measure CMA activity in intact cells the photoswitchable KFERQ-PS-Dendra2 
reporter was transduced into cells using lentiviral delivery 
189
. As represented in Fig. 8, cells 
were first photoactivated with a 405 nm light emitting diode (LED: Norlux) for 4 min with a 
3.5 mA (constant current) intensity. After 16 h, cells were fixed with 4% PFA and slides 
prepared using mounting medium containing DAPI to highlight the cell nucleus. CMA 
activation was detected as changes in the fluorescence pattern from diffuse/cytosolic to 
punctate/lysosomal and quantified as the average number of fluorescent puncta per cell or as 
the cellular area positive for KFERQ-Dendra puncta. All images were acquired with an 
Axiovert 200 fluorescence microscope (Albert Einstein College of Medicine, NY, USA) with 
a 100X objective and 1.4 numerical aperture, mounted with an ApoTome.2 slider. Where 
indicated, high content microscopy was used instead to better determine dose-dependence 
effects in a larger number of cells. Briefly, cells were plated in glass-bottom 96-well plates, 
treated for the indicated times and after fixation images were acquired using a high-content 
microscope (Operetta, Perkin Elmer, Albert Einstein College of Medicine, NY, USA).  
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2.23. Measurement of chaperone mediated autophagy in vitro  
 
CMA activity in vitro was measured using isolated intact lysosomes incubated with 
purified recombinant proteins and subjected to immunoblot 
187
. Binding was calculated as the 
amount of substrate protein bound to the lysosomal membrane in the absence of protease 
inhibitors and uptake by subtracting the amount of protein associated with lysosomes in the 
presence (protein bound to the lysosomal membrane and taken up by lysosomes) and absence 
(protein bound to the lysosomal membrane) of protease inhibitors (Fig. 9A). 
Proteolytic activity was determined by incubating lysosomes with a cocktail of long-
lived radiolabeled proteins (
3
H-pool) previously demonstrated to be enriched in CMA 
substrates 
187, 190
 in the presence of 0.1% Triton-X100 to disrupt the lysosomal membrane. 
Samples were incubated in 20mM MOPS, 1mM DTT, 5.4 µM cysteine pH 7.3, and 0.25 M 
sucrose for 20 min at 37 º C. At the end of the incubation, 10% TCA was added to all the 
samples and they were subjected to filtration through 0.2 m filter. Proteolysis was calculated 
as the percentage of acid precipitable radioactivity (protein) at the begging of the incubation 
that became acid soluble (amino acids) at the end of the incubation (Fig. 9B). 
 
Figure 8. Scheme showing how the KFERQ-PS-Dendra2 reporter allows monitoring CMA activity in cultured 
cells. Photoactivation allows tracking the already existing protein over the newly synthesized. Because the 
reporter contains a KFERQ motif, it is delivered to lysosomes upon CMA activation, displaying a characteristic 
punctate pattern. 
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2.24. Image analysis 
 
Different band intensities corresponding to immunoblot detection of protein samples 
were quantified using ImageJ software (NIH). Fluorescence intensity and M1 and M2 
colocalization coefficients were measured by Mander's analysis using the ImageJ JACoP 
plugging. The number of puncta per cell was analyzed with the ‘Analyze particles’ plugin of 
ImageJ after thresholding in non-saturated images. In the case of high content microscopy, 
images of 9 different fields per well were captured, resulting in an average of 2,500-3,000 
cells per condition. Nuclei and puncta were identified using the manufacturer's software. The 
number of particles/puncta per cell was quantified using the `particle identifier‘ function in 
the cytosolic region after thresholding in non-saturated images. DHE fluorescence intensity 
was quantified with ImageJ and is presented as the corrected total cell fluorescence (CTCF; 
Figure 9. Scheme showing the experimental design for the uptake assays (A) and proteolysis measurement (B). 
A, Incubation of CMA substrates with intact lysosomes treated or not with protease inhibitors (PI) allows 
determination of the amount of substrate bound to the lysosomal membrane (without PI) or associated with 
lysosomes both in the membrane and the lumen (+PI). Total uptake can be calculated by subtracting the amount 
of “bound” substrate from the total amount of substrate associated with the protease-inhibited lysosomes. B, 
Proteolysis was calculated after incubating a pool of radiolabeled substrates with broken lysosomes as the 
percentage of acid precipitable radioactivity (protein) at the begging of the incubation that became acid soluble 
(amino acids) at the end of the incubation. Figure modified from Patel et al, 2015. 
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CTCF = integrated density - (area of selected cell x mean fluorescence of background 
readings)). Perinuclear LAMP2A fluorescence was measured with the ‘Radial profile angle’ 
plugin of ImageJ after properly calibrating the image. A circular mask with a radius of 100 
pixels (25 µm, approximately) was used to analyze fluorescence intensity per cell. For each 
cell, the algorithm measured the mean signal intensity in a series of concentric circles drawn 
along the established radius, starting from the nucleus and towards the cell periphery. 
Quantifications were performed in 50-75 cells per condition in three independent 
experiments. 
 
2.25.  Data mining of gene expression in cancer and statistical analysis 
 
The expression levels of NFE2L2 and LAMP2 genes in tumors determined by RNAseq 
compiled at The Cancer Genome Atlas (TCGA) was downloaded with the Xena Browser 
database (https://xenabrowser.net/). We then calculated the Pearson correlation coefficient 
(R). The statistical significance of the R was calculated as a function of the t distribution. 
Kaplan-Meier curves and logrank test statistical analysis were also obtained from Xena 
Browser database. 
For other analysis, unless otherwise indicated, all experiments were performed at least 
three times and all data presented in the graphs are the mean of at least three independent 
samples ± standard error of the mean (SEM). Student's t-test was used to assess differences 
between groups with Graph Pad Prism 5.0. and p<0.05 was considered significant. 
  
 87 
 
 
 
 
 
Results 
 
  
Results 
88 
 
 
 
 
 
 
 
 
I. The transcription factor NRF2 is a 
regulator of macroautophagy gene 
expression 
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1. Identification of putative AREs in macroautophagy genes. 
 
We first performed a bioinformatics analysis in search for putative AREs in the 
promoter region of macroautophagy-related genes. For this purpose, we searched the 
Encyclopedia of DNA Elements at UCSC (ENCODE) of the human genome (Feb. 2009) 
(https://genome.ucsc.edu/encode/). This database gathers extensive information about the 
human genome, including experimental data from chromatin immunoprecipitation (ChIP) 
studies of several transcription factors. Although NRF2 is not included, we analyzed the 
presence of binding sequences for three other ARE-binding factors MAFF, MAFK and 
BACH1, for which information is available. We found evidence of MAFF, MAFK or BACH1 
binding in many genes involved directly or indirectly in autophagy. These sequences were 
usually located in DNAse sensitive regions (indicative of open chromatin conformation) 
191, 
192
 and enriched in H3K27Ac (acetylation in the 27
th
 Lys of histone H3, which correlates with 
active transcription) 
193
. Then, we developed a position specific scoring matrix (PSSM), based 
on the nucleotide frequencies from the human consensus ARE of the JASPAR database 
(Table 6).  
In order to scan the putative AREs retrieved from the ENCODE with the PSSM, a 
Python 3.4-script was generated (Appendix I) that provides a relative score for each sequence 
analyzed. The relative score represents the probability of a certain sequence of being a real 
ARE. As summarized in Table 7, this bioinformatics approach enabled the detection of 30 
putative AREs with a relative score over 80% (a commonly used threshold for TFBS -
computational framework for transcription factor binding site- analysis using PSSM) in 17 
macroautophagy genes. As internal controls, the algorithm also retrieved the already known 
AREs in the NRF2 bona fide target genes NQO1 and HMOX1. AREs in the autophagy genes 
SQSTM1 
67
 or CALCOCO2 
68
, coding for p62 and NDP52, respectively, had been previously 
described. In addition to these sequences, our analysis detected new potential AREs in these 
and in other macroautophagy-related genes. 
 
2. Validation of putative AREs by ChIP analysis. 
 
The newly identified ARE sequences were subsequently validated by ChIP. Because 
of the lack of adequate antibodies to immunoprecipitate endogenous NRF2 efficiently, we 
used HEK293T cells transfected with an expression vector for V5-tagged NRF2. Moreover, 
this construct lacked the KEAP1 regulatory domain ETGE (NRF2-
ΔEGTE
-V5), facilitating 
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Table 6. Position specific scoring matrix (PSSM). A score is given for each 
nucleotide in each position based on the nucleotide frequencies matrix from 
the human consensus ARE of the JASPAR database (depicted below the 
table). 
 
NRF2 stabilization, translocation to the nucleus and binding to its target genes. Thus, ChIPs 
were performed with anti-V5 antibody and also with anti-IgG as a negative control. 
Immunoprecipitated DNA was analyzed by quantitative real time PCR (qRT-PCR) with 
specific primers surrounding the putative AREs. 
Among the 30 putative AREs detected in macroautophagy genes, we found consistent 
enrichment of 11 ARE regions in V5- over IgG-immunoprecipitated chromatin, indicating 
that NRF2 binds these promoter regions (Fig. 10A and 10B). Our study also detected 
enrichment of the two positive controls from the bona fide NRF2 targets NQO1 and HMOX1. 
No enrichment was detected with specific primers for ACTB, for an upstream region of NQO1 
that does not contain AREs 
194
 or for ATG3, in which MAFF, MAFK and/or BACH1 binding 
sequences yielded low relative scores. In the SQSTM1 gene, we identified a previously 
reported ARE 
67
 plus three more (Fig. 10B). 
 
3. Pharmacological activation of NRF2 with sulforaphane induces macroautophagy 
gene expression in human and murine cells. 
 
To examine the potential regulation of the selected macroautophagy genes by NRF2, 
we next analyzed its expression levels upon NRF2 pharmacological activation. We treated 
human HEK293T cells with 15 μM of the NRF2 activator sulforaphane (SFN) for 12 h. SFN 
makes adducts with, at least, Cys-151 of KEAP1, preventing NRF2 proteasomal degradation 
and allowing newly synthesized protein to accumulate, translocate to the nucleus and exert its 
transcriptional function 
51
. As observed in Fig. 11A, the transcript levels of the selected 
macroautophagy genes were analyzed by qRT-PCR, demonstrating increased expression of 
human SQSTM1, CALCOCO2, ULK1, ATG2B, ATG4D, ATG5 and GABARAPL1 upon SFN  
 1 2 3 4 5 6 7 8 9 10 11 
A 
          
C 
       

 
G 
          
T 
          
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Gene 
Localization in the human 
genome 
Max 
Score 
Relative 
score 
ARE putative 
binding sequence 
SQSTM1         (1) 
                        (2) 
                        (3) 
                        (4) 
chr5:179247562-179247551 
chr5:179246594-179246583 
chr5:179247479-179247490 
chr5:179246116-179246105 
19.11 
18.97 
11.44 
13.39 
1.0 
0.997 
0.816 
0.863 
ATGACTCAGCA 
GTGACTCAGCA* 
GCGACCTAGCA 
GTGAGTCAGCG 
CALCOCO2   (1) 
                        (2) 
chr17:46906385-46906374 
chr17:46906430-46906441 
12.65 
12.34 
0.845 
0.838 
ATGAGTAAGCC* 
GTGAGGAAGCA 
ULK1 chr12:132381043-132381032 12.62 0.844 ATTAGTCAGCA 
ULK2 chr17:19783789-19783800 15.74 0.919 GTGACAGAGCA 
ATG2B chr14:96849918 -96849929 11.38 0.815 CTGCCTAAGCA 
ATG4C chr1:63212369-63212380 13.03 0.854 ATGAAATAGCA 
ATG4D           (1) 
                        (2) 
chr19:10652326-10652315 
chr19:10655902-10655891 
14.96 
10.94 
0.9 
0.804 
ATGACAATGCA 
GTGACTTTGAA 
ATG5 chr6:106873861-106873872 11.01 0.806 CTGACCTTGCA 
ATG7              (1) 
                        (2) 
                        (3) 
                        (4) 
chr3:11347170-11347159 
chr3:11320731-11320720 
chr3:11347216-11347227 
chr3:11320599-11320610 
15.94 
13.65 
11.08 
11.07 
0.924 
0.869 
0.807 
0.807 
ATGAGTCAGCA 
CTGACTCAGCT 
AGGACTTGGCA 
ATGATTGAGCT 
MAP1LC3B2 (1) 
                        (2) 
                        (3) 
chr6:41681230-41681219 
chr6:41680999-41681010 
chr6:41706984-41706973 
13.39 
11.55 
14.65 
0.863 
0.818 
0.893 
GTGAGTCAGCG 
ATGAGTCACCA 
GTCACTCAGCA 
GABARAPL1 (1)  
                        (2) 
chr12:10364974-10364963 
chr12:10366072-10366083 
14.58 
18.97 
0.891 
0.997 
GTGACTCAGGA 
GTGACTCAGCA 
ATG9B chr7:150723213-150723224 14.24 0.883 CTGACTCAGCC 
ATG10 chr5:81278192-81278181 16.65 0.941 CTGACTCAGCA 
ATG16L1       (1) 
                        (2) 
chr2:234134609-234134598 
chr2:234134578-234134589 
16.53 
13.56 
0.938 
0.867 
ATGATTCAGCA 
ATGACCTAGCC 
WIPI2 chr7:5239766-5239755 16.65 0.941 ATGACTGAGCA 
LAMP1 chr13:113951364-113951353 12.06 0.831 GTGACCCGGCC 
AMBRA1        (1) 
                        (2) 
chr11:46576251-46576240 
chr11:46572300-46572311 
11.51 
10.84 
0.818 
0.802 
TTGACTTAGCT 
ATGACTAATCT 
NQO1 chr16:69760919-69760908 18.97 0.997 GTGACTCAGCA
* 
HMOX1          (1) 
                        (2) 
                        (3) 
                        (4) 
chr22:35768205-35768216 
chr22:35768021-35768010 
chr22:35768127-35768116 
chr22:35747111-35747100 
12.3 
18.97 
18.97 
13.24 
0.837 
0.997 
0.997 
0.859 
ATGCCTCAGCC 
GTGACTCAGCA* 
GTGACTCAGCA* 
GTTACTCAGCC 
 
 
Table 7. Putative Antioxidant Response Elements (AREs) in the promoter regions of autophagy genes with a 
relative score higher than 80%. The table also shows the max score and the localization in the human genome. 
Asterisks denote AREs that have been described previously and were retrieved with our script as positive controls. 
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Figure 10. Validation of NRF2 binding to putative AREs in autophagy genes. A, HEK293T cells were 
transfected with an expression vector for NRF2-
ΔETGE
-V5. ChIP analysis was performed with anti-IgG or anti-V5 
antibodies and the potential AREs with the highest score were analyzed by qRT-PCR. ATG3, ACTB and an 
upstream region of NQO1 that does not contain any ARE (NQO1*) were analyzed as negative controls. 
Previously described AREs in HMOX1, NQO1, SQSTM1(2) and CALCOCO2 were analyzed as positive controls. 
B, Same ChIP analysis of putative AREs in the promoter region of SQSTM1. The figures show representative 
data normalized as the fold of enrichment with the anti-V5 antibody vs. the IgG antibody (dashed line). These 
experiments were repeated three times with similar results. Numbers in brackets indicate the AREs from Table 7 
specifically amplified. 
 
 
 
 
 
 
Figure 11. Sulforaphane (SFN) enhances autophagy gene expression. HEK293T (A) and HT22 (B) cells were 
submitted to 15 µM SFN for 12 h and 6 h, respectively. Messenger RNA levels of the indicated genes were 
determined by qRT-PCR and normalized to Actb levels. Data are mean ± SEM (n = 3). Statistical analysis was 
performed with Student’s t test. *p<0.05, ** p<0.01 and *** p<0.001 vs. vehicle-treated conditions. 
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4. Reduced expression of autophagy-related genes in the absence of NRF2. 
 
Initially, we tested the effect of pharmacological inhibition of NRF2 in HT22 cells 
with the alkaloid trigonelline, which, although not specific for NRF2 inhibition, was reported 
to inhibit NRF2 nuclear translocation 
55
. Fig. 12A shows that treatment of HT22 cells with 0.1 
µM trigonelline for 12 h resulted in reduced expression of Hmox1 as a positive control and 
had no effect on Atg3, as expected. With the exception of Ulk1, the other genes exhibited a 
significant reduction in expression.  
Considering the lack of specificity of trigonelline or other NRF2 inhibitors, we 
addressed the impact of NRF2 deficiency on macroautophagy gene expression in mouse 
embryo fibroblasts (MEFs) from Nrf2-WT and Nrf2-KO mice by qRT-PCR (Fig. 12B). 
Impaired expression of Sqstm1, Calcoco2, Ulk1, Atg2b, Atg4d, Atg5, Atg7 and Gabarapl1 
was observed in Nrf2-KO
 
MEFs. Moreover, reduced expression of Sqstm1, Calcoco2 and 
Atg7 products in the absence of NRF2 was also confirmed at the protein level with available 
antibodies (Fig. 12C and 12D). These results point to a critical role of NRF2 on the basal 
expression of macroautophagy genes. 
We next combined chemical and genetic manipulation of this transcription factor. We 
treated wild type and Nrf2-KO MEFs with SFN (15 μM, 6 h) and analyzed mRNA levels of 
macroautophagy genes by qRT-PCR. As shown in Fig. 12E, SFN consistently increased the 
expression of the macroautophagy related genes. However, Nrf2-KO MEFs exhibited 
impaired induction of autophagy genes, indicating that the effect of SFN is mediated at least 
in part by NRF2. 
Finally, we conducted rescue experiments in which Nrf2-KO MEFs were infected with 
a lentivirus expressing NRF2-
ΔEGTE
-V5 and maintained in vitro during 3 or 10 days. We first 
analyzed the expression levels of Hmox1 and Nfe2l2 (because the gene coding for NRF2 has 
an ARE itself 
195
 by qRT-PCR, and confirmed effective NRF2 overexpression and induction 
of target genes (Fig. 12F). Moreover, overexpression of NRF2-
ΔEGTE
-V5 in Nrf2-KO MEFs 
resulted in increased expression of macroautophagy genes when compared to Nrf2-KO MEFs 
infected with a control GFP-expressing lentivirus (Fig. 12F). 
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represented as percentage of expression vs. Nrf2-WT MEFs. Statistical analysis was performed with Student’s t 
test. *p<0.05, ** p<0.01 and *** p<0.001 vs. Nrf2-WT MEFs. C, Representative immunoblots for the indicated 
proteins of Nrf2-WT and Nrf2-KO MEFs. D, Densitometric quantification of representative blots from C relative 
to GAPDH levels. Data are mean ± SEM (n = 3). Statistical analysis was performed using Student’s t test. 
*p<0.05, ** p<0.01 and ***p < 0.001 vs. Nrf2-WT MEFs. E, Nrf2-WT and Nrf2-KO MEFs were submitted to 
SFN (15 µM, 6 h). Messenger RNA levels of the indicated genes were determined by qRT-PCR and normalized 
to Actb levels. Data are mean ± SEM (n=3), represented as the fold of change vs. vehicle-treated cells (dashed 
line). Statistical analysis was performed with Student’s t test. *p<0.05 and ** p<0.01 vs. vehicle-treated cells. F, 
Nrf2-KO MEFs were transduced with NRF2-
ΔETGE
-V5 or GFP-expressing lentivirus and mRNA levels of the 
indicated genes were analyzed by qRT-PCR following 3 and 10 days after transduction. Bars represent the fold 
of change normalized to GFP-lentivirus infected cells, depicted with the dashed line. Data are mean ± SEM (n = 
3). Statistical analysis was performed with Student’s t test. * p<0.05 and ** p<0.01 vs. GFP-infected cells. 
Figure 12. NRF2 deficiency results in 
reduced autophagy gene expression. A, 
HT22 cells were submitted to trigonelline 
(Trig, 0.1 µM) for 12 h. Messenger RNA 
levels of the indicated genes were 
determined by qRT-PCR and normalized to 
Actb levels. Data are mean ± SEM (n = 3). 
Statistical analysis was performed with 
Student’s t test. *p<0.05 and ** p<0.01 vs. 
vehicle-treated conditions. B, Expression 
levels of the indicated genes from Nrf2-WT 
(WT) and Nrf2-KO (KO) MEFs were 
determined by qRT-PCR and normalized to 
Actb levels. Data are mean ± SEM (n=3), 
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Altogether, these data indicate that NRF2 controls the expression of at least murine 
Sqstm1, Calcoco2, Ulk1, Atg2B, Atg4D, Atg5, Atg7 and Gabarapl1 genes involved in 
macroautophagy.  
 
5. Analysis of autophagy flux in NRF2-deficient cells. 
 
In order to evaluate the functional impact of NRF2-dependent macroautophagy gene 
regulation, we first analyzed the conversion of protein LC3B-I (non-lipidated and slower 
migrating form) to LC3B-II (phosphatidylethanolamine-lipidated and faster migrating form) 
as an indicator of autophagosome formation. This was combined or not with inhibition of 
lysosomal degradation by ammonium chloride (NH4Cl, 20 mM), which impairs lysosomal 
acidification, and leupeptin (Leup, 100 µM), which is an inhibitor of proteases 
196
. As shown 
in Fig. 13A and 13B, treatment with NH4Cl and leupeptin (NL, 4 h) increased LC3B-II levels, 
reflecting the accumulation of autophagosomes that are not being degraded. Activation of 
autophagy with serum-deprivation, led to a slight increase in LC3B-II levels due to enhanced 
formation of autophagosomes. Nevertheless, we could not detect significant differences in the 
levels of LC3B-II between Nrf2-WT and Nrf2-KO MEFs under basal or induced autophagy 
with short term lysosomal inhibition. When we examined the accumulation of 
autophagosomes with time in Nrf2-WT and Nrf2-KO MEFs, we observed a subtle reduction 
in LC3B-II levels in the absence of NRF2 at longer time points, that may reflect the existence 
of slight differences in the dynamics of autophagosomes formation between Nrf2-WT and 
Nrf2-KO MEFs (Fig. 13C and 13D). 
We then analyzed the role of NRF2 in controlling the autophagy flux under oxidative 
stress conditions. For this purpose, wild type and Nrf2-KO MEFs were treated with increasing 
concentrations of H2O2 for 6 h as indicated in Fig. 13E and 13F. H2O2 increased LC3B-II 
levels in both cell types, but to a lesser extent in Nrf2-KO MEFs, suggesting that NRF2 is 
necessary for a proper autophagy induction under oxidative stress conditions.  
Altogether, these results suggest that basal expression of autophagy genes in Nrf2-KO 
MEFs may be sufficient to sustain basal or SD-induced autophagy, but transcriptional input 
from NRF2 is necessary for a proper induction of autophagy under oxidative or stress 
conditions.  
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Figure 13. NRF2 deficiency impairs autophagy flux in response to stress. A, Representative immunoblots for the 
indicated proteins of Nrf2-WT (WT) or Nrf2-KO (KO) MEFs under basal conditions or deprived from serum 
(SD) during 6 h in the absence or presence of NH4Cl/Leupeptin (NL) for the last 4 h. B, Densitometric 
quantification of representative blots from A relative to ACTB levels. Data are mean ± SEM (n = 4). Statistical 
analysis was performed using Student’s t test vs. Nrf2-WT MEFs. C, Representative immunoblots for the 
indicated proteins of Nrf2-WT or Nrf2-KO MEFs treated with NL for the indicated times. D, Densitometric 
quantification of representative blots from C relative to ACTB levels. Data are mean ± SEM (n = 3). Statistical 
analysis was performed using Student’s t test. E, Representative immunoblots for the indicated proteins of Nrf2-
WT or Nrf2-KO MEFs treated with the indicated concentrations of H2O2 for 6 h. F, Densitometric quantification 
of representative blots from E relative to ACTB levels. Data are mean ± SEM (n = 3). Statistical analysis was 
performed using Student’s t test. *p<0.05 vs. Nrf2-WT MEFs. 
 
6. Generation of a new mouse model of proteinopathy. 
 
To understand the loss of homeostasis recapitulated by NRF2 deficiency and its 
impact on proteostasis, we generated a new mouse model of AD based on the expression of 
human mutant APP(V717I) and TAU(P301L) under the neuronal Thy1 promoter in a 
C57BL/6 wild type (denoted as AT-Nrf2-WT mice) or Nrf2-KO (named AT-Nrf2-KO mice)  
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Figure 14. Generation of a new mouse model of AD. Scheme showing the generation of a new mouse model of 
AD based on the expression of human APP(V717I) and TAU(P301L) under the control of the neuronal Thy1 
promoter on an Nrf2-wild type (AT-Nrf2-WT mice) or Nrf2-knockout (AT-Nrf2-KO) genetic background. 
 
genetic background (Fig. 14). The APP(V717I) mutation, called the “London mutation”, is 
one of the most common APP mutations identified in familial cases of AD. This mutation is 
located very close to the γ-secretase cleavage site, inducing the amyloidogenic cleavage of 
APP to Aβ42 as well as subsequent TAU phosphorylation 197, 198. On the other hand, 
TAU(P301L) affects the microtubule binding region of TAU, being the most common 
mutation found in frontotemporal dementia of chromosome 17 and accelerating the formation 
of aggregates and NFTs 
199
. 
 
6.1. Characterization of TAU and Aβ/APP expression in brains from AT-Nrf2-
WT and AT-Nrf2-KO mice. 
 
The tissue distribution of human TAU(P301L) and APP(V717I) in AT-Nrf2-WT and 
AT-Nrf2-KO mice was analyzed by immunohistochemistry of sagittal brain sections with 
anti-TAU (clon HT7) and anti-APP/Aβ (clon 4G8) antibodies. Fig. 15A-C and Fig. 16A-C 
show representative images of TAU and APP/Aβ positive neurons located in different brain 
regions, including cortex (mainly in the entorhinal cortex and M1 and M2 motor cortex), 
hippocampus (CA1, CA2, subiculum and hilum), brainstem (being more abundant in the 
reticular formation of the bulb and the pons) or cerebellum (deep cerebellum nuclei and 
granular layer). We also detected positive neurons and fibers in the spinal cord. 
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Figure 15. Analysis of tissue distribution of human TAU positive neurons in the brain of the indicated genotypes. 
A, Scheme showing different brain regions were human TAU positive neurons were detected. 1, Frontal cortex; 
2, Temporal cortex; 3, Entorhinal cortex; 4, CA1; 5, Subiculum; 6, Thalamus; 7, Pons; 8, Cerebellum; 9, Medulla, 
10, Spinal cord. B, Representative images of TAU (HT7 clon) positive neurons in the brain regions depicted in A. 
C, Higher magnification of TAU positive neurons from the indicated genotypes in the brain regions from A. D, 
Representative immunohistochemistry images of human TAU (HT7) staining in the hippocampus of AT-Nrf2-
WT and AT-Nrf2-KO mice at the indicated ages. 
 
 
We further characterized TAU expression as well as development of amyloid plaques 
in AT-Nrf2-WT and AT-Nrf2-KO as a function of ageing. For this purpose, we performed 
immunohistochemistry analysis employing anti-TAU (clon HT7) or anti-APP/Aβ (clon 4G8) 
antibodies in sagittal brain sections of the hippocampus from 6, 9, 11 and 13-months old 
mice. As shown in Fig. 15D, TAU expression was detectable at all the different ages analyzed  
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Figure 16. Analysis of tissue distribution of human APP/Aβ positive neurons in the brain of the indicated 
genotypes. A, Scheme showing different brain regions were human APP/Aβ positive neurons were detected. 1, 
Frontal cortex; 2, Temporal cortex; 3, Entorhinal cortex; 4, CA1; 5, Subiculum; 6, Thalamus; 7, Pons; 8, 
Cerebellum; 9, Medulla, 10, Spinal cord. B, Representative images of APP/Aβ (4G8 clon) positive neurons in the 
brain regions depicted in A. C, Higher magnification of APP/Aβ positive neurons from the indicated genotypes in 
the brain regions from A. D, Representative immunohistochemistry images of human APP/Aβ staining in the 
hippocampus of AT-Nrf2-WT and AT-Nrf2-KO mice at the indicated ages. Higher magnification images showing 
big compact amyloid plaques in AT-Nrf2-WT vs. small diffuse or even intracellular amyloid in AT-Nrf2-KO 
mice. 
 
and displayed no major changes with age or between genotypes. As observed in Fig. 16D, 
amyloid plaques started to appear at 11-13 months of age and were mainly present in the 
subiculum. Surprisingly, we detected fewer plaques in the subiculum of AT-Nrf2-KO than in 
the wild type counterparts. A more detailed analysis of Aβ/APP and TAU pathological 
specimens will be described in the next section. 
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6.2. NRF2 deficiency accelerates premature death due to APP(V717I) and 
TAU(P301L) expression. 
 
We first evaluated the lifespan of Nrf2-WT, Nrf2-KO, AT-Nrf2-WT and AT-Nrf2-KO 
animals. As observed in the Kaplan-Meier survival curves depicted in Fig. 17, Nrf2-WT and 
Nrf2-KO mice lived longer than 20 months and AT-Nrf2-WT mice lived for an average of 14 
months. Approximately 50% of the AT-Nrf2-KO mice died before the age of 12 months, with 
hardly any survivor reaching the 14 months of age (Fig. 17). This observation highlights the 
importance of NRF2 in a stressful environment, such as the one generated by proteinopathy in 
the APP/TAU-expressing mice.  
 
6.3. Cognitive and long term potentiation impairment is aggravated by NRF2 
deficiency. 
 
In order to address memory capabilities, we subjected 6-months-old Nrf2-WT, Nrf2-
KO, AT-Nrf2-WT and AT-Nrf2-KO to the Morris water maze test. This test consists in daily 
training of mice in an open swimming pool where they must find a submerged platform. As 
the mice learn, the time to reach the platform (acquisition time) decreases. Prior to the test, we 
observed that all genotypes showed similar swimming speed at this age, indicating 
uncompromised motor abilities. As observed in Fig. 18A, after 5 days of trials, all mice found 
the platform in approximately 20 s except for the AT-Nrf2-KO mice, who took significantly 
longer (almost 40 s). Spatial memory was assessed at the seventh day by removing the 
platform. As shown in Fig. 18B, Nrf2-WT, Nrf2-KO and AT-Nrf2-WT mice exhibited a 
tendency to swim around the area were the platform used to be located. AT-Nrf2-KO mice,  
 
Figure 17.  Early death of the AT-mice is accelerated 
in the absence of NRF2. Kaplan-Meier curves of Nrf2-
WT (n=250), Nrf2-KO (n=217), AT-Nrf2-WT (n=269) 
and AT-Nrf2-KO (n=209) mice over 3 years of 
observation. A p value of ***p<0.001 was obtained 
comparing AT-Nrf2-WT and AT-Nrf2-KO curves. 
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Figure 18.  Spatial learning and memory 
are impaired in AT-Nrf2-KO mice. A, 
Acquisition time to reach the hidden 
platform in each of the five trials during 
Morris Water Maze test performed to 6 
months-old mice of the indicated 
genotypes. Data are mean ± SEM (n = 10). 
Statistical analysis was performed with 
Two way ANOVA followed by 
Bonferroni post-hoc test. *p<0.05 and **p 
< 0.01 vs. Nrf2-WT mice. B, Upper circles 
are representative swimming tracks of the 
indicated genotypes during the probe 
phase in which the platform was removed. 
Lower graph shows the frequency spent at 
the platform quadrant. Data are mean ± 
SEM (n = 10). Statistical analysis was 
performed with One way ANOVA 
followed by Bonferroni post-hoc test. 
*p<0.05 vs. Nrf2-WT mice. 
 
however, displayed random swimming-tracks all over the pool, reflecting their inability to 
remember the original platform location. These results demonstrate impaired cognition in AT-
Nrf2-KO mice already at 6 months of age. 
To further analyze synaptic function in AT-Nrf2-KO mice and its wild type 
counterparts, we measured long term potentiation (LTP). This mechanism of synaptic 
plasticity, involving a long-lasting increase in the strength of synaptic transmission after 
prolonged high frequency input, is known to participate in memory formation 
200
. We 
recorded synaptic transmission in the dentate gyrus upon electrophysiological stimulation of 
the performant path (Fig. 19). High frequency stimulation increased the field excitatory post-
synaptic potential (fEPSP) in control Nrf2-WT mice, but to a lesser extent in both Nrf2-KO 
and AT-Nrf2-WT mice, indicating that NRF2 deficiency or proteinopathy alone are sufficient  
to impair LTP. Moreover, the combination of proteinopathy and NRF2 deficiency in the AT-
Nrf2-KO mice resulted in a more profound effect, drastically reducing the fEPSP (Fig. 19). 
  
6.4. Increased oxidative markers in AT-Nrf2-KO mice. 
 
We next evaluated the presence of oxidative markers in the brains of 12-14 months-
old Nrf2-WT, Nrf2-KO, AT-Nrf2-WT and AT-Nrf2-KO mice. As observed in Fig. 20A, 
NRF2 deficiency or proteinopathy did not significantly modify the ratio of GSH/GSSG as 
compared to wild type animals. However, the AT-Nrf2-KO mice showed a decreased 
GSH/GSSG ratio, indicating diminished availability of reduced glutathione and,  
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consequently, less antioxidant capacity. Next, we evaluated the oxidative damage to 
macromolecules, including protein carbonylation, which reflects oxidation of specific 
aminoacids (preferentially Lys, Arg or Pro). Protein carbonylation was measured with 2,4-
dinitrophenylhydrazine (DNPH). This method revealed similar levels of protein carbonylation 
between genotypes, except for the AT-Nrf2-KO mice, which exhibited increased levels of 
carbonylated proteins (Fig. 20B). Lipid peroxidation, indicative of direct oxidation of 
polyunsaturated fatty acids mainly, due to oxidation of methylene groups, was quantified 
according to the generation of malondialdehyde (MDA). As observed in Fig. 20C, Nrf2-WT, 
Nrf2-KO and AT-Nrf2-WT mice all had similar levels of peroxidized lipids, whereas AT-
Nrf2-KO mice displayed a significant increase. 
Altogether, these results suggest that only the combination of proteinopathy and NRF2 
deficiency renders subtle but significant alterations in redox homeostasis towards a more 
oxidized environment.  
 
6.5. Low-grade chronic inflammation in APP(V717I) and TAU(P301L)- 
expressing mice that lack NRF2. 
 
We examined astrogliosis and microgliosis in 12-14 months-old Nrf2-WT, Nrf2-KO, 
AT-Nrf2-WT and AT-Nrf2-KO mice. Astrogliosis was determined with Glial Fibrillar Acidic 
Protein (GFAP) immunostaining of CA1 and subiculum. As observed in Fig. 21A-21C, no 
significant changes in the number of GFAP positive cells between Nrf2-WT and Nrf2-KO 
mice either in the hippocampal CA1 or subiculum regions were detected. The expression of 
APP(V717I) and TAU(P301L) led to a slight increase in the number of GFAP positive cells  
 
Figure 19. Long term potentiation is drastically 
reduced by NRF2 deficiency. Field excitatory post-
synaptic potential (fEPSP) in 6 months-old animals of 
the indicated genotypes before and after tetanic 
stimulation of the perforant pathway. c5, c10, c15: 
baseline recordings before tetanic stimulation. Data are 
mean ± SEM (n = 6). Statistical analysis was 
performed with two-way ANOVA followed by 
Bonferroni post-hoc test. *p<0.05, **p<0.01 and 
***p<0.001 vs. Nrf2-WT mice. 
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Figure 20.  Increased oxidative markers in the brains of AT-Nrf2-KO mice. A, Ratio of reduced glutathione 
(GSH) and oxidized glutathione (GSSG) in the brains of 12-14 months old mice of the indicated genotypes. B, 
Protein carbonyl content in the brains of the indicated genotypes determined by 2,4-dinitrophenylhydrazine levels 
and normalized to total protein levels. C, Peroxidized lipids (Px-lipids) determined by malondialdehyde levels 
normalized to total protein levels. Data are mean ± SEM (n = 4). Statistical analysis was performed with One way 
ANOVA followed by Newman-Keuls post-hoc test. *p<0.05 and ***p<0.001 vs. Nrf2-WT mice. 
 
in the subiculum, which display activated-specific morphology with thick cell bodies and 
small cytoplasmic branches (Fig. 21B). Nevertheless, abolishment of NRF2 expression did 
not change the number of GFAP positive cells in either of these brain regions.  
We then analyzed microgliosis in the hippocampus of these mice with Cluster of 
Differentiation molecule 11B (CD11b) immunostaining. No evident changes were observed 
between Nrf2-WT and Nrf2-KO mice (Fig. 21D-21F). The APP/TAU-expressing mice 
showed a trend to have increased microgliosis and the absence of NRF2 in these mice resulted 
in a significant larger number of CD11b positive microglia in both CA1 and subiculum (Fig. 
21D-21F). 
To delve into the differences observed in the microglial population between the AT-
Nrf2-KO vs. the AT-Nrf2-WT mice, we analyzed the expression of the Major 
Histocompatibility Complex class II molecule (MHCII) as a marker of microglial activation 
in the hippocampus. As observed in Fig. 22A, MHCII immunostaining yielded very low 
specific signal in the AT-Nrf2-WT mice while the lack of NRF2 resulted in increased MHCII 
immunostaining in the hippocampus of APP/TAU-expressing mice. Importantly, MHCII co-
localized with Ionized calcium binding adaptor molecule 1 (IBA1) microglial marker, 
resulting in abundant yellow dots indicative of increased microglial activation (Fig. 22A).  
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Figure 21. Neuroinflammation in the hippocampus of AT-Nrf2-WT and AT-Nrf2-KO mice. A and B, 
Representative immunofluorescence images of GFAP staining in CA1 (A) and subiculum (B) regions of the 
hippocampus of 12-14 months old mice of the indicated genotypes. The area inside the boxes is shown at a higher 
magnification. C, Quantification of the number of GFAP positive cells relative to the total number of cells in CA1 
and subiculum. Data are mean ± SEM (n = 3). Statistical analysis was performed with Student’s t test. *p<0.05 
vs. AT-Nrf2-WT mice. D and E, Representative immunofluorescence images of CD11b staining in CA1 (D) and 
subiculum (E) regions of the hippocampus of 12-14 months old mice of the indicated genotypes. The area inside 
the boxes is shown at a higher magnification. F, Quantification of the number of CD11b positive cells relative to 
the total number of cells in CA1 and subiculum. Data are mean ± SEM (n = 3). Statistical analysis was performed 
with Student’s t test. *p<0.05 vs. AT-Nrf2-WT mice. 
 
The expression levels of some inflammatory genes were analyzed by qRT-PCR (Fig. 
22B). In line with our previous results, no significant changes in the expression of Gfap were 
detected between AT-Nrf2-KO and AT-Nrf2-WT mice. However, AT-Nrf2-KO mice  
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Figure 22. NRF2 deficiency increases microglial activation and pro-inflammatory gene expression. A, 
Representative immunofluorescence images of IBA1 and MHCII staining in the hippocampus of 12-14 months 
old mice of the indicated genotypes. The area inside the boxes is shown at a higher magnification. B, Expression 
levels of the indicated genes from hippocampus of AT-Nrf2-WT and AT-Nrf2-KO mice were determined by 
qRT-PCR and normalized to ActB levels. Data are mean ± SEM (n=4). Statistical analysis was performed with 
Student’s t test. *p<0.05, vs. AT-Nrf2-WT mice. 
 
 
exhibited a modest but significant increase in the expression levels of the pro-inflammatory 
Cd11b, Il6 and Nos2 genes when compared to age-matched AT-Nrf2-WT mice. 
Altogether, these results indicate that the proteinopathy induced by APP(V717I) and 
TAU(P301L) induces a modest gliosis and neuroinflammation that is detectable at 12-14 
months of age. 
 
7. NRF2 deficiency impairs autophagy in vivo. 
 
7.1. NRF2 deficiency results in reduced levels of macroautophagy markers in 
neurons.  
 
First of all, we analyzed macroautophagy gene expression in hippocampal/cortical 
primary neurons by qRT-PCR (Fig. 23). In line with our previous results in MEFs, Nrf2-KO
 
cells exhibited impaired expression of Sqstm1, Calcoco2, Ulk1, Atg2b, Atg5, Atg7 and 
Gabarapl1. These results confirm the role of NRF2 in the modulation of autophagy-related 
genes in neurons. 
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Figure 23. NRF2 deficiency impairs autophagy gene 
expression in neurons. Expression levels of the 
indicated genes from Nrf2-WT and Nrf2-KO primary 
hippocampal/cortical neurons were determined by 
qRT-PCR and normalized to Actb levels. Data are 
mean ± SEM (n=3). Statistical analysis was performed 
with Student’s t test. *p<0.05, vs. Nrf2-WT neurons. 
 
 
Autophagy gene expression was then evaluated in the hippocampus of Nrf2-WT, Nrf2-
KO, AT-Nrf2-WT and AT-Nrf2-KO mice by qRT-PCR. In agreement with previous studies 
201
, 11-13 months old Nrf2-KO
 
mice had minimal changes in the expression levels of bona 
fide NRF2-dependent genes compared to Nrf2-WT mice, Aox1 (coding aldehyde oxidase 1) 
being the most significant. Comparison of AT-Nrf2-WT vs. AT-Nrf2-KO hippocampus also 
showed a small but significant change in the expression of Sqstm1, Atg2b, and Gabarapl1 
(Table 8). 
Due to the small changes found in whole brain tissue, we reasoned that the effect of 
NRF2 on autophagy might be more evident in the neurons that express human mutant APP 
and TAU proteins. Therefore, we performed immunofluorescence analysis of autophagy 
 
 Gene Nrf2-WT Nrf2-KO  AT-Nrf2-WT  AT-Nrf2-KO 
p-value 
(Nrf2-WT 
vs Nrf2-
KO) 
p-value 
(AT-Nrf2-
WT vs AT-
Nrf2-KO) 
Sqstm1 1,0±0,15 0,63±0,14 0,67±0,03 0,55±0,04 0.12 *0.05 
Calcoco2 1,00±0,02 1,56±0,27 1,24±0,15 1,12±0,23 0.08 0.67 
Ulk1 1,00±0,07 0,98±0,15 0,85±0,04 0,70±0,09 0.9 0.17 
Atg2b 1,00±0,05 1,06±0,12 0,69±0,04 0,48±0,02 0.66 **0.003 
Atg3 1,00±0,15 1,2±0,15 1,13±0,11 1,12±0,10 0.38 0.95 
Atg4d 1,00±0,11 1,17±0,09 1,09±0,19 1,06±0,13 0.27 0.9 
Atg5 1,00±0,27 1,32±0,05 1,51±0,14 1,35±0,09 0.28 0.37 
Atg7 1,00±0,11 1,05±0,09 0,84±0,18 0,73±0,13 0.73 0.63 
Gabarapl1 1,00±0,06 1,21±0,22 1,45±0,07 0,83±0,16 0.39 *0.021 
Hmox1 1,00±0,03 1,11±0,05 1,27±0,17 1,23±0,10 0.1 0.84 
Aox1 1,00±0,17 0,44±0,08 0,90±0,07 0,56±0,11 *0.02 *0.04 
 
 
 
 
Table 8. Analysis of NRF2-dependent genes in the hippocampus of Nrf2-WT, Nrf2-KO, AT-Nrf2-WT and AT-
Nrf2-KO 11-13 months old mice. Expression levels of the indicated genes were determined by qRT-PCR and 
normalized to Actb levels. Data are mean ± SEM (n=4). Statistical analysis was performed with Student’s t test. 
*p<0.05 and **p<0.01 vs. the indicated genotype. 
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proteins in APP- or TAU-expressing neurons in sagittal brain sections of AT-Nrf2-WT and 
AT-Nrf2-KO mice. As shown in Fig. 24, the protein levels of p62, NDP52, ULK1, ATG5 and 
GABARAPL1 were reduced in neurons of the AT-Nrf2-KO mice expressing APP, compared 
to those of AT-Nrf2-WT mice. The same approach was followed with TAU-expressing 
neurons, obtaining similar results (Fig. 25). Moreover, we analyzed LC3B staining in the 
hippocampus as an estimate of overall autophagy. We found that LC3B protein levels were 
also reduced in neurons of AT-Nrf2-KO vs. AT-Nrf2-WT mice expressing APP (Fig. 24F) or 
TAU (Fig. 25F). Together, these results indicate the relevance of NRF2 in the regulation of 
macroautophagy under proteotoxic stress in vivo. 
 
 
Figure 24. Reduced autophagy markers in APP/Aβ-expressing neurons from AT-Nrf2-KO mice. A-F, Confocal 
analysis of double immunofluorescence with anti-APP/Aβ (4G8, red) and anti-p62, NDP52, ULK1, ATG5, 
GABARAPL1 or LC3B (green) antibodies in the brains of AT-Nrf2-WT and AT-Nrf2-KO mice. Fluorescence 
intensity was analyzed in the cytosol of 100 randomly chosen APP/Aβ-positive neurons of each genotype. 
Quantification was derived from 3 independent experiments with 2 fields per experiment. Fluorescence intensity 
was quantified in 1.5-µm-thick stacks using ImageJ software. Data are mean ± SEM (n=3). Statistical analysis 
was performed with Student’s t test. *p<0.05, **p<0.01, ***p<0.001, vs. AT-Nrf2-WT mice. 
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Figure 25. Reduced autophagy markers in TAU-expressing neurons from AT-Nrf2-KO mice. A-F, Confocal 
analysis of double immunofluorescence with anti-TAU (HT7, red) and anti-p62, NDP52, ULK1, ATG5, 
GABARAPL1 or LC3B (green) antibodies in the brains of AT-Nrf2-WT and AT-Nrf2-KO mice. Fluorescence 
intensity was analyzed in the cytosol of 100 randomly chosen APP/Aβ-positive neurons of each genotype. 
Quantification was derived from 3 independent experiments with 2 fields per experiment. Fluorescence intensity 
was quantified in 1.5-µm-thick stacks using ImageJ software. Data are mean ± SEM (n=3). Statistical analysis 
was performed with Student’s t test. *p<0.05, **p<0.01 and ***p<0.001, vs. AT-Nrf2-WT mice. 
 
7.2. Higher oligomeric Aβ*56 levels and intracellular APP/Aβ aggregates in AT-
Nrf2-KO mice. 
 
To better understand the impact of reduced macroautophagy markers in neurons from 
AT-Nrf2-KO mice, we subsequently analyzed the toxic and aggregated forms of APP/Aβ and 
TAU. We first determined the expression levels of Adam10, Adam17, Bace1 and Psen1, 
encoding enzymes involved in APP processing. As shown in Fig. 26A, the mRNAs of these 
genes were not significantly altered by the lack of NRF2 in the APP/TAU-expressing mice. 
We then analyzed the levels of Aβ-oligomeric species that have been proposed to correlate 
with cognitive impairment in humans 
202
. Hippocampi from AT-Nrf2-WT and AT-Nrf2-KO 
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mice were separated into extracellular (EC) (Fig. 26B and 26C) and membrane-bound (MB) 
fractions (Fig. 26B and 26D), and subjected to immunoblot with antibodies specific for 
certain APP and Aβ domains (Fig. 26B). We did not detect significant differences in the 
levels of full-length APP (holoAPP), the soluble form released by α-secretase cleavage 
(sAPPα), the soluble form released by β-secretase cleavage (sAPPβ), or the oligomers Aβ (3-
mer), Aβ (6-mer) or Aβ (2-mer). However, NRF2 deficiency significantly increased the levels 
of the toxic Aβ*56 oligomer in both the extracellular and the membrane-bound fractions (Fig. 
26C-E).  
 
 
 
Figure 26. NRF2 deficiency leads to Aβ*56 accumulation. A, Scheme showing APP processing by α-, β- and γ-
secretases and the location of the epitopes recognized by the different antibodies employed. B and C, 
Hippocampal homogenates of 12-14 months old AT-Nrf2-WT and AT-Nrf2-KO mice were separated into 
extracellular (EC) and membrane-bound (MB) fractions and immunoblotted with the indicated antibodies. 
Samples from APP/PS1 and wild type mice were used as positive and negative controls, respectively. The 
asterisks indicate non-specific bands. D, Densitometric quantification of immunoblots from B and C. Data are 
mean ± SEM (n=5). Statistical analysis was performed with Student’s t test. *p<0.05 and **p<0.01 vs. AT-Nrf2-
WT mice. E, Expression levels of the indicated genes determined by qRT-PCR and normalized to ActB levels. 
Data are mean ± SEM (n=4). Statistical analysis was performed with Student’s t test. *p<0.05, vs. AT-Nrf2-WT 
mice. 
 
Results 
110 
Increased A*56 levels might be related to either oxidative alterations of the 
amyloidogenic pathway or impaired clearance of the oligomers. To gain a better 
understanding on the formation of Aβ peptides in these mice, the soluble and insoluble levels 
of the amyloidogenic Aβ40 and Aβ42 peptides were determined by ELISA. Similar levels of 
soluble Aβ40 and Aβ42 peptides were detected in AT-Nrf2-WT and AT-Nrf2-KO mice (Fig. 
27A and 27B). However, NRF2 deficiency resulted in reduced insoluble Aβ40 (Fig. 27A) and 
Aβ42 (Fig. 27B) in the hippocampus. These results are consistent with the fewer number of 
amyloid plaques that we had observed in the AT-Nrf2-KO mice (Fig. 16D), where most of the 
insoluble Aβ accumulates. Because macroautophagy has been shown to be necessary for Aβ 
secretion 
157
, we performed immunohistochemical staining of hippocampal sections of AT-
Nrf2-WT and AT-Nrf2-KO mice to determine APP/Aβ localization. As observed in Fig. 27D 
and 27E, we found more intracellular vesicles in neurons from AT-Nrf2-KO mice when 
compared to AT-Nrf2-WT sections. This was most notorious in the subiculum, which was the 
first brain region to develop amyloidopathy. Taken together, these results suggest that NRF2 
deficiency impairs proteostasis of APP/Aβ leading to the accumulation of this protein inside 
neurons. 
 
7.3. AT-Nrf2-KO mice have increased levels of insoluble hyperphosphorylated 
TAU. 
 
Different post-translationally modified forms of TAU, including 
hyperphosphorylation, can abnormally aggregate into paired helical filaments (PHFs) and 
neurofibrillary tangles (NFTs) in AD. This insoluble TAU fraction can be extracted with 
sarkosyl detergent. Despite not observing major differences in TAU immunostaining in the 
hippocampus of AT-Nrf2-KO vs. their wild type counterparts (Fig. 28A), we detected with 
anti-total TAU antibody (clon TAU46) a modest but significant increase in the levels of both 
murine endogenous and human transgenic TAU in the sarkosyl-insoluble fractions from AT-
Nrf2-KO when compared to AT-Nrf2-WT hippocampal homogenates (Fig. 28B and 28C). 
These results reflected that both transgenic and endogenous TAU are prone to accumulate in 
the insoluble fraction in the absence of NRF2.  
 
Results 
111 
 
Figure 27. NRF2 deficiency leads to intracellular APP/Aβ accumulation. A-B, Determination of Aβ levels by 
ELISA in hippocampal brain homogenates of 12-14 months old AT-Nrf2-WT and AT-Nrf2-KO mice. Aβ40 (A) 
and Aβ42 (B) levels were measured in the soluble (SF) and insoluble (IF) fractions (formic acid extracted) and 
normalized by total protein amount. C, Ratio of IF/SF of Aβ40 and Aβ42 peptides. Data are mean ± SEM (n = 
10). Statistical analysis was performed with Student’s t test. * p<0.05 and ** p < 0.01 vs. AT-Nrf2-WT mice. D, 
Representative immunohistochemistry images of APP/Aβ (4G8) in the hippocampus of 13 months old AT-
Nrf2-WT (a, b, c) and AT-Nrf2-KO (d, e, f) mice; a and d, low magnification of the hippocampus; b and e, 
details of the CA1 layer ; c and f, details of subiculum. E, Quantification of the number of APP/Aβ positive 
granules in CA1 and subiculum from 12-14 months old AT-Nrf2-WT and AT-Nrf2-KO mice. Data are mean ± 
SEM (n = 8). Statistical analysis was performed with Student’s t test. *p<0.05 and **p < 0.01 vs. AT-Nrf2-WT 
mice. 
 
To gain more insight on how NRF2 deficiency can affect TAU phosphorylation, we 
analyzed the hippocampus by immunohistochemistry with the anti-pTAU antibody (clon 
AT8) specific for phosphorylated hTAU at residues Ser-202 and Thr-205 (Fig. 29A). As 
shown in Fig. 29B, no clear differences in phospho-TAU pattern were observed in either CA1 
or subiculum regions of the hippocampus between AT-Nrf2-WT and AT-Nrf2-KO mice. We 
next analyzed phospho-TAU in the soluble and insoluble fractions employing anti-pTAU 
antibody (PHF1) specific for phosphorylated hTAU at residues Ser-396 and Thr-404. As  
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Figure 28. NRF2 deficiency leads to the accumulation of insoluble TAU. A, Representative 
immunohistochemistry images of human TAU (HT7) staining in the hippocampus (CA1 -b and e- and subiculum-
c and f-) of 12-14 months old mice of the indicated genotypes. B, Hippocampal tissue lysates from AT-Nrf2-WT 
(WT) and AT-Nrf2-KO (KO) mice were separated into sarkosyl-soluble (SS) and sarkosyl-insoluble (SI) 
fractions. Total human and murine TAU levels were determined by immunoblot with anti-TAU (TAU46) 
antibody. C, Densitometric quantification of representative immunoblots from B. Data are mean ± SEM (n=6). 
Statistical analysis was performed with Student’s t test. *p<0.05, vs. AT-Nrf2-WT mice. 
 
shown in Fig. 29C, three forms of phospho-TAU, termed hP1, hP2 and hP3, were detected 
with the PHF1 antibody when separated by SDS-PAGE, which represent various degrees of 
phosphorylation. AT-Nrf2-KO mice exhibited higher levels of phosphorylated TAU in both 
fractions, and increased insoluble to soluble ratio of the hP2 TAU form was found in 
comparison to the AT-Nrf2-WT mice (Fig. 29C and 29D).  
These results strongly suggest that the loss of NRF2 impairs TAU proteostasis, leading 
to its abnormal hyperphosphorylation and accumulation into insoluble aggregates. 
 
7.4. Decreased co-localization of APP/Aβ and TAU with p62 in the absence of 
NRF2. 
 
To discern if the accumulation of intracellular APP/Aβ and TAU in the AT-Nrf2-KO 
mice was due to impaired macroautophagy, we analyzed the localization of human APP/Aβ 
and TAU proteins in connection to the macroautophagy receptor p62 by double 
immunofluorescence staining. As observed in Fig. 30A and 30B, in AT-Nrf2-WT mice most 
APP/Aβ vesicles were decorated with the NRF2-regulated autophagy gene product p62, 
resulting in multiple yellow dots. In contrast, AT-Nrf2-KO mice showed less co-localization 
of APP/Aβ with p62, as reflected by fewer yellow dots and reduced Mander’s co-localization  
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coefficients. Moreover, we could detect larger and apparently swollen APP/Aβ positive 
vesicles compared to those in the AT-Nrf2-WT mice (Fig. 30A). TAU showed a more diffuse 
pattern than APP/Aβ, but again AT-Nrf2-KO mice exhibited less co-localization between 
TAU and p62 (Fig. 30C and 30D). Overall, these results suggest that the expression of human 
mutant APP and TAU proteins increase the need for macroautophagy, which cannot be 
fulfilled efficiently in NRF2-deficient mice due to the reduced expression of macroautophagy 
genes.  
 
8. Evidence of altered NRF2 and macroautophagy in AD patients. 
 
In order to determine if this new functional axis has an impact on the AD brain, we 
examined the levels of NRF2 and several macroautophagy products in lysates from brain 
hippocampus of asymptomatic control individuals and AD donors (Fig. 31A and 31B). The 
levels of NRF2 and one of its downstream targets, HMOX1, were increased in AD patients  
 
Figure 29. Increased insoluble phospho-TAU in the absence of NRF2. A, Scheme of 4R TAU showing the 
phosphorylated residues recognized by the AT8 and PHF1 antibodies. B, Representative immunohistochemistry 
images of human phospho-TAU (AT8) staining in CA1 and subiculum zones of the hippocampus from 12-14 
months old AT-Nrf2-WT and AT-Nrf2-KO mice. C, Immunoblot analysis of sarkosyl-insoluble (SI) and sarkosyl-
soluble (SS) phospho-TAU fractions with the PHF1 antibody. D, Densitometric quantification of representative 
immunoblots from C. Data are mean ± SEM (n=6). Statistical analysis was performed with Student’s t test. 
*p<0.05, vs. AT-Nrf2-WT mice. 
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Figure 30. NRF2 modulates neuronal autophagy. A, Confocal analysis of double immunofluorescence with anti-
APP/Aβ (4G8, red) and anti-p62 (green) antibodies in subiculum of AT-Nrf2-WT and AT-Nrf2-KO mice. B, 
Quantification of co-localization between APP/Aβ and p62 staining expressed as Mander’s coefficients. C, 
Confocal analysis of double immunofluorescence with anti-TAU (HT7, red) and anti-p62 (green) in subiculum of 
AT-Nrf2-WT and AT-Nrf2-KO mice. D, Quantification of co-localization between TAU and p62 expressed as 
Mander’s coefficients. For B and D, Mander’s coefficients were derived from 3 independent experiments with 2 
fields per experiment. Fluorescence was quantified in 1.5-µm-thick stacks using the JACoP plugin of ImageJ 
software. Data are mean ± SEM (n=6). Statistical analysis was performed with Student’s t test. *p<0.05 and 
***p<0.001  vs. AT-Nrf2-WT mice. 
 
vs. controls. The levels of at least the macroautophagy proteins p62, NDP52 and ATG7 were 
also increased. A slower migrating band, which could represent phosphorylated p62, was 
increased in AD samples. These results show a positive correlation between NRF2 levels and 
macroautophagy proteins in AD samples when compared to controls. 
Then, we analyzed more specifically the NRF2/p62 pathway in neurons from AD 
patients by immunohistochemistry. Because it was technically not possible to perform triple 
labeling due to the different retrieval requirements for each of the antigens, we analyzed 3 
adjacent sections (each 4 μm-thick) containing the same cells. We observed intracellular 
APP/Aβ in dense vesicles, similar to the ones observed in AT-Nrf2-WT and AT-Nrf2-KO 
mice (Fig. 31C). Neurons in the AD brains with the highest abundance of vesicular APP/Aβ 
were found in the entorhinal cortex, and also expressed high levels of NRF2 and p62 (Fig. 
31C a-c). Similarly, some scattered neurons were found in the cortex that presented TAU-
positive neurofibrillary tangles, stained with anti-TAU (clon HT7). Such neurons that were 
intensely stained for TAU were also expressing high levels of nuclear NRF2 and p62 (Fig. 
31C d-f). These results confirm in human brain that NRF2 and its target p62 are up-regulated 
in neurons suffering from proteotoxic APP/Aβ or TAU insults. 
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Figure 31. Evidence of NRF2 up-regulation in neurons of AD subjects expressing high levels of APP/Aβ and 
TAU. A, Immunoblot analysis of NRF2, HMOX1, p62, NDP52, and ATG7 in hippocampus of asymptomatic 
controls and patients with diagnosed AD with combined amyloidopathy and tauopathy. B, Densitometric 
quantification of protein levels from representative immunoblots of A relative to ACTB. Data are mean ± SEM 
(n=5 controls and n=5 AD subjects). Statistical analysis was performed with Student’s t test. *p<0.05, *p<0.01 
and ***p<0.001  vs.  comparing control vs. AD groups. C, Adjacent 4-µm-thick brain sections from AD subjects 
were immunostained with anti-APP/Aβ (4G8) (a), anti-TAU (HT7) (d), anti-NRF2 (b and e) and anti-p62 (c and 
f) antibodies. Red arrows point to the same neuron expressing APP/Aβ or TAU, NRF2 and p62; blue arrows 
depict internal negative controls for cells that do not express APP/Aβ or TAU and present basal staining for 
NRF2 and p62. 
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II. NRF2 controls chaperone mediated 
autophagy through the regulation of 
Lamp2a 
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1. Identification of putative AREs in the LAMP2 gene. 
 
Following the same approach as with macroautophagy genes, we first searched the 
ENCODE database of the human genome for putative AREs in the LAMP2 gene. Although 
there are other important players for CMA, the levels of LAMP2A are considered the limiting 
step for this process 
127
.  
As shown in Fig. 32A, the human LAMP2 gene contains several MAFF, MAFK and 
BACH1 binding sites located in H3K27-histone acetylated and DNAse-sensitive regions, both 
factors being typical of active enhancers. We scanned these binding regions with the script 
described in the previous section seeking for putative AREs. We detected 8 putative AREs 
(Table 9) and 3 of them showed a relative score higher than the 80%, which is considered an 
adequate threshold for significance as previously mentioned.  
 
2. NRF2 binds to functional AREs in the LAMP2 gene. 
 
 To validate the AREs with the highest score (ARE1, ARE2 and ARE3), we analyzed 
NRF2 binding to these sequences by ChIP analysis. HEK293T cells were transfected with an 
expression vector for V5-tagged NRF2-
ΔEGTE
 to facilitate NRF2 stabilization and binding to 
its target genes. NRF2 was immunoprecipitated with an anti-V5 antibody and an anti-IgG 
antibody was used as a negative control. NRF2 binding was analyzed by qRT-PCR employing 
as template the immunoprecipitated DNA and primers designed to specifically amplify ARE1, 
ARE2 or ARE3. We detected NRF2 binding to the well-known positive control AREs in 
HMOX1, NQO1 and SQSTM1, whereas NRF2 did not bind to ACTB or to a region of NQO1 
that does not contain any ARE (NQO1*). Immunoprecipitation with V5 showed enrichment  
 
Gene Localization of the potential 
ARE  
Max 
Score 
Relative 
score 
Putative binding 
sequence 
LAMP2    (1) 
                 (2) 
                 (3) 
                 (4) 
                 (5) 
                 (6) 
                 (7) 
                 (8) 
chrX:119596430-119596441 
chrX:119 619599-119619610 
chrX:119619560-119619571 
chrX:119562034-119562045 
chrX:119603247-119603258 
chrX:119603427-119603416 
chrX:119562112-119562101 
chrX:119596457-119596446 
15.83 
13.24 
13.07 
10.62 
10.25 
10.0 
9.05 
4.84 
0.921 
0.859 
0.855 
0.796 
0.787 
0.781 
0.758 
0.657 
ATGACACTGCA 
TTGACTCAGCG 
ATGACAAACCA 
ATTACACATCA 
GTGATGTAGCG 
GTAACAAAGCT 
GTGGCTTAGAA 
AAAACCTAGCC 
Table 9. Putative Antioxidant Response Elements (AREs) in the LAMP2 gene. The table also shows the 
localization in the human genome, the max score and the relative score. 
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Figure 32. NRF2 binds to 2 functional antioxidant response elements (AREs) in the LAMP2 gene. A, Scheme of 
the LAMP2 gene from The Encyclopedia of DNA Elements at UCSC (ENCODE) for human genome, showing 
the 3 splice variants: LAMP2A, LAMP2B and LAMP2C. Putative AREs in the LAMP2 gene were identified taking 
as reference the available information from ChIP of ARE-binding factors MAFK, MAFF and BACH1. These 
regions were localized in 200-400 base-pair-long DNAse-sensitive and H3K27Ac-rich regions, i.e. most likely 
regulatory promoter regions. B, HEK293T cells were transfected with an expression vector for NRF2-
ΔETGE
-V5 
(lacking the KEAP1 regulatory domain). ChIP analysis was performed with anti-IgG or anti-V5 antibodies and 
the potential AREs with the highest score, termed ARE1, ARE2 and ARE3 (Table 9), were analyzed by qRT-
PCR. The figure shows representative data normalized as the fold of enrichment with the anti-V5 antibody vs. the 
IgG antibody. The presence of already known AREs in HMOX1, NQO1 and SQSTM1 was analyzed as positive 
control and ACTB, and a region of NQO1 that does not contain an ARE (NQO1*) were amplified as negative 
controls. C, Luciferase reporter constructs carrying 3 tandem putative ARE sequences from the LAMP2 gene (i-
iii) or a scramble sequence as negative control (iv) controlling the expression of luciferase. D, Nrf2-KO mouse 
embryo fibroblasts were co-transfected with the reporters represented in C and increasing amounts of NRF2-
ΔETGE
-V5 construct. Values were normalized to pTK-Renilla activity and presented as fold of change. Data are 
mean ± SEM (n = 3). Statistical analysis was performed using Student’s t test. *p< 0.05, ** p<0.01 and *** 
p<0.001 vs. basal levels.  
 
in ARE1 and ARE2 in LAMP2 but not in ARE3 (Fig. 32B). Therefore, NRF2 binds to at least 
two regulatory regions of LAMP2 gene denoted here as ARE1 and ARE2. 
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3. AREs found in LAMP2 are transcriptionally activated by NRF2. 
 
To address the functionality of the putative AREs found in the LAMP2 gene, we next 
generated luciferase reporters. Three tandem nucleotide sequences of each ARE1, ARE2 or 
ARE3, as well as a control aleatory sequence, were cloned in the promoter region of a 
luciferase reporter (pGL3bv) as shown in Fig. 32C. Nrf2-deficient cells were transiently co-
transfected with each of these constructs plus a Renilla expression vector (pTK-Renilla) used 
for normalization and increasing amounts of NRF2-
ΔETGE
-V5, measuring luciferase expression 
48 h after. We found that NRF2 expression induced luciferase activity in a concentration-
dependent manner in reporters carrying ARE1 and ARE2 but not ARE3 or the negative 
control (Fig. 32D).  
 
 
 
Figure 33. Importance of conserved residues for transcriptional activity of AREs in LAMP2. A, Consensus 
antioxidant response element (ARE) from the JASPAR database. The bigger a letter is, the more conserved is the 
nucleotide in that position among different already-known AREs. The asterisk shows the conserved G substituted 
to A. B, Luciferase reporter constructs carrying the 2 functional ARE sequences from the LAMP2 gene (i-ii) and 
the same sequences with a substitution G>A in the 9th position (iii-iv) controlling the expression of luciferase. C, 
Nrf2-KO mouse embryo fibroblasts were co-transfected with the control and mutated reporters in B and 0.1 µg of 
NRF2-
ΔETGE
-V5 construct. Values were normalized to pTK-Renilla activity and presented as fold of change. Data 
are mean ± SEM (n = 3). Statistical analysis was performed using Student’s t test. * p< 0.05, ** p<0.01 and *** 
p<0.001 vs. empty vectors. ## p<0.01 and ### p<0.001 vs. not mutated vectors. 
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According to the JASPAR consensus ARE shown in Fig. 33A, the most conserved 
nucleotides are a T, a G and an A in the 2
nd
, 3
rd
 and 4
th
 positions, respectively, together with a 
G and a C in the 9
th
 and 10
th
 positions. ARE1 and ARE2 (Fig. 33B a and c) contain all these 
conserved nucleotides, while ARE3 has a C instead of a G in the 9
th
 position. Therefore, we 
replaced the highly conserved G to A in ARE1 and ARE2, generating two new reporters 
shown in Fig. 33B b and d and analyzed luciferase/Renilla activity after co-transfection with 
0.1 µg NRF2-
ΔETGE
-V5. As shown in Fig. 33C, replacement of this single nucleotide reduced 
NRF2-induced luciferase expression in both ARE1 and ARE2. 
Altogether, these results confirm that ARE1 and ARE2 are transcriptionally activated 
by NRF2 and point to the importance of the conserved G in the 9
th 
position for their activity, 
probably explaining why ARE3 is not functional. 
 
4. Genetic manipulation of NRF2 results in alteration of LAMP2A levels. 
 
We analyzed the relevance of NRF2 on LAMP2A expression in HEK293T cells 
infected with a lentiviral vector expressing NRF2-
ΔETGE
-V5 or GFP as a negative control. At 3 
days post-infection, we analyzed mRNA expression and protein levels of the bona fide NRF2-
targets HMOX1 and p62, as well as LAMP2A. As shown in Fig. 34A-C, NRF2 
overexpression led to a modest but consistent increase in both the mRNA and protein levels 
of LAMP2A, as well as in the positive controls HMOX1 and p62.  
In addition, we used a knockdown strategy to reduce NRF2 activity in the lung 
carcinoma cell line A549, characterized by constitutive NRF2 activation 
178, 179
. A549 cells 
were infected with a lentiviral vector expressing a short hairpin RNA against human NFE2L2 
(shNRF2) or a random sequence used as a negative control (shCTRL). We analyzed mRNA 
and protein levels after 3 days of infection, observing that NRF2-knockdown reduced both 
mRNA and protein levels of HMOX1, p62 and also LAMP2A (Fig. 34D-F). We did not 
observe consistent differences in the expression levels of the LAMP2B or LAMP2C isoforms 
upon NRF2 overexpression (Fig. 34A-C) or silencing (Fig. 34D-F) (see Discussion).  
Our combined results in both human cell lines support a NRF2-dependent basal 
regulation of LAMP2A levels. Because CMA has been well characterized in liver, we focused 
most of the functional study on the regulation of LAMP2A by NRF2 in mouse hepatocytes. 
First, we determined mRNA levels of Lamp2a in Nrf2-WT vs. Nrf2-KO immortalized 
hepatocytes. In line with our results in human cells, NRF2 deficiency resulted in reduced 
Hmox1, Sqstm1 and Lamp2a expression levels (Fig. 35A). 
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Figure 34. LAMP2A levels are modified upon genetic manipulation of NRF2. A, HEK293T cells were 
transduced with GFP- or NRF2-
ΔETGE
-V5-expressing lentivirus (LV-GFP or LV-NRF2, respectively). Expression 
levels of the indicated genes were determined 3 days post-infection by qRT-PCR and normalized to ACTB levels. 
Data are mean ± SEM (n = 4). Statistical analysis was performed with Student’s t test. ***p<0.001 vs. LV-GFP-
infected cells. B, Representative immunoblots for the indicated proteins in cells transduced in A. C, 
Densitometric quantification of representative immunoblots from B relative to ACTB protein levels. Data are 
mean ± SEM (n=4). Statistical analysis was performed using Student’s t test. *p<0.05 vs. LV-GFP-infected cells. 
D, A549 cells were transduced with a lentivirus carrying shRNA against a scramble sequence (shCTRL) or 
against NRF2 (shNRF2). Expression levels of the indicated genes were determined 3 days post-infection by qRT-
PCR and normalized to ACTB levels. Data are mean ± SEM (n = 4). Statistical analysis was performed with 
Student’s t test. *p<0.05, **p<0.01 and ***p<0.001 vs. shCTRL infected cells. E, Representative immunoblots 
for the indicated proteins in cell lysates from cells transduced as in D. F, Densitometric quantification of 
representative immunoblots from E relative to ACTB protein levels. Data are mean ± SEM (n=4). Statistical 
analysis was performed using Student’s t test. . *p<0.05; **p<0.01 and ***p<0.001 vs. shCTRL infected cells. 
 
We next performed a rescue experiment, in which lentivirally-induced overexpression 
of NRF2-
ETGE
-V5 partially rescued the mRNA expression of these 3 genes in Nrf2-KO 
hepatocytes (Fig. 35B). Accordingly, a modest reduction in LAMP2A protein levels was 
detected in whole cell lysates of Nrf2-KO hepatocytes when compared to Nrf2-WT lysates 
(Fig. 35C and 35D). We then isolated lysosomes and immunoblotted them for LAMP2A, 
taking LAMP1 as a control lysosomal protein that is not involved in CMA. Very relevant,  
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Figure 35. LAMP2A levels are reduced in the absence of NRF2. A, Expression levels of Hmox1, Sqstm1 and 
Lamp2a from Nrf2-WT and Nrf2-KO immortalized hepatocytes were determined by qRT-PCR and normalized to 
Actb levels. Data are mean ± SEM (n = 4). Statistical analysis was performed with Student’s t test. **p<0.01 and 
***p<0.001 vs. Nrf2-WT cells. B, Nrf2-KO immortalized hepatocytes were rescued with an NRF2-
ΔETGE
-V5-
expressing lentivirus (LV-NRF2). Expression levels of Hmox1, Sqstm1 and Lamp2a were analyzed 3 days post-
infection by qRT-PCR and normalized to Tbp levels. The dotted line represents expression levels of cells 
transduced with a control lentivirus (LV-GFP). Data are mean ± SEM (n=4). Statistical analysis was performed 
with Student’s t test. **p<0.01 and ***p<0.001 vs. LV-GFP infected cells. C, Representative immunoblots for 
the indicated proteins in Nrf2-WT and Nrf2-KO hepatocytes. D, Densitometric quantification of representative 
immunoblots from C relative to LAMIN B levels. Data are mean ± SEM (n=3). Statistical analysis was performed 
using Student’s t test. **p<0.01 and ***p<0.001 vs. Nrf2-WT cells. E, Representative immunoblots of LAMP2A 
and LAMP1 in homogenates (Hom) and isolated lysosomes (Lys) from Nrf2-WT and Nrf2-KO hepatocytes. F, 
Densitometric quantification of representative immunoblots from E relative to LAMP1 levels. Data are mean ± 
SEM (n=6). Statistical analysis was performed using Student’s t test. ***p<0.001 vs. Nrf2-WT levels. G, 
Confocal analysis of double immunofluorescence with anti-LAMP2A (red) and anti-LAMP1 (green) antibodies 
in Nrf2-WT and Nrf2-KO hepatocytes. The inset shows a higher magnification of the indicated cell. H, 
Quantification of the total number of LAMP2A-positive puncta per cell. Values are mean ± SEM (n=3, with >50 
cells counted per experiment). Statistical analysis was performed using Student’s t test. *p<0.05 vs. Nrf2-WT 
cells. 
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there was a dramatic reduction in lysosomal LAMP2A levels in the absence of NRF2, 
whereas no changes or even a slight increase in LAMP1 could be observed (Fig. 35E and 
35F). Finally, we analyzed LAMP2A levels in lysosomes by immunofluorescence and, as 
shown in Fig. 35G and 35H, the overall intensity and the number of puncta per cell of 
LAMP2A (red), which co-localized with LAMP1 (green), were dramatically reduced in Nrf2-
KO compared with Nrf2-WT hepatocytes. From these results we conclude that the absence of 
NRF2 correlates with a reduction in mRNA and protein levels of LAMP2A, especially in the 
lysosomal fraction.  
 
5. NRF2 induces LAMP2A upon oxidative stress. 
 
The physiological significance of this novel regulation was evaluated in the context of 
oxidative stress. First, we characterized the redox status of immortalized hepatocytes derived 
from Nrf2-WT or Nrf2-KO mice. We employed the fluorescent dye dihydroethidium (DHE), 
which can be oxidized to ethidine by ROS (especially superoxide), exhibiting bright red 
fluorescence. As shown in Fig. 36A and 36B, DHE staining did not reflect major differences 
in ROS levels between Nrf2-WT or Nrf2-KO hepatocytes under basal conditions. However, 
upon treatment with the oxidative stress-inducing drug paraquat (PQ, 200 µM, 16 h), Nrf2-
KO hepatocytes exhibited increased DHE fluorescence compared to Nrf2-WT cells.  
Considering that NRF2 controls the production of the universal reducing agent 
NADPH, we analyzed the ratio between oxidized NADP
+
 and reduced NADPH in these cells 
by a colorimetric method. As expected, Nrf2-KO hepatocytes showed an augmented 
NADP
+
/NADPH ratio, indicative of increased oxidative status (Fig. 36C). Altogether, these 
results suggest that the NADPH levels in Nrf2-KO hepatocytes may be sufficient to handle 
ROS under basal conditions (similar DHE staining), but not in the presence of oxidants such 
as PQ (increased ROS in Nrf2-KO cells as reflected by DHE staining). In the context of 
CMA, a more oxidant environment should result in increased Lamp2a levels. Nevertheless, 
treatment with increasing concentrations of PQ (Fig. 36D and 36E) and H2O2 (Fig. 36F and 
36G) for 16 h, led to increased NRF2, HMOX1, p62 and LAMP2A levels in Nrf2-WT but not 
in Nrf2-KO hepatocytes.  
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Figure 36. Oxidants induce LAMP2A in a NRF2-dependent manner. A, Representative images of ROS levels 
determined with dihydroethidium (DHE) in immortalized Nrf2-WT and Nrf2-KO hepatocytes under basal 
conditions (VEH) or after treatment with paraquat (PQ, 200 µM, 16 h). The probe was added to a final 
concentration of 5 µM 1 h before in vivo imaging of the cells. B, Corrected total cell fluorescence of 
representative images from A. Values are mean ± SEM (n=100 cells, derived from at least 3 different fields). 
Statistical analysis was performed using Student’s t test. ***p<0.001 vs. untreated conditions; ###p<0.001 vs. 
Nrf2-WT cells. C, NADP:NADPH ratio in Nrf2-WT and Nrf2-KO hepatocytes. Data are mean ± SEM (n=4). 
Statistical analysis was performed using Student’s t test. **p<0.01 vs. Nrf2-WT cells. D-G, Immortalized 
hepatocytes from Nrf2-WT and Nrf2-KO mice were submitted to the indicated concentrations of PQ (D-E) or 
hydrogen peroxide (H2O2) (F-G) for 16 h. Representative immunoblots for the indicated proteins in cell lysates. E 
and G, Densitometric quantification of representative immunoblots from D and F, respectively, relative to 
LAMIN B protein levels. Data are mean ± SEM (n=3). Statistical analysis was performed using Student’s t test. 
*p<0.05, **p<0.01 and ***p<0.001 vs. untreated conditions 
Results 
125 
6. NRF2 controls CMA activity under basal and oxidant conditions. 
 
We analyzed CMA activity in Nrf2-WT vs. Nrf2-KO hepatocytes by using a lentivirus 
expressing the photoactivable CMA-specific fluorescent substrate KFERQ-PS-Dendra 
(modified from 
189
). Upon 405 nm light exposure, Dendra protein is modified to emit red 
fluorescence. This tool allows tracking the subcellular localization of this protein without the 
interference of newly synthesized protein. CMA activity is then detected as a change from 
diffuse (cytosolic) fluorescence to a punctate (lysosomal) pattern, as the fluorescence 
substrate is delivered to CMA-active lysosomes (see Fig. 8 in ‘Materials and Methods’). As 
shown in Fig. 37A and 37C, Nrf2-WT cells exhibited a low cytosolic signal and some 
Dendra-positive fluorescent puncta, reflecting basal CMA activity. However, a more intense 
and diffuse fluorescent pattern throughout the cytoplasm, together with an extremely reduced 
number of Dendra-positive puncta per cell, were observed in Nrf2-KO cells, consistent with 
impaired basal CMA activity. This observation indicates that the KFERQ-PS-Dendra reporter 
is not being properly degraded by CMA and accumulates in the cytosol. Besides, when cells 
were treated with PQ, a well-characterized activator of CMA 
124
, we found a significant 
increase in Dendra-positive puncta per cell in Nrf2-WT but not in Nrf2-KO hepatocytes, 
indicating impaired induction of CMA by PQ in the absence of NRF2 (Fig. 37B and 37C).  
 
 
Figure 37. The oxidant agent paraquat (PQ) induces CMA in a NRF2-dependent manner. A and B, Nrf2-WT and 
Nrf2-KO hepatocytes were transduced with a lentivirus carrying the CMA reporter KFERQ-PS-Dendra and, after 
photoswitching, were cultured without additions (A) or in the presence of 100 µM paraquat (PQ) (B) for 16 h. 
CMA was analyzed as the number of fluorescent puncta per cell at the end of the incubation time. Representative 
full-field images and inset showing black and white high magnification of the boxed regions in the Dendra 
channel. C, Quantification of the number of puncta per cell after the indicated treatment. Values are mean ± SEM 
(n=3, with >75 cells per experiment). Statistical analysis was performed using Student’s t test. **p<0.01 and 
***p<0.001 vs. Nrf2-WT cells or untreated conditions. 
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7. Pharmacological activation of NRF2 induces LAMP2A and CMA. 
 
We next used two well-established activators of NRF2, sulforaphane (SFN) and 
dimethylfumarate (DMF), to test if pharmacological activation of NRF2 could lead to 
augmented LAMP2A levels. As observed in Fig. 38A to 38D, treatment of Nrf2-WT 
hepatocytes with increasing concentrations of SFN (Fig. 38A-B) or DMF (Fig. 38C-D) for 16 
h led to increased protein levels of NRF2, HMOX1, p62 and also LAMP2A, and this response 
was abolished in Nrf2-KO cells.  
As shown in Fig. 38E and 38F, immunofluorescence analysis of LAMP2A (red) and 
LAMP1 (green) revealed that SFN-treated cells displayed mobilization of lysosomes (labeled 
either with LAMP2A or LAMP1) toward the perinuclear region, a typical characteristic of 
CMA activation 
124
. Nevertheless, perinuclear LAMP2A fluorescence was much lower in the 
absence of NRF2.   
To confirm CMA activation, we transduced cells with the KFERQ-PS-Dendra reporter 
(Fig. 39A and 39B). Under basal conditions, we found some Dendra positive puncta in Nrf2-
WT vs. a much more diffuse pattern with almost no puncta in Nrf2-KO hepatocytes. SFN 
treatment induced a significant dose-dependent increase in Dendra-positive puncta per cell in 
Nrf2-WT cells (note that because perinuclear relocation made individual puncta indiscernible, 
data are presented as punctate KFERQ-Dendra positive area per cell). By contrast, SFN 
treatment failed to upregulate CMA in the absence of NRF2.  
All in all, NRF2 pharmacological up-regulation induces LAMP2A expression and, 
consequently, CMA activation. 
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Figure 38. Pharmacological activation of NRF2 induces LAMP2A. A-D, Immortalized hepatocytes from Nrf2-
WT and Nrf2-KO mice were submitted to the indicated concentrations of sulforaphane (SFN) or dimethyl 
fumarate (DMF) for 16 h. Representative immunoblots for the indicated proteins in cell lysates. B and D, 
Densitometric quantification of representative immunoblots from A and C, respectively, relative to LAMIN B 
protein levels. Data are mean ± SEM (n=3). Statistical analysis was performed using Student’s t test. *p<0.05 and 
**p<0.01 vs. untreated conditions. E, Confocal analysis of double immunofluorescence with anti-LAMP2A (red) 
and anti-LAMP1 (green) antibodies in immortalized Nrf2-WT and Nrf2-KO hepatocytes treated with vehicle 
(VEH) or sulforaphane (SFN, 15 µM, 16 h). The inset shows a higher magnification of the indicated cells. F, 
Radial profile of LAMP2A fluorescence in cells treated with SFN in E. The graph shows the total mean 
fluorescence as a function of radial distance to the center of the cell. The dashed line represents the nuclear limits. 
Quantification was done with Z-stack. Values are mean ± SEM (n=3, with >50 cells counted per experiment).  
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Figure 39. Nrf2-WT and Nrf2-KO hepatocytes were transduced with a lentivirus carrying the CMA reporter 
KFERQ-PS-Dendra and, after photoswitching, were cultured without additions or in the presence of 10 µM or 20 
µM SFN for 16 h. CMA was analyzed as the area positive for fluorescent puncta per cell at the end of the 
incubation time. Representative full-field images and inset showing black and white high magnification of the 
boxed regions in the Dendra channel. B, Quantification of the KFERQ-Dendra-positive area per cell. Values are 
mean ± SEM (n=3, with >75 cells per experiment). Statistical analysis was performed using Student t test. 
**p<0.01 and ***p<0.001 vs. untreated conditions. 
 
8. CMA activation by NRF2 is independent on macroautophagy. 
 
 Previous studies have shown multiple levels of cross-talk between CMA and 
macroautophagy 
132, 137, 203
. Because we have shown that NRF2 regulates macroautophagy, we 
investigated if CMA activation by NRF2 was a direct effect or a consequence of changes in 
macroautophagy. We employed Atg5-KO MEFs since ATG5 is a non-redundant and essential 
protein in macroautophagy, enabling LC3 conjugation to phosphatidylethanolamine, as 
demonstrated by the fact that Atg5-KO cells are unable to construct autophagosomes properly 
204
. We treated Atg5-KO MEFs with increasing concentrations of SFN for 16 h, and still 
observed induction of LAMP2A (Fig. 40A and 40B). We also evaluated CMA in Atg5-WT 
and Atg5-KO MEFs transduced with the KFERQ-PS-Dendra reporter. As presented in Fig. 
40C and 40D, basal CMA activity was slightly higher in Atg5-KO cells, consistent with CMA 
up-regulation due to impairment of macroautophagy. However, SFN resulted in a similar 
increase in the area positive of puncta per cell independent on the genotype. These findings 
indicate that the regulation of CMA by NRF2 occurs, for the most part, independently of 
changes in macroautophagy.  
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Figure 40. Pharmacological activation of NRF2 with sulforaphane (SFN) modulates LAMP2A and CMA 
independently of macroautophagy. A and B, MEFs from Atg5-KO mice were submitted to the indicated 
concentrations of SFN for 16 h. Representative immunoblot of LAMP2A levels (A) and expression levels of 
Lamp2a determined by qRT-PCR and normalized to Actb levels (B). Data are mean ± SEM (n = 3). Statistical 
analysis was performed using Student's t test. **p<0.01 untreated conditions. C, Atg5-WT and Atg5-KO MEFs 
were transduced with a lentivirus carrying the CMA reporter KFERQ-PS-Dendra and, after photoswitching, were 
cultured in 96-well glass-bottom plates without additions or in the presence of sulforaphane (SFN, 30 µM, 16 h). 
Cells were imaged using high-content microscopy and CMA was analyzed as the number of fluorescent puncta 
per cell at the end of the incubation time. Representative full-field images and inset at higher magnification. D, 
Quantification of the number of puncta per cell after the indicated treatment. Values are mean ± SEM (n=3, with 
>25000 cells per experiment). Statistical analysis was performed using Student’s t test. ***p<0.001 vs. untreated 
conditions. 
 
9. Conservation of the NRF2/LAMP2A axis among different cell types. 
 
We analyzed the regulation of LAMP2A by NRF2 in different cell types upon genetic 
and pharmacological NRF2 manipulation. In addition to human A549 and murine 
hepatocytes, reduction of LAMP2A/Lamp2a levels in the absence of NRF2 was also 
confirmed in human astrocytes and mouse HT22 cells with NRF2-knockdown, as well as 
MEFs and cortical neurons derived from Nrf2-WT vs Nrf2-KO mice (Fig.41A and 41B).  
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Figure 41. NRF2-LAMP2A axis is functional in different cell types. A, Immunoblot of the indicated proteins in 
human primary astrocytes transduced with lentivirus carrying shRNA against a scramble sequence (shCTRL) or 2 
different shRNA against Nrf2 (shN-36 and shN-37). B, Expression levels of Hmox1, Sqstm1 and Lamp2a in 
primary mouse embryonic fibroblasts (MEFs) and primary cortical neurons obtained from Nrf2-WT and Nrf2-KO 
mice, as well as hippocampal murine HT22 cells transduced with lentivirus carrying shRNA against a scramble 
sequence (shCTRL) or Nrf2 (shNrf2), were determined by qRT-PCR and normalized to Actb levels. Data are 
mean ± SEM (n = 3). Statistical analysis was performed using Student's t test. *p<0.05 and **p<0.01 vs. Nrf2-
WT or shCTRL cells.  
 
 
Figure 42. NRF2-LAMP2A axis is functional in different cell types. A, Mouse embryonic fibroblasts (MEFs) 
and neuroblastoma N2A cells were submitted to the indicated concentrations of SFN (16 h). Representative 
immunoblots of the indicated proteins. B, Different cell types were submitted to the indicated concentrations of 
SFN for the indicated periods of time. Expression levels of Hmox1 and Lamp2a were determined by qRT-PCR 
and normalized to Actb levels. Data are mean ± SEM (n = 3). Statistical analysis was performed using Student's t 
test. *p<0.05 and ***p<0.001 vs. untreated conditions. 
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Moreover, pharmacological activation of NRF2 with SFN also led to increased 
LAMP2A/Lamp2a mRNA and protein levels in human HEK293T, mouse HT22, MEFs and 
N2A cells (Fig. 42A and 42B). Altogether, these results point to the conservation of this 
NRF2/LAMP2A axis among different cell types in humans and mice. 
 
10.   Impaired CMA in lysosomes from livers of Nrf2-KO mice. 
 
To analyze the functional role of NRF2 in the modulation of CMA in vivo, we 
analyzed the expression levels of Hmox1, Sqstm1 and Lamp2a in livers of Nrf2-WT and Nrf2-
KO mice by qRT-PCR. Consistent with our results with cultured hepatocytes, mRNA levels 
of these three genes were reduced in the absence of NRF2 (Fig. 43A). Analysis of lysosomes 
isolated from these livers revealed a discrete decrease in LAMP2A levels in the Nrf2-KO 
group (Fig. 43B and 43C). The discrete differences in lysosomal LAMP2A levels might be 
the consequence of an overall increase in the ratio between lysosomal components and cargo 
in the Nrf2-KO mice because of their lower CMA activity. In fact, contrary to the decrease in 
LAMP2A, the levels of other lysosomal resident proteins such as HSC70 or β-
Glucocerebrosidase (GBA) were relatively higher in the lysosomes of Nrf2-KO mice when 
compared to their wild type counterparts (Fig. 43B and 43C).  
 
 
 
Figure 43. Role of NRF2 in the modulation of CMA in vivo. A, Expression levels of Hmox1, Sqstm1 and Lamp2a 
in livers from Nrf2-WT and Nrf2-KO mice were determined by qRT-PCR and normalized by the geometric mean 
between Actb, Gapdh and Tbp levels. Data are mean ± SEM (n=4). Statistical analysis was performed using 
Student’s t test. **p<0.01 and ***p<0.001 vs. Nrf2-WT mice. B, Immunoblots for the indicated proteins in 
homogenates and isolated lysosomes from livers of Nrf2-WT or Nrf2-KO mice. C, Densitometric quantification 
of lysosomal proteins in B relative to LAMP1 levels. Data are mean ± SEM (n=3 livers per mouse genotype). 
Statistical analysis was performed using Student’s t test. *p<0.05 vs. Nrf2-WT mice. (GBA, β-
glucocerebrosidase). 
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To directly measure CMA in isolated lysosomes, we incubated them with purified 
recombinant RNAse A, a bona fide substrate of CMA 
116
, in the absence or presence of 
proteasome inhibitors (PI). The amount of RNAse A recovered in untreated lysosomes 
represents the fraction bound at the lysosomal membrane, because the protein internalized 
during the incubation time is rapidly degraded. Pretreatment with PI allows recovering 
lysosomes with both the RNAse A bound and the one internalized for degradation (see Fig. 9 
in ‘Materials and Methods’). Thus, uptake was calculated as the difference in RNAse A levels 
between non-treated and PI-treated conditions. As shown in Fig. 44A and 44B, lysosomes 
from Nrf2-KO mice showed a trend toward reduced RNAse A uptake in comparison with 
Nrf2-WT littermates, although it did not reach statistical significance. We confirmed that the 
observed differences were not due to differences in lysosomal membrane integrity (Fig. 44C) 
or reduced proteolytic activity, which was in fact higher in the absence of NRF2 (Fig. 44D).  
 
 
 
 
Figure 44. RNAse A uptake in lysosomes extracted from livers of Nrf2-WT and Nrf2-KO mice. A, Lysosomes 
isolated from livers of Nrf2-WT and Nrf2-KO mice were pretreated or not with protease inhibitors (PI) to inhibit 
lysosomal proteolysis and incubated with purified RNAse A for 20 min at 37ºC. At the end of the incubation, 
lysosomes were recovered by centrifugation and subjected to SDS-PAGE and immunoblot for the indicated 
proteins. LAMP1 is shown as control of similar lysosomal recovery after the incubation. B, Densitometric 
quantification of RNAse A binding and uptake in Nrf2-WT or Nrf2-KO isolated lysosomes. Data are mean ± 
SEM (n=3 livers per mouse genotype). Statistical analysis was performed using Student’s t test. C, Lysosomes 
isolated from livers of Nrf2-WT and Nrf2-KO mice were collected by centrifugation right after isolation or after 
20 min incubation at 37ºC, and β-hesoxaminidase activity was measured in pellets and supernatant. Broken 
lysosomes were calculated as the percentage of total lysosomal β-hesoxaminidase activity detected in the media. 
Data are mean ± SEM (n = 3 livers per mouse genotype). D, Lysosomes isolated from livers of Nrf2-WT and 
Nrf2-KO mice were treated with 0.1% Triton X-100 to disrupt the lysosomal membrane (broken lysosomes) and 
incubated with a pool of 3H-labeled cytosolic proteins for 20 min at 37ºC. At the end of the incubation samples 
were precipitated in acid and filtered to calculate the amount of proteolysis as the percentage of initial 
radioactivity in protein (precipitable) detected in free amino acids and small peptides (soluble) at the end of the 
incubation. Data are mean ± SEM (n = 3 livers per mouse genotype). Statistical analysis was performed using 
Student’s t test. *p<0.05 vs. Nrf2-WT mice. 
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Figure 45. Impaired degradation of endogenous GAPDH in 
lysosomes from Nrf2-KO mice. A, Nrf2-WT and Nrf2-KO 
mice were starved for 24 h. Lysosomal proteolysis was 
inhibited in vivo with 2 intraperitoneal injections of leupeptin 
(Leup, 2 mg/100g body weight) 16 and 2 h before sacrifice. 
Representative immunoblots of the indicated endogenous 
proteins in lysosomal-enriched fractions from livers of Nrf2-
WT (WT) and Nrf2-KO (KO) mice. B, Densitometric 
quantification of representative immunoblots from A relative 
to total protein levels stained with Ponceau Red. Data are 
mean ± SEM (n=3). Statistical analysis was performed using 
Student’s t test. *p<0.05 vs. Nrf2-WT vehicle-treated mice.  
 
We also measured the degradation of the endogenous CMA substrate GAPDH 
116
 in 
lysosomes from Nrf2-WT and Nrf2-KO mice. Mice were starved for 24 h to maximally 
induce CMA, and then injected intraperitoneally with vehicle or leupeptin to block proteolysis 
inside lysosomes. Because LAMP2A and LAMP1 levels may oscillate with leupeptin due to 
changes in the ratio between cargo and lysosomal components, we normalized lysosomal 
GAPDH levels with total lysosomal protein as stained with Ponceau Red. As shown in Fig. 
45A and 45B, GAPDH accumulated in lysosomes from leupeptin-treated Nrf2-WT mice but 
not Nrf2-KO mice, which already exhibited higher basal levels of lysosomal GAPDH in the 
absence of NRF2. Altogether, these results suggest that NRF2 deficiency impairs basal CMA 
at the level of substrate internalization.   
 
11.   Pathophysiological significance of the new NRF2/LAMP2A axis in cancer. 
 
Because both NRF2 and CMA activity have been reported to be up-regulated in 
multiple cancers, we analyzed the correlation between NFE2L2 and LAMP2 expression in 30 
cohorts of The Cancer Genome Atlas (TCGA) from different tumors with the available 
RNAseq data from the Xena Browser database (https://xenabrowser.net/). Table 10 
summarizes the 15 TCGA datasets with the best correlation coefficients (R) between NFE2L2 
and LAMP2.  
The best correlation coefficient with the available datasets showed up for large B cell 
lymphomas (DLBC). However, the number of samples analyzed in this dataset was low (48). 
Therefore, the most significant correlation between NFE2L2 and LAMP2 was found in 
cohorts from low grade glioma and glioblastomas (GBMLGG). As shown in Fig. 46A, the 
expression of both NFE2L2 and LAMP2 shows a positive correlation in these datasets. 
Kaplan-Meier curves reflected reduced mean survival in patients from the GBMLGG cohort 
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which exhibited higher NFE2L2 expression compared to the ones with lower expression, and 
a similar tendency was also observed with LAMP2 expression (Fig. 46B).  
Of note, this approach compares transcriptional changes of these two genes (and not 
specifically the LAMP2A isoform), and up-regulation of both NRF2 and LAMP2A could also 
occur at the protein level. To gain a more precise insight in the connection between NRF2 and 
LAMP2A in glioblastomas, we next knocked-down NRF2 in glioblastoma explants from four 
independent patients with lentivirally-transduced shRNA against NFE2L2 for 7 days. As 
observed in Fig. 47A and 47B, all primary cultures exhibited a drastic decrease in NRF2 
expression to just the 10-20% of the original levels. In parallel, a significant down-regulation 
of LAMP2A mRNA levels and, to a lesser extent, protein levels was observed when silencing 
NRF2.  
 
Type of cancer (cohort) 
Number of 
samples 
p-value  R 
Large B cell lymphoma (DLBC) 48 1,61752E-07  0.69 
Low grade glioma and glioblastoma 
(GBMLGG) 
702 7,99519E-56  0.54 
Testicular cancer (TGCT) 156 1,18752E-12  0.52 
Thymoma (THYM) 122 1,47967E-09  0.51 
Endometrioid cancer (UCEC) 201 8,77315E-13  0.47 
Acute myeloid leukemia (LAML) 173 4,31053E-07  0.37 
Kidney clear cell carcinoma (KIRC) 606 9,69561E-19  0.34 
Esophageal cancer (ESCA) 196 1,01965E-06 
 
0.34 
Melanoma (SKCM) 474 4,74664E-12 
 0.3 
Cervical cancer (CESC) 308 3,93214E-08 
 
0,3 
Pancreatic cancer (PAAD) 183 2,43098E-05 
 
0.3 
Liver cancer (LIHC) 423 
1,61692E-08 
 
 
0.27 
Breast cancer (BRCA) 1218 1,67128E-21 
 
0.26 
Lung cancer (LUNG) 1129 7,00284E-18 
 
0.25 
Prostate cancer (PRAD) 550 7,42241E-08 
 
0.22 
 
 
 
 
Table 10. Correlation analysis between NFE2L2 and LAMP2 expression in human cancers. The table 
summarizes the analysis of the 15 datasets of The Cancer Genome Atlas (TCGA) with the most significant 
correlation between NFE2L2 and LAMP2 expression according to the Pearson’s correlation coefficient (R). The 
number of samples included in each dataset is also provided. 
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Altogether, our in silico and in vitro results support the functionality of the novel 
NRF2/LAMP2A axis in gliomas and glioblastomas, unveiling a new pathway to be further 
explored for therapeutic applications. 
 
 
 
 
Figure 46. NFE2L2 and LAMP2 expression positively correlate in human gliomas and glioblastomas. A, Graphs 
showing positive correlation between NFE2L2 and LAMP2 expression in the TCGA datasets from low grade 
glioma and glioblastoma (GBMLGG). Expression levels, expressed as log2(x+1) transformed RSEM normalized 
counts, were directly obtained from the Xena Browser database. Pearson’s correlation coefficient (R) and p-value 
calculated as a function of the t distribution are also shown. B, Kaplan-Meier curves obtained from the dataset in 
A from the Xena Browser database. The p-value resulting from the logrank analysis is depicted. 
 
 
 
 
Figure 47. Genetic manipulation of NRF2 modifies LAMP2A levels in glioblastoma explants. A-C, Four human 
glioblastoma explants (GB1-4) were transduced with a lentivirus encoding control shRNA (shCTRL) or against 
NFE2L2 (shNRF2). A, Expression levels of NFE2L2 and LAMP2A were determined by qRT-PCR and 
normalized to GAPDH levels. Data are mean ± SEM (n=4). Statistical analysis was performed using Student’s t 
test. *p<0.05 and ***p<0.001 vs. shCTRL levels. B, Immunoblot analysis of the indicated proteins from lysates 
as in A. C, Densitometric quantification of immunoblots in B relative to LAMIN B protein levels. Data are mean 
± SEM (n=4). Statistical analysis was performed using Student’s t test. ***p<0.001 vs. shCTRL cells. 
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1. NRF2 is a regulator of macroautophagy gene expression 
 
Transcription factor NRF2 and autophagy are essential elements to maintain cellular 
homeostasis, especially under stressful conditions. It had been reported that electrophiles, 
ROS or nitric oxide, all of which activate NRF2, can also can induce autophagy 
91, 205, 206
. 
Here we report a mechanistic link based on NRF2 dependent regulation of at least 8 
macroautophagy related genes that participate in autophagy initiation (ULK1), cargo 
recognition (SQSTM1 and CALCOCO2), autophagosome formation and elongation (ATG4D, 
ATG2B, ATG5, ATG7 and GABARAPL1) and autolysosome clearance (ATG4D). Previous 
studies had described that the cargo recognition proteins p62 
67
 and NDP52 
68
 encompass in 
their promoter regulatory regions one and three AREs, respectively. We have confirmed and 
extended these observations by finding three additional functional AREs in the p62 encoding 
gene. The upregulation of p62 is particularly relevant as phosphorylated p62 competes with 
NRF2 for KEAP1 binding and sequesters this E3 ligase adapter in protein inclusions 
99
 or 
takes it to degradation by autophagy 
207
, thus relieving NRF2 from this constrain. By doing 
so, we suggest that p62 can act as a molecular switch that, through NRF2 activation, leads to 
global up-regulation of autophagy genes. 
Few studies have performed direct ChIP analysis of NRF2, because of the low or even 
misleading specificity of available antibodies 
208
. Therefore, we undertook a different 
approach based on the analysis of other proteins that bind AREs, specifically MAFF, MAFK 
and BACH1, for which ChIP sequencing data are available in the ENCODE database, 
because at the time that these experiments were performed the ENCODE did not have an 
online resource to analyze NRF2 binding. The fact that MAFF, MAFK or BACH1 proteins 
might bind these sequences does not necessarily mean that NRF2 does, as sequence variations 
determine preference for different binding partners 
209
. For this reason, we generated a PSSM 
and a script in order to compare each of the sequences from the ENCODE database with the 
consensus human ARE for NRF2 according to the JASPAR database 
(http://jaspar.genereg.net/). The script can be applied to the analysis of any gene of the 
ENCODE and, because this database in based on empirical data, it should provide more 
reliable information than theory-based softwares. Of note, this script identified with a high 
relative score the already known AREs in the HMOX1 and NQO1 promoters. 
In previous studies, the effect of SFN on autophagy was attributed to the modulation 
of signaling events of the mTOR pathway through RPS6KB1/pS6K1 (Ribosomal protein S6 
kinase beta-1) 
210
, activation of AMPK 
211
 or the MAPK/ERK pathways 
205
 rather than to 
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targeting NRF2 itself. However, we show in this work that the induction of macroautophagy 
genes by SFN is impaired in Nrf2-KO MEFs, therefore indicating that NRF2 is, at least, 
partially involved. In fact, these observations might be also extrapolated to invertebrates 
where loss of the homologue of KEAP1 in D. melanogaster (DmKEAP1) results in Atg8 
(homologue to mammalian LC3) and macroautophagy induction dependent on CncC/NRF2 
and independent on MITF/TFEB 
212
. Interestingly, slight differences may be found in the 
response to NRF2 depending on species, cell type or the mechanism of NRF2 activation or 
inhibition. For instance, although we found binding of NRF2 to an ARE in ATG7 and reduced 
mRNA and protein levels of this gene in Nrf2-KO MEFs, SFN treatment did not significantly 
increase its expression in HEK293T or HT22 under the experimental conditions used in this 
work. This may reflect cell-specific and stimulus-dependent regulation of macroautophagy 
90, 
213
.  
The proteins involved in macroautophagy are thought to be expressed in sufficient 
amounts to sustain basal activity, making post-translational modifications and protein-protein 
interactions critical for its regulation 
214
. However, mild changes in gene expression combined 
with other signaling pathways, may account for large variations in autophagy activity. Thus, 
we have observed that NRF2 deficiency by itself did not significantly alter either basal 
autophagy flux under non-stressing conditions or autophagy induction by serum deprivation, 
as determined by LC3B-II levels. However, impaired autophagosome formation was detected 
in Nrf2-KO MEFs in response to stressful conditions elicited by H2O2 treatment. More 
importantly, NRF2 deficiency also aggravated proteinopathy in our mouse model of AD. 
These results support that NRF2 is necessary to achieve an optimal autophagic response upon 
stressful conditions.  
   
2. Functional relevance of NRF2 in a new mouse model of AD 
 
In spite of the efforts made over the last decades, the etiology of AD remains largely 
unknown. This is in part caused by incomplete reproduction of the human pathology in 
animal models merely exhibiting proteinopathy associated to Aβ and TAU. Current AD 
models do not completely recapitulate molecular mechanisms that correlate with the general 
decline of homeostatic capacity during ageing and may contribute significantly to the disease 
process. These mechanisms include oxidative, inflammatory and metabolic stress, which may 
precede the accumulation of protein aggregates in prodromal and early phases of sporadic AD 
144, 215
. NRF2 activity has been shown to decrease with age 
43, 165, 166, 216
, probably resulting in 
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homeostatic disturbances related to AD. Based on this rationale and to address the impact of 
NRF2 on proteinopathy in vivo, especially in regard to macroautophagy, we generated a new 
mouse model based on the expression of human APP(V717I) and TAU(P301L) in a wild type 
(AT-Nrf2-WT mice) or Nrf2-knockout (AT-Nrf2-KO mice) genetic background. 
Previous studies have addressed the impact of NRF2 loss in mouse models of AD with 
either amyloidopathy 
217, 218
 or tauopathy 
53, 219
 alone, but not in combination as presented 
here. Although we did not detect significant differences in the hippocampus of Nrf2-KO vs. 
Nrf2-WT mice, AT-Nrf2-KO mice exhibited a modest increase in oxidative and pro-
inflammatory markers compared to AT-Nrf2-WT mice, suggesting that the proteotoxic 
challenge represented by human mutant APP and TAU expression rendered them more 
sensitive to oxidative and inflammatory stress. It must be born in mind that the slight increase 
in oxidative and inflammatory markers is persistent over the life span of the animals and 
mimics the low-grade but chronic oxidative and inflammatory stress characteristic of human 
pathology 
220
. Memory and learning were severely impaired in the AT-Nrf2-KO mice as early 
as 6 months, preceding the presence of amyloid plaques and TAU fibrillary aggregates. These 
findings suggest that the lack of NRF2 replicates a prodromal condition of human AD and is 
in line with other findings in other animal models 
221-223
. 
Although a reduced expression of bona fide NRF2-target genes was detected in 
cultured primary neurons derived from NRF2-WT vs. Nrf2-KO mice, we found minimal 
changes of ARE-gene expression in the hippocampus of 13-month-old animals. This is in line 
with a previous study 
201
 and our own transcriptomic data 
224
 showing no significant changes 
in the expression levels of well-known NRF2 targets in brains of NRF2-deficient mice, and 
also consistent with the lack of oxidative stress in the hippocampus of Nrf2-KO vs. Nrf2-WT 
mice. In fact, disruption of the gene coding for NRF2 in mice causes no overt phenotype if 
they are cared for under the optimal unstressed conditions of some animal facilities 
225
. This 
fact suggests that NRF2 is not required under unstressed conditions or that there are 
compensatory mechanisms with other bZIP transcription factors. Indeed, NRF3 was reported 
to partially compensate for the lack of NRF2 in skin of NRF2-null mice 
62, 226
. However, 
NRF2-deficient mice are extremely vulnerable to various toxic insults, such as cigarette 
smoke 
227, 228
, hepatotoxic chemicals 
229, 230
, traumatic brain injury 
231
 or neurotoxic chemicals 
232, 233
. Our results support that the lack of NRF2 makes mice more sensitive to proteotoxic 
insults as well. 
Reduced clearance of aggregation-prone proteins is a hallmark of many diseases, 
including AD 
234
. In fact, macroautophagy deficiency has been shown to produce 
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neurodegeneration in mice 
155, 235
. In accordance with a previous study in the APP/PS1 mice 
201
, our results show modest or no changes in macroautophagy gene expression in the whole 
hippocampus of AT-Nrf2-KO vs. AT-Nrf2-WT mice. However, in double-
immunofluorescence assays, we did find differences in the levels of macroautophagy proteins 
when we compared APP- and TAU-expressing neurons from AT-Nrf2-WT vs the AT-Nrf2-
KO brains. Therefore, the effect of NRF2 was detected specifically in the neurons under 
proteotoxic attack. 
 Impaired autophagy in neurons from the AT-Nrf2-KO mice correlated with altered 
APP processing, stalled in multiple swollen vacuoles with reduced levels of p62. It was 
surprising to find lower total levels of Aβ as well as an apparent reduction in amyloid plaques 
in AT-Nrf2-KO compared to AT-Nrf2-WT, as this observation implies a reduction of the 
amyolidogenic processing of APP. However, similar results have been reported for neuronal 
ATG7-deficient mice, which show impaired secretion, reduced total Aβ levels and fewer 
amyloid plaques 
157
. Several studies have found that autophagosomes are a place for 
generation of Aβ 236, 237 and β-secretase and γ-secretase appear to be localized at least in part 
in autophagosomes 
238, 239
. Thus, a reduction of autophagosomes might lead to lower Aβ load. 
In support of this hypothesis, we found reduced levels of the autophagy markers p62, NDP52, 
ULK1, AGT5, GABARAPL1 and LC3B in the AT-Nrf2-KO mice. 
Our results are also consistent with a recent study in which the amyloidogenic mouse 
model APP/PS1 lacking NRF2 exhibits enhanced accumulation of APP in multivesicular 
bodies, endosomes, and lysosomes and shows an altered production of amyloid proteins due 
to impaired autophagic flux 
201
. In these mice, NRF2-deficiency leads to increased amyloid 
plaque accumulation, whereas our AT-Nrf2-KO mice exhibited a tendency to develop fewer 
amyloid plaques compared to the wild type counterparts despite presenting worse cognitive 
performance and reduced LTP. These findings may be reconciled considering that the 
APP/PS1 mice exhibit a very strong amyloidogenic processing of APP (due to combined APP 
and PS1 mutations), while our model exhibits mild amyloidogenic processing (APP-mutated 
only), suggesting reduced availability of extracellular Aβ peptides for plaque formation 
similar to what is observed in the “APP-only” transgenic mice with ATG7-deficiency 157. 
Moreover, we also observed increased levels of the soluble Aβ*56 oligomer in AT-Nrf2-KO 
mice. This oligomer results in memory impairment, is associated with pathological forms of 
TAU 
240-242
 and, very importantly, negatively correlates with plaque deposition 
243, 244
.  
Although TAU can be degraded through several proteolytic pathways, it is 
increasingly being recognized that impaired autophagy also plays a central role in tauopathy 
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245
. For instance, macroautophagy activation in the brain led to a reduction in the number of 
neurons containing TAU inclusions as well as decreased amount of insoluble TAU, together 
with diminished p62 levels 
246
. Our results are fully consistent with at least partial NRF2-
dependent autophagic degradation of TAU, given its co-localization with p62 in autophagic 
vacuoles. Consistently, we found more insoluble and hyperphosphorylated TAU in AT-Nrf2-
KO mice. These observations also fit with a previous report showing that TAU is a cargo for 
NDP52, regulated by NRF2. Our study supports, therefore, that lack of the transcription factor 
NRF2 aggravates tauopathy in mice 
245
.  
Altogether, the generation and characterization of our new mouse model of AD point 
to a critical role of NRF2 in modulating oxidative, inflammatory and proteostatic events, at 
least in part, through the regulation of macroautophagy. 
 
3. NRF2 regulates CMA through the transcriptional control of Lamp2a  
 
We have also described a molecular link between NRF2 and CMA, which occurs 
through the control of LAMP2A transcription. Knockout of Lamp2a or Nrf2 results in 
increased susceptibility to different stressors 
132, 247
, indicating a crucial role of these pathways 
in the maintenance of cellular homeostasis under different circumstances. In fact, the redox 
status controls CMA activity, presumably to eliminate oxidized proteins during mild oxidative 
damage 
124
. Interestingly, Kiffin and co-workers showed that CMA induction upon oxidative 
stress occurred through increased Lamp2a transcription 
124
. Our results indicate that LAMP2A 
induction and consequent CMA activation after H2O2 or PQ treatment were severely impaired 
in Nrf2-KO cells. Therefore, NRF2 is an essential transcriptional regulator of CMA upon 
oxidative challenge. 
In this work, we have identified two functional AREs in the LAMP2 gene. Chemical 
and genetic manipulation of NRF2 results in modest changes in cellular Lamp2a mRNA and 
protein levels, albeit similar to those observed for the NRF2 target p62. LAMP2A has a slow 
turnover, with a half-life of approximately 46 h for total LAMP2A and 57 h for lysosomal 
LAMP2A 
118
. Hence, small changes in mRNA Lamp2a levels may have a marked impact on 
protein levels and CMA activity. Other studies show similar oscillations, further supporting 
this notion 
117, 126, 139, 248
. In contrast with the discrete changes in total cellular LAMP2A 
levels, the effects of NRF2-deficiency are much more evident in isolated lysosomes, the place 
where LAMP2A is required for CMA. In fact, the lysosomal levels of LAMP2A correlate 
with changes in the rate of CMA 
127
. Thus, CMA was barely detectable in Nrf2-KO 
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hepatocytes, suggesting a crucial role for NRF2 in the modulation of CMA also under basal 
conditions. 
The LAMP2 gene encodes three splice variants, LAMP2A, LAMP2B and LAMP2C that 
possess different transmembrane and cytosolic regions and enable specific functions. 
Although several roles have been proposed for LAMP2B and LAMP2C 
130, 249-251
, only 
LAMP2A is involved in CMA 
117, 132, 162
.  Somewhat intriguingly, we could not detect 
consistent differences in the expression levels of LAMP2B or LAMP2C upon genetic 
manipulation of NRF2 despite being coded by the same gene. An explanation may stem from 
the fact that the three spliced variants exhibit differential regulation 
127, 130, 252
 and tissue-
specific patterns 
130, 131
. While LAMP2A and LAMP2B are highly expressed in most tissues, 
LAMP2C appears to be very restricted 
130
, supporting a differential splicing regulation of the 
LAMP2 gene. Importantly, a previous study showed that paraquat transcriptionally induced 
Lamp2a expression without affecting the other two isoforms 
253
. Altogether, these data 
suggest the existence of additional post-transcriptional regulatory mechanisms of the Lamp2 
gene that still need to be unveiled. 
While we have described the transcriptional regulation of Lamp2a by NRF2, other 
layers of CMA regulation are still possible. For example, lysosomes from Nrf2-KO livers 
exhibited higher levels of HSC70 compared to Nrf2-WT livers. Although it is plausible that 
higher levels of HSC70 are a result of the relative decrease in lysosomal cargoes, we cannot 
discard that this increase represents a compensatory mechanism to counteract impaired CMA. 
In fact, increased HSC70 levels have been previously reported in other conditions with 
reduced lysosomal levels of LAMP2A, such as livers from old mice and in Lamp2a-KO mice 
162, 203
.  
The impairment of CMA in Nrf2-KO mice was evidenced by a deficient uptake in an 
in vitro reconstituted system with RNase A but, more importantly, by the reduced degradation 
in vivo of the endogenous bona fide CMA substrate GAPDH. The fact that the differences in 
the uptake in vivo for the endogenous substrate are more pronounced than for the exogenously 
added protein in the isolated in vitro system could be attributed to the lack of other competing 
substrates in this last one. Interestingly, a previous report showed that astrocyte-specific 
NRF2 overexpression reduced the levels of another CMA substrate, MEF2D (myocyte 
enhancer factor 2D) 
254
. However, this study was just correlative and ours is the first one to 
show that changes in CMA substrates are at the level of lysosomal degradation by CMA.  
The crosstalk between both autophagic pathways has been extensively reported both in 
vivo and in vitro, whereby one reacts compensatorily to the loss of activity in the other 
132, 137, 
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203
. However, in this work we show that the functional connection between NRF2 and CMA 
is independent of macroautophagy. Therefore, NRF2 might act as a regulatory node in the 
proteolytic network represented by macroautophagy and CMA (Fig. 48). 
 
4. Complex transcriptional networks assure cell proteostasis 
 
In higher eukaryotes, the family of FOXO (Forkhead box protein O) transcription 
factors, GATA1 (Erythroid transcription factor) and TFEB (Transcription factor EB), activate 
macroautophagy 
107, 255, 256
 while ZKSCAN3 (Zinc finger protein with KRAB and SCAN 
domains 3) and GATA4 (Transcription factor GATA-4) are involved in the repression 
257, 258
. 
Our study has added NRF2, suggesting different roles of these factors in the adaptation to 
specific autophagic needs. 
The transcriptional inducers TFEB and FOXO3/FOXO3A participate in multiple 
scenarios and nutrient-deprivation is the best characterized 
259, 260
. Nonetheless, NRF2 may be 
more relevant in tissues that support highly oxidative metabolism. By this mechanism, 
oxidative stress-induced NRF2 may function under nutrient-rich conditions to upregulate 
transcription of genes encoding proteins required for autophagy, similar to what has been 
found for the transcription factors TFEB and FOXO3 under starvation conditions. As the 
brain is not allowed to starve and must function under all nutritional conditions, NRF2 may be 
particularly a relevant to activate autophagy in neurons. 
Different transcription factors might also regulate LAMP2 expression. AP-1 and SP-1 
binding sites were found in the LAMP2 promoter 
261
, although were not confirmed to be 
functional enhancers. MAF proteins, binding partners of NRF2, also heterodimerize with 
NFAT (nuclear factor of activated T-cells), which has been shown to modulate Lamp2a 
transcription upon activation of T lymphocytes 
139
. We have identified two functional AREs 
in the LAMP2 gene that lose activity when a highly conserved G is replaced to A. This 
conserved G constitutes the binding site for MAFs in the heterodimer 
262
 and consequently we 
suggest that MAFs participate in a dual regulation of LAMP2 by binding to both NFAT and 
NRF2. Of note, NRF2 would control not only inducible but also Lamp2a basal expression, as 
Nrf2-deficient cells exhibited reduced Lamp2a mRNA and protein levels.  
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Figure 48. NRF2 controls autophagy through the regulation of macroautophagy and CMA related genes. 
Different mechanisms, including reactive oxygen species (ROS) or signaling events leading to p62 
phosphorylation, result in NRF2 induction and subsequent induction of autophagy- related genes, with a 
functional impact in macroautophagy and chaperone mediated autophagy. P62 creates a positive feedback loop in 
which autophagosomal degradation of KEAP1 results in induction of autophagy related genes through 
upregulation of NRF2. 
 
Therefore, different transcription factors may co-exist to assure proteostasis under 
several circumstances and in distinct cell types. In fact, levels of basal macroautophagy and 
CMA activity and the amplitude of the induction are highly variable 
122, 134, 139, 173
. The 
existence of transcriptional networks would allow compensation when the activity of a certain 
transcription factor is impaired, at least under certain conditions. Similar to what has been 
discussed here for NRF2, no significant reduction of well-known TFEB target genes is 
observed in Tfeb-KO mice unless mTOR is inhibited 
106
.  
All things considered, while post-translational modifications and protein-protein 
interactions represent quick adaptations to the cellular needs, transcriptional regulation of 
autophagy might to be critical for long term adaptation to specific stressful conditions. 
 
 
 
 
Discussion 
147 
5. Therapeutic potential of NRF2 and autophagy in chronic diseases 
 
Chronic diseases demonstrate a high degree of connectivity and a need for more 
precise, mechanism-based disease rather than the current organ- and symptom-based 
definitions 
263
. In fact, several chronic diseases share common molecular mechanisms, 
including oxidative stress, chronic inflammation and metabolic unbalance. Based on a 
network medicine approach, NRF2 was proposed as a key molecular node within a particular 
cluster of diseases, including AD or cancer 
60
. In this work, we have analyzed the impact of 
NRF2 in the context of a disease with impaired macroautophagy (AD) and a disease usually 
characterized by over-activation of CMA (cancer). 
 
a. Relevance of NRF2 and autophagy in AD  
 
While there is overwhelming evidence of impaired autophagy in AD 
264-267
, the role of 
NRF2 is still controversial. A highly cited study showed by immunohistochemistry with anti-
NRF2 polyclonal antibodies available at that time that NRF2 is predominantly localized in the 
cytoplasm of AD hippocampal neurons, suggesting reduced NRF2 transcriptional activity in 
the brain 
268
. However, other studies have reported increased ARE-regulated proteins in AD 
brains, such as HMOX1, NQO1, or p62 
269-272
. Interestingly, the rodent Octodon degus 
naturally develops proteinopathic hallmarks of AD with aging that correlate with increased 
Nfe2l2 mRNA levels 
273
, suggesting upregulation of NRF2 to combat proteinopathy. Our 
results with hippocampal lysates and immunohistochemistry are in line with these latter 
reports, as we observed increased nuclear NRF2 expression in proteinopathic AD neurons. 
Aside from technical reasons, one possible explanation for this discrepancy is that NRF2 
levels might change during disease progression and in different brain regions. 
In this regard, a corollary of our study is that NRF2 might be a therapeutic target for 
proteinopathies such as AD. On the one hand, we found that NRF2-deficiency impairs 
macroautophagy in AT-Nrf2-KO mice. We interpret these data as a need of NRF2 for an 
optimal response to proteinopathy. On the other hand, NRF2 and at least HMOX1, p62, 
NDP52 and ATG7 are upregulated in the hippocampus of AD patients as determined by 
immunoblot, and NRF2 and p62 proteins are increased in APP- and TAU-injured neurons as 
determined by immunohistochemistry. Interestingly, Atg7-KO mice display p62 and KEAP1 
accumulation in ubiquitin-positive inclusion bodies, which leads to NRF2 stabilization and 
induction of target genes 
98
. The excessive accumulation of p62 together with ubiquitinated 
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proteins has been identified in neurodegenerative diseases, including AD, PD and ALS 
164
. 
Our work supports the observation that phosphorylated p62 is increased in AD samples 
272
. 
This modified form of p62 has higher binding affinity for KEAP1 and drives this NRF2 
repressor to autophagosomes 
102
. It is then plausible that impairment of autophagy in AD 
leads to p62-mediated removal of KEAP1 and NRF2 accumulation, which in turn would 
induce the expression of p62 as well as other autophagy genes providing a feed-forward loop. 
In fact, Lipinski and co-workers found that AD brains showed increased transcription of 
autophagy related genes, in contrast to normal aging individuals 
159
. 
In addition to the proposed mechanism of p62-mediated activation of NRF2 in 
proteinopathies, other mechanisms regulating proteostasis may impact NRF2 activity. Thus, 
accumulation of unfolded/misfolded proteins will induce the unfolded protein response (UPR) 
in the ER and, therefore, the activation of PERK (double-stranded RNA-activated protein 
kinase-like ER kinase) and MAPK (mitogen activated protein kinases) that may result in 
NRF2 activation 
35, 36
. Moreover, protein oligomers and aggregates have been shown to 
inhibit proteasomal activity 
274
, probably avoiding NRF2 degradation.  
 
Figure 49. NRF2 as a hub connecting emergency signals derived 
from proteotoxic insults to a protective transcriptional response. The 
accumulation of unfolded/misfolded proteins will lead to the 
activation of the unfolded protein response (UPR) in the ER. 
Activation of PERK or MAPK may result in the transcriptional 
induction of the ER resident Gpx8 and several enzymes regulating 
GSH levels, critical to ensure correct protein folding. Protein 
aggregates inhibit proteasome activity (UPS), probably avoiding 
NRF2 degradation. Although regulation of proteasome genes appears 
to be related to the paralogue NRF1, NRF2 has been reported to 
modulate the transcription of proteasome genes such as Psma3, 
Psma6, Psmb1, Psmb5 and Pomp genes and others. Autophagy is the 
main pathway for the degradation of protein aggregates. Autophagy 
also regulates NRF2, connecting this degradation pathway with 
NRF2 transcriptional induction of p62, Ndp52, Ulk1, Atg2b, Atg4c, 
Atg5, Atg7, Gabarapl1 and Lamp2a. 
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As a result, NRF2 can be envisioned as a hub connecting proteotoxicity-derived 
emergency signals to a protective transcriptional response (Fig. 49), controlling the 
expression of different enzymes critical to ensure correct protein folding 
66, 275
; modulating the 
transcription of several proteasomal subunits 
64, 65
; and, as shown in this work, several 
autophagy-related genes, therefore re-inforcing proteostasis. 
However, a key remaining question is whether it will be useful or deleterious to 
increase NRF2 levels in the brain. As discussed by Hayes and colleagues 
276
, NRF2 effect 
might have an U-shaped response, meaning that too low NRF2 levels may result in a loss of 
cytoprotection and increased susceptibility to stressors, while too much NRF2 might disturb 
homeostatic balance towards a reductive scenario, which would favor protein misfolding and 
aggregation. Interestingly, analysis of epidemiological data indicates that the NFE2L2 gene is 
highly polymorphic, and some haplotypes are associated with decreased risk and/or delayed 
onset of AD 
167
. Similar observations have been done in regard to other proteinopathies 
277, 278
. 
This physiological variability in NFE2L2 expression at the population level and low NRF2 
levels in the brain 
279
 support the idea that a slight up-regulation in NRF2 activity may be 
sufficient to reinforce proteostasis and achieve a benefit under pathological conditions. In 
fact, the protective role of pharmacological NRF2-mediated protein clearance has been shown 
in different cell culture and in vivo models of neurodegeneration (reviewed in 
66
). For 
instance, autophagy-mediated degradation of phospho- and insoluble-TAU was reported with 
the organic flavonoid fisetin. This compound was able to induce autophagy by simultaneously 
promoting the activation and nuclear translocation of both TFEB and NRF2, along with some 
of its target genes. This response was prevented by TFEB or NRF2 silencing 
280
. Interestingly, 
Jo and colleagues demonstrated that SFN reduced the levels of phosphorylated TAU and 
increased BECLIN1 and LC3-II, suggesting NRF2 activation may facilitate degradation of 
this toxic protein through autophagy 
68
.  
Although we have not specifically analyzed here the role of NRF2/LAMP2A axis in 
AD, the fact that a) CMA activity declines in old rodents and humans 
162, 203
, favoring the 
accumulation of oxidized substrates and contributing to the general decline in proteostasis 
with age; and b) TAU has been shown to be a CMA substrate 
281, 282
, make it conceivable that 
CMA activation could be beneficial in this context. We have shown that both 
macroautophagy related genes and Lamp2a can be up-regulated by pharmacological 
activation of NRF2 with SFN, but future work will be needed to definitely determine if 
pharmacological activation of NRF2 may be a valid strategy to facilitate degradation of toxic 
proteins in the brain. 
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b. Potential implications of the novel NRF2/autophagy axis in cancer 
 
Although the role of autophagy and NRF2 in cancer is complex, the general view is 
that these homeostatic processes are necessary in order to prevent tumor initiation, but once 
the tumor has been established, they promote survival of transformed cells, tumor 
development and resistance to chemotherapeutic agents.  
 In this study, we have analyzed a potential connection between NRF2 and CMA in 
glioblastomas. NRF2 activity is generally increased in glioblastoma cell lines 
283, 284
 and 
glioblastoma patients 
279, 285
 and, very importantly, ablation of NRF2 expression was shown to 
inhibit the proliferation and self-renewal of glioma stem cells (GSCs) 
286
. Therefore, we have 
analyzed the correlation between NFE2L2 and LAMP2 expression levels in different cancers, 
finding a positive correlation in gliomas and glioblastomas. The correlation coefficient in 
mRNA expression between both genes was roughly 0,5 but this value is quite significant if we 
consider a) that it integrates all-type of gliomas independently of their classification and 
source of collection; b) this type of analysis does not differentiate between LAMP2 isoforms, 
otherwise it may result in better correlations with LAMP2A; and c) NRF2 levels are probably 
increased at the protein level, so that a mild effect at the mRNA level is observed as a 
consequence of a subtle induction of the NFE2L2 gene through its own AREs 
195
. 
In line with previous studies 
279, 285
 the Kaplan-Meier curves reflect that higher 
NFE2L2 expression levels correlate with reduced mean survival in low grade glioma and 
glioblastoma patients, and vice versa. We observed a parallel association between LAMP2 
expression and survival, indicating that individuals with high LAMP2 expression have worse 
prognosis than those with low LAMP2 expression. These results point to the fact that 
increased CMA may represent an advantage in this type of tumors. For instance, degradation 
of tumor-suppressor mammalian STE20-like kinase 1 (MST1) by CMA was shown to 
promote tumorigenesis 
175
. Moreover, augmented CMA may also make cancer cells more 
resistant to different stressors such as oxidative stress 
174
. By contrast, blockage of CMA 
reduced tumorigenicity in cancer cell lines and reduced tumor size and metastasis in mouse 
xenografts 
173
. 
Although further research is needed to directly confirm increased CMA activity and its 
precise consequences in specific types of cancers, current evidence is consistent with the 
hypothesis that reducing the activity of NRF2 and, consequently, CMA, would constitute an 
interesting therapeutic strategy. In fact, NRF2 inhibition has been proposed as a mechanism to 
sensitize cancer cells to chemotherapeutic drugs or radiotherapy 
287
. For instance, ascorbic 
acid (vitamin C), a well-known ROS scavenger, was found to sensitize imatinib-resistant 
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cancer cells by decreasing the levels of the NRF2/ARE complex, reducing the expression of 
GCLC and dropping GSH levels 
288
. NRF2 inhibition with the natural compound trigonelline 
was also shown to render pancreatic cancer cells more susceptible to apoptosis 
55
. 
Interestingly, we observed reduced expression of macroautophagy related genes after 
trigonelline treatment in HT22 cells. All-transretinoic acid (ATRA) is another example of 
NRF2 inhibitor that significantly decreases NRF2 activation in vitro and in vivo. ATRA 
activates the RARα (retinoic acid receptor α), which forms a complex with NRF2, hence 
impeding the binding of the transcription factor to ARE genes 
289
. ATRA was also shown to 
decrease CMA through inhibition of LAMP2A transcription 
290
. Although these inhibitors may 
have many unspecific effects, we report here that NRF2 silencing with shRNA in explants 
obtained from different glioblastoma patients resulted in reduced LAMP2A mRNA and 
protein levels. This NRF2/LAMP2A may also be exploited in other types of tumors. 
Adenocarcinoma A549 cells have been shown to display increased NRF2 
178, 179
 and CMA 
173
 
activities. Of note, reduction of NRF2 levels in A549 with a specific shRNA resulted in 
reduced LAMP2A levels.  
Proteolytic networks show a great degree of crosstalk, and one pathway can act 
compensatorily to the failure of another 
132, 137, 203
. It is plausible to think, then, that 
specifically inhibiting CMA in cancer would result in macroautophagy induction. If this is 
indeed demonstrated, inhibiting NRF2 may be of greater interest as it can transcriptionally 
regulate both pathways.  
Therefore, until more selective NRF2 small-molecule inhibitors are developed, our 
results may serve, at least, as a proof-of-concept for reduced autophagy gene expression when 
inhibiting NRF2. All in all, we believe that the new regulation of macroautophagy and CMA 
related genes by NRF2 described in this work constitutes a very interesting targetable 
pathway to be considered for future research for chronic diseases such as cancer.  
 
6. Concluding remarks and future perspectives 
 
As demonstrated in the last years, NRF2 transcriptional signature is not only essential 
for orchestrating an adequate antioxidant response, but to maintain general homeostasis. In 
this work, we have described the role of NRF2 in the transcriptional regulation of 
macroautophagy and CMA, and re-inforced the view of this transcription factor as a 
regulatory node in the proteolytic network. Therefore, therapeutic possibilities may arise 
based on the exploitation of NRF2 as a crucial regulator of autophagy in chronic diseases. 
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1. NRF2 regulates macroautophagy through the transcriptional control of 
several genes involved in this process. 
 
2. NRF2 modulates CMA through the transcriptional control of Lamp2a. 
 
3. NRF2 regulates proteostasis, especially under stressful conditions. 
 
4. Modulation of macroautophagy and CMA via NRF2 pharmacological 
intervention points to a new potential therapeutic target for chronic diseases.  
 
____________________________________________________________ 
 
1. NRF2 regula la macroautofagia a través del control transcripcional de varios 
genes implicados en este proceso. 
 
2. NRF2 modula la CMA a través del control transcripcional de Lamp2a. 
 
3. El factor de transcripción NRF2 regula la proteostasis, especialmente frente a 
condiciones de estrés.  
 
4. La modulación de la macroautofagia y la CMA a través de la regulación 
farmacológica de NRF2 sugiere una posible nueva diana terapéutica para 
enfermedades crónicas. 
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Appendix I. Script created with Python 3.4 to compare in human genes the putative AREs with the PSSM and 
calculate their relative score. 
 
 
import sys 
import re 
 
def Get_PSSM(FileName): 
tmp={} 
MyFile=open(FileName,’r’) 
for Nt in [“A”,“C”,“G”,“T”]: 
pos=MyFile.readline() 
tmp[Nt]=pos.strip().split(“\t”) 
MyFile.close() 
return(tmp)  
 
def Get_Coordin(Coord): 
MyRE=r’(\w*)(chr[0-9XY]{1,2}):(\d+)-(\d+)’ 
MyReg=re.compile(MyRE) 
Res=MyReg.search(Coord) 
return(Res.groups()) 
 
def Get_MaxScore(Seq,PSSM): 
MaxSc=-100000 
book={} 
for idx in range(len(Seq)-len(PSSM[“A”])+1): 
tmpSc=0 
sseq=”” 
sequence=[] 
sequence2=[] 
for pos in range(len(PSSM[“A”])): 
tmpSc=tmpSc+float(PSSM[Seq[idx+pos]][pos]) 
sseq=sseq + Seq[idx+pos] 
if MaxSc<tmpSc: 
MaxSc=tmpSc 
sequence.append(str(tmpSc)) 
sequence2.append(sseq) 
book=dict(list(book.items()) + list((dict(zip(sequence,sequence2))).items())) 
return(MaxSc) 
 
def Get_Seq(Seq,PSSM): 
MaxSc=-100000 
book={} 
for idx in range(len(Seq)-len(PSSM[“A”])+1): 
tmpSc=0 
sseq=”” 
sequence=[] 
sequence2=[] 
for pos in range(len(PSSM[“A”])): 
tmpSc=tmpSc+float(PSSM[Seq[idx+pos]][pos]) 
sseq=sseq + Seq[idx+pos] 
if MaxSc<tmpSc: 
MaxSc=tmpSc 
sequence.append(str(tmpSc)) 
sequence2.append(sseq) 
book=dict(list(book.items()) + list((dict(zip(sequence,sequence2))).items())) 
return(book[str(MaxSc)])) 
 
def Main(Args): 
PSSM={} 
PSSM=Get_PSSM(Args[1]) 
MyFile=open(Args[2],’r’) 
for Line in MyFile: 
Fields=Line.strip().split(“\t”) 
(Name,Chr,Str,End)=Get_Coordin(Fields[0]) 
directseq=Fields[1] 
basecomplement={“A”:”T”:”C”:”G”,”T”:”A”:”G”:”C”} 
rDNAsense=directseq[::-1] 
antisenseDNA=”” 
for base in rDNAsense: 
antisenseDNA = antisenseDNA+basecomplement[base] 
MaxScore=Get_MaxScore(Fields[1].upper(),PSSM) 
MaxScore2=Get_MaxScore(antisenseDNA.upper(),PSSM) 
Sequence=Get_Seq(Fields[1].upper(),PSSM) 
Sequence2=Get_Seq(antisenseDNA.upper(),PSSM) 
finded= Fields[1].find(Sequence) 
finded2= antisenseDNA.find(Sequence2) 
if int(Str)>int(End): 
print(Name,”\t”,Chr,”\t”,str(int(Str)-finded),”\t”,str(int(Str)-finded-15),”\t”,  
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round(MaxScore,2),”\t”,round(MaxScore+22.54)/(19.111+22.54),3),”\t”, 
Sequence,”\t”, str(finded2+int(End)),”\t”, str(finded2+int(End)+11),”\t”,  
round(MaxScore2,2),”\t”,round(MaxScore2+22.54)/(19.111+22.54),3),”\t”,Sequence2) 
else: 
print(Name,”\t”,Chr,”\t”,str(finded+int(Str)),”\t”,str(finded+int(Str)+11),”\t”, 
round(MaxScore,2),”\t”,round(MaxScore+22.54)/(19.111+22.54),3),”\t”, 
Sequence,”\t”,str(int(End)-finded2),”\t”,str(int(End)-finded2-11),”\t”, 
round(MaxScore2,2),”\t”,round(MaxScore2+22.54)/(19.111+22.54),3),”\t”,Sequence2) 
MyFile.close() 
 
if__name__==’__main__’: 
if len(sys.argv)<2: 
print(“You must provide the name of the files containing the sequences and PSSM”) 
else: 
Main(sys.argv) 
sys.exit()  
 
 
 
 
